Compositions and methods for TCR reprogramming using fusion proteins

JP2024501831A5Inactive Publication Date: 2024-12-04TCR2 THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023538969
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-19
Filing Date
2021-12-23
Publication Date
2024-12-04
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing cancer immunotherapy methods face challenges in effectively targeting cancer cells due to autologous tumor antigens and cancer cells' mechanisms to evade immune attack, leading to difficulties in achieving clinical efficacy and serious side effects.

Method used

Development of genetically engineered T cells expressing a fusion protein of TCR subunits and IL-15 or IL-15Rα, which enhance T cell recognition and targeting of cancer cells while reducing inflammatory cytokine release.

Benefits of technology

The engineered T cells demonstrate improved cancer cell killing efficiency with reduced cytokine levels, leading to sustained therapeutic effects and prolonged survival in cancer patients.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided herein are recombinant nucleic acids encoding T cell receptor (TCR) fusion proteins (TFPs) and interleukin-15 (IL-15) polypeptides and / or interleukin-15 receptor alpha (IL-15Rα) polypeptides, engineered T cells expressing the encoded molecules, and methods of their use for the treatment of diseases, including cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 129,829, filed December 23, 2020, U.S. Provisional Application No. 63 / 225,821, filed July 26, 2021, U.S. Provisional Application No. 63 / 250,329, filed September 30, 2021, and U.S. Provisional Application No. 63 / 257,345, filed October 19, 2021, each of which is incorporated by reference in its entirety into this specification. [Background technology]

[0002]

[0002] Most patients with advanced solid tumors are incurable by standard treatments. In addition, conventional treatment options often have severe side effects. Numerous attempts have been made to induce the patient's immune system to reject cancer cells, a method collectively called cancer immunotherapy. However, several obstacles make it quite difficult to achieve clinical efficacy. Hundreds of so-called tumor antigens have been identified, but these are often of autologous origin, which may direct cancer immunotherapy against healthy tissues, or are poorly immunogenic. Furthermore, cancer cells use multiple mechanisms to either make themselves invisible or resist the initiation and propagation of immune attacks by cancer immunotherapy.

[0003]

[0003] Human T cell therapy utilizes enriched or engineered human T cells to target and kill cancer cells in patients. To enhance the ability of T cells to target and kill specific cancer cells, methods have been developed to engineer T cells to express constructs that direct T cells to specific target cancer cells. Chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) that contain binding domains that can interact with specific tumor antigens enable T cells to target and kill cancer cells that express specific tumor antigens.

[0004]

[0004] Successful treatment of patients with engineered T cells may require that genetically modified T cells expressing a CAR or engineered TCR, in addition to being capable of recognizing and destroying the respective target cells in vitro / ex vivo, be capable of robust activation, proliferation, persistence over time, effective tumor targeting, and, in the case of recurrent disease, a "memory" response. Summary of the Invention

[0005]

[0005] There is a clear need to improve engineered T cells to have broad activity against a variety of human malignancies and to extend the survival of engineered T cells to generate durable responses in cancer patients.

[0006]

[0006] Described herein are recombinant nucleic acids that express fusion proteins of TCR subunits, including CD3ε, CD3γ, CD3δ, TCRγ, TCRδ, TCRα, and TCRβ chains, with binding domains specific for cell surface antigens, potentially overcoming limitations of existing approaches. The nucleic acid molecules described above can express IL-15 or a fragment thereof, or a second protein comprising IL-15-Rα or a fragment thereof. In some embodiments, the IL-15-Rα fusion protein described above comprises the extracellular domain of PD-1 fused to the intracellular domain of CD28, and the C-terminus of the intracellular domain of CD28 is fused to the intracellular domain of IL-15-Rα. The recombinant nucleic acids described above can be expressed in T cells. Advantageously, these IL-15 and / or IL-15-Rα proteins, when expressed in combination with the TCR fusion proteins described above, can confer improved persistence, prolonged activity, and improved efficacy to T cells for treating malignancies described herein. The modified T cells may have the ability to kill target cells more efficiently than CARs, but release similar or lower levels of inflammatory cytokines than CARs, which may represent an advantage of the modified T cells compared to CARs, since elevated cytokine levels are associated with dose-limiting toxicity of adoptive CAR-T therapy.

[0007]

[0007] Provided herein are modified T cells comprising a T cell receptor (TCR) fusion protein (TFP) and an IL-15 or IL-15Rα polypeptide, methods for making the modified T cells, and methods for using them to treat disease.

[0008]

[0008] In some aspects, provided herein is a recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a T cell receptor (TCR) fusion protein (TFP), the TFP comprising a TCR subunit comprising at least a portion of the TCR extracellular domain and the TCR transmembrane domain, and an antigen binding domain, wherein the TCR subunit and the antigen binding domain are operably linked, and a second nucleic acid sequence encoding an interleukin-15 (IL-15) polypeptide or a fragment thereof.

[0009] In some embodiments, the TFP further comprises a TCR intracellular signaling domain. In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are operably linked by a first linker. In some embodiments, the first linker comprises a protease cleavage site. In some embodiments, the protease cleavage site is a 2A cleavage site.

[0010] In some embodiments, the IL-15 polypeptide is secreted upon expression in T cells. In some embodiments, the IL-15 polypeptide comprises the sequence of SEQ ID NO: 375. In some embodiments, the second nucleic acid sequence further encodes an IL-15 receptor (IL-15R) subunit or a fragment thereof. In some embodiments, the IL-15R subunit is IL-15Rα (IL-15Rα). In some embodiments, the IL-15 and IL-15Rα are operably linked by a second linker. In some embodiments, the second linker is not a cleavable linker. In some embodiments, the second linker is a (G 4 S) n(wherein G is glycine, S is serine, and n is an integer from 1 to 10). In some embodiments, n is an integer from 1 to 4. In some embodiments, n is 3. In some embodiments, the second linker comprises the sequence of SEQ ID NO: 378. In some embodiments, the second linker comprises the sequence of SEQ ID NO: 405.

[0011] In some embodiments, the second nucleic acid sequence encodes a fusion protein comprising an IL-15 polypeptide linked to an IL-15Rα subunit. In some embodiments, the IL-15 polypeptide is linked to the N-terminus of the IL-15Rα subunit. In some embodiments, the fusion protein comprises amino acids 30-162 of IL-15. In some embodiments, the fusion protein comprises amino acids 31-267 of IL-15Rα. In some embodiments, the fusion protein further comprises a sushi domain. In some embodiments, the fusion protein comprises the sequence of SEQ ID NO:389.

[0012] In some embodiments, the fusion protein is expressed on the cell surface when expressed in a T cell, hi some embodiments, the fusion protein is secreted when expressed in a T cell.

[0013] In some embodiments, the recombinant nucleic acid molecule further comprises a third nucleic acid sequence encoding a PD-1 polypeptide operably linked via its C-terminus to the N-terminus of the intracellular domain of the costimulatory polypeptide. In some embodiments, the recombinant nucleic acid molecule further comprises a third nucleic acid sequence encoding an anti-PD-1 antibody, or an antigen-binding fragment thereof, operably linked via its C-terminus to the N-terminus of the intracellular domain of the costimulatory polypeptide. In some embodiments, the PD-1 polypeptide or anti-PD-1 antibody is linked to the intracellular domain of the costimulatory polypeptide via the transmembrane domain of PD-1. In some embodiments, the costimulatory polypeptide is selected from the group consisting of OX40, CD2, CD27, CDS, ICAM-1, ICOS (CD278), 4-1BB (CD137), GITR, CD28, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, CD226, FcγRI, FcγRII, and FcγRIII.

[0014]

[0014] In some embodiments, the recombinant nucleic acid molecule comprises the sequence of SEQ ID NO:377, SEQ ID NO:380, or SEQ ID NO:381.

[0015]

[0015] In some aspects, provided herein is a recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a T cell receptor (TCR) fusion protein (TFP), the TFP comprising a TCR subunit comprising at least a portion of the TCR extracellular domain and the TCR transmembrane domain, and an antigen binding domain, wherein the TCR subunit and the antigen binding domain are operably linked, and a second nucleic acid sequence encoding an interleukin-15 receptor alpha (IL-15Rα) polypeptide or a fragment thereof.

[0016] In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are operably linked by a first linker. In some embodiments, the first linker comprises a protease cleavage site. In some embodiments, the protease cleavage site is a 2A cleavage site.

[0017] In some embodiments, the second nucleic acid sequence further encodes PD-1 or a fragment thereof. In some embodiments, the second nucleic acid sequence encodes the extracellular domain of PD-1. In some embodiments, the second nucleic acid sequence encodes the extracellular domain and transmembrane domain of PD-1. In some embodiments, the second nucleic acid sequence further encodes CD28 or a fragment thereof. In some embodiments, the second nucleic acid sequence encodes the intracellular domain of CD28. In some embodiments, the second nucleic acid sequence encodes a fusion protein comprising the PD-1 extracellular domain and transmembrane domain linked to a CD28 intracellular domain linked to IL-15Rα. In some embodiments, the CD28 intracellular domain is linked to the intracellular domain of IL-15Rα. In some embodiments, the second nucleic acid sequence comprises the sequence of SEQ ID NO: 390.

[0018] In some embodiments, the recombinant nucleic acid molecule further comprises a third nucleic acid sequence encoding an interleukin-15 (IL-15) polypeptide or a fragment thereof. In some embodiments, the IL-15 polypeptide or a fragment thereof is secreted upon expression in T cells.

[0019]

[0019] In some embodiments, the recombinant nucleic acid molecule comprises the sequence of SEQ ID NO:361, SEQ ID NO:376, SEQ ID NO:377, or SEQ ID NO:381.

[0020] In some embodiments, the TFP, when expressed in a T cell, functionally interacts with the endogenous TCR complex. In some embodiments, the TCR intracellular domain comprises a stimulatory domain from the intracellular signaling domain of CD3γ, CD3δ, or CD3ε. In some embodiments, the TCR intracellular domain comprises an intracellular domain from TCRα, TCRβ, TCRγ, or TCRδ. In some embodiments, the antigen binding domain is linked to the TCR extracellular domain by a third linker sequence. In some embodiments, the third linker is 120 amino acids or less in length. In some embodiments, the third linker sequence is a sequence similar to (G 4 S) n where G is glycine, S is serine, and n is an integer from 1 to 10. In some embodiments, n is an integer from 1 to 4.

[0021] In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from the same TCR subunit. In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from TCR alpha. In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from TCR beta. In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from TCR gamma. In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from TCR delta. In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from CD3 epsilon. In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from CD3 delta. In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from CD3γ.

[0022]

[0022] In some embodiments, all three of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from the same TCR subunit. In some embodiments, the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from CD3ε. In some embodiments, the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from CD3δ. In some embodiments, the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from CD3γ. In some embodiments, the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain comprise or consist of a constant domain of TCRα. In some embodiments, the constant domain of TCRα is murine. In some embodiments, the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain comprise or consist of a constant domain of TCRβ. In some embodiments, the constant domain of TCRβ is murine. In some embodiments, the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain comprise or consist of the constant domain of TCR gamma. In some embodiments, the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain comprise or consist of the constant domain of TCR delta.

[0023] In some embodiments, the antigen binding domain is a camelid antibody or binding fragment thereof. In some embodiments, the antigen binding domain is a murine antibody or binding fragment thereof. In some embodiments, the antigen binding domain is a human antibody or a humanized antibody or binding fragment thereof. In some embodiments, the antigen binding domain is a single chain variable fragment (scFv) domain or a single domain antibody (sdAb) domain. In some embodiments, the antigen binding domain is a single domain antibody (sdAb). In some embodiments, an sdAb is a V HHIn some embodiments, the antigen binding domain is selected from the group consisting of an anti-CD19 binding domain, an anti-B cell maturation antigen (BCMA) binding domain, an anti-mesothelin (MSLN) binding domain, an anti-CD20 binding domain, an anti-CD70 binding domain, an anti-MUC16 binding domain, an anti-nectin-4 binding domain, an anti-GPC3 binding domain, and an anti-TROP-2 binding domain.

[0024]

[0024] In some embodiments, T cells expressing TFP suppress tumor growth when expressed in T cells. In some embodiments, the recombinant nucleic acid molecule described herein further comprises a leader sequence. In some embodiments, the recombinant nucleic acid molecule is selected from the group consisting of DNA and RNA. In some embodiments, the recombinant nucleic acid molecule is mRNA. In some embodiments, the recombinant nucleic acid molecule is circRNA. In some embodiments, the recombinant nucleic acid molecule comprises nucleotide analogs. In some embodiments, the nucleotide analog is selected from the group consisting of 2'-O-methyl, 2'-O-methoxyethyl (2'-O-MOE), 2'-O-aminopropyl, 2'-deoxy, 2'-deoxy-2'-fluoro, 2'-O-aminopropyl (2'-O-AP), 2'-O-dimethylaminoethyl (2'-O-DMAOE), 2'-O-dimethylaminopropyl (2'-O-DMAP), 2-O-dimethylaminoethyloxyethyl (2'-O-DMAEOE), 2'-ON-methylacetamide (2'-O-NMA) modifications, locked recombinant nucleic acid molecules (LNA), ethylene recombinant nucleic acid molecules (ENA), peptide recombinant nucleic acid molecules (PNA), 1',5'-anhydrohexitol recombinant nucleic acid molecules (HNA), morpholino, methylphosphonate nucleotides, thiolphosphonate nucleotides, and 2'-fluoro N3-P5'-phosphoramidites. In some embodiments, the recombinant nucleic acid molecule described herein further comprises a promoter. In some embodiments, the recombinant nucleic acid molecule is an in vitro transcribed nucleic acid. In some embodiments, the recombinant nucleic acid molecule further comprises a sequence encoding a poly(A) tail. In some embodiments, the recombinant nucleic acid molecule further comprises a 3'UTR sequence.

[0025]

[0025] In some aspects, provided herein is a polypeptide encoded by a recombinant nucleic acid molecule disclosed herein. In some aspects, provided herein is a vector comprising a recombinant nucleic acid molecule disclosed herein. In some aspects, provided herein is a cell comprising a recombinant nucleic acid molecule disclosed herein, a polypeptide disclosed herein, or a vector disclosed herein. In some embodiments, the cell is a T cell. In some embodiments, the T cell is a human T cell. In some embodiments, the T cell is a CD8 + T cells or CD4 + In some embodiments, the cell is a T cell. In some embodiments, the T cell is a human αβ T cell. In some embodiments, the T cell is a human γδ T cell. In some embodiments, the cell is a human NKT cell. In some embodiments, the cell is an allogeneic cell or an autologous cell.

[0026]

[0026] In some aspects, provided herein is a recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a T cell receptor (TCR) fusion protein (TFP), the TFP comprising a TCR subunit comprising at least a portion of the TCR extracellular domain and the TCR transmembrane domain, and an antigen binding domain, wherein the TCR subunit and the antigen binding domain are operably linked, and a second nucleic acid sequence encoding an interleukin-15 (IL-15) polypeptide or a fragment thereof.

[0027] In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are comprised in a single nucleic acid molecule. In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are comprised in two separate nucleic acid molecules. In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are operably linked by a first linker. In some embodiments, the first linker comprises a protease cleavage site. In some embodiments, the protease cleavage site is a 2A cleavage site.

[0028] In some embodiments, the TFP further comprises a TCR intracellular signaling domain. In some embodiments, the IL-15 polypeptide is secreted upon expression in a T cell. In some embodiments, the IL-15 polypeptide comprises the sequence of SEQ ID NO: 375. In some embodiments, the second nucleic acid sequence further encodes an IL-15 receptor (IL-15R) subunit or a fragment thereof. In some embodiments, the IL-15R subunit is IL-15Rα (IL-15Rα). In some embodiments, the IL-15 and IL-15Rα are operably linked by a second linker. In some embodiments, the second linker is not a cleavable linker. In some embodiments, the second linker is a (G 4 S) n (wherein G is glycine, S is serine, and n is an integer from 1 to 10). In some embodiments, n is an integer from 1 to 4. In some embodiments, n is 3. In some embodiments, the second linker comprises the sequence of SEQ ID NO: 378. In some embodiments, the second linker comprises the sequence of SEQ ID NO: 405.

[0029] In some embodiments, the second nucleic acid sequence encodes a fusion protein comprising an IL-15 polypeptide linked to an IL-15Rα subunit. In some embodiments, the IL-15 polypeptide is linked to the N-terminus of the IL-15Rα subunit. In some embodiments, the fusion protein comprises amino acids 30-162 of IL-15. In some embodiments, the fusion protein comprises amino acids 31-267 of IL-15Rα. In some embodiments, the fusion protein further comprises a sushi domain. In some embodiments, the fusion protein comprises the sequence of SEQ ID NO:389.

[0030] In some embodiments, the fusion protein is expressed on the cell surface when expressed in T cells, hi some embodiments, the fusion protein is secreted when expressed in T cells.

[0031] In some embodiments, the cell further comprises a third nucleic acid sequence encoding a PD-1 polypeptide operably linked via its C-terminus to the N-terminus of the intracellular domain of the costimulatory polypeptide. In some embodiments, the cell further comprises a third nucleic acid sequence encoding an anti-PD-1 antibody, or an antigen-binding fragment thereof, operably linked via its C-terminus to the N-terminus of the intracellular domain of the costimulatory polypeptide. In some embodiments, the third nucleic acid sequence is comprised in the same nucleic acid molecule as the first and second nucleic acid sequences.

[0032] In some embodiments, the PD-1 polypeptide or anti-PD-1 antibody is linked to the intracellular domain of a costimulatory polypeptide via the transmembrane domain of PD-1. In some embodiments, the costimulatory polypeptide is selected from the group including OX40, CD2, CD27, CDS, ICAM-1, ICOS (CD278), 4-1BB (CD137), GITR, CD28, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, CD226, FcγRI, FcγRII, and FcγRIII.

[0033]

[0033] In some aspects, provided herein is a cell comprising a first nucleic acid sequence encoding a T cell receptor (TCR) fusion protein (TFP), the TFP comprising a TCR subunit comprising at least a portion of the TCR extracellular domain and the TCR transmembrane domain, and an antigen binding domain, wherein the TCR subunit and the antigen binding domain are operably linked, and a second nucleic acid sequence encoding an interleukin-15 receptor alpha (IL-15Rα) polypeptide or a fragment thereof.

[0034] In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are comprised in a single nucleic acid molecule. In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are comprised in two separate nucleic acid molecules. In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are operably linked by a first linker. In some embodiments, the first linker comprises a protease cleavage site. In some embodiments, the protease cleavage site is a 2A cleavage site.

[0035] In some embodiments, the second nucleic acid sequence further encodes PD-1 or a fragment thereof. In some embodiments, the second nucleic acid sequence encodes the extracellular domain of PD-1. In some embodiments, the second nucleic acid sequence encodes the extracellular domain and transmembrane domain of PD-1. In some embodiments, the second nucleic acid sequence further encodes CD28 or a fragment thereof. In some embodiments, the second nucleic acid sequence encodes the intracellular domain of CD28. In some embodiments, the second nucleic acid sequence encodes a fusion protein comprising the PD-1 extracellular domain and transmembrane domain linked to a CD28 intracellular domain linked to IL-15Rα. In some embodiments, the CD28 intracellular domain is linked to the intracellular domain of IL-15Rα. In some embodiments, the second nucleic acid sequence comprises the sequence of SEQ ID NO: 390.

[0036] In some embodiments, the cell further comprises a third nucleic acid sequence encoding an interleukin-15 (IL-15) polypeptide or a fragment thereof. In some embodiments, the IL-15 polypeptide or a fragment thereof is secreted upon expression in the T cell.

[0037] In some embodiments, the cells secrete IL-15 polypeptides in response to a T cell activator. In some embodiments, IL-15 signaling is increased in response to a T cell activator. In some embodiments, the T cell activator comprises an anti-CD3 antibody or fragment thereof, an anti-CD28 antibody or fragment thereof, a cytokine, an antigen that binds to the antigen binding domain of TFP, or any combination thereof. In some embodiments, the cells have improved viability compared to cells that do not express an IL-15 or IL-15Rα polypeptide. In some embodiments, the cells have improved effector function compared to cells that do not express an IL-15 or IL-15Rα polypeptide. In some embodiments, the cells have improved cytotoxicity compared to cells that do not express an IL-15 or IL-15Rα polypeptide.

[0038] In some embodiments, the TFP, when expressed in a T cell, functionally interacts with the endogenous TCR complex. In some embodiments, the TCR intracellular domain comprises a stimulatory domain from the intracellular signaling domain of CD3γ, CD3δ, or CD3ε. In some embodiments, the TCR intracellular domain comprises an intracellular domain from TCRα, TCRβ, TCRγ, or TCRδ. In some embodiments, the antigen binding domain is linked to the TCR extracellular domain by a third linker sequence. In some embodiments, the third linker is 120 amino acids or less in length. In some embodiments, the third linker sequence is a sequence similar to (G 4 S) n where G is glycine, S is serine, and n is an integer from 1 to 10. In some embodiments, n is an integer from 1 to 4.

[0039] In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from the same TCR subunit. In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from TCR alpha. In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from TCR beta. In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from TCR gamma. In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from TCR delta. In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from CD3 epsilon. In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from CD3 delta. In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from CD3γ.

[0040]

[0040] In some embodiments, all three of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from the same TCR subunit. In some embodiments, the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from CD3ε. In some embodiments, the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from CD3δ. In some embodiments, the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from CD3γ. In some embodiments, the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain comprise or consist of a constant domain of TCRα. In some embodiments, the constant domain of TCRα is murine. In some embodiments, the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain comprise or consist of a constant domain of TCRβ. In some embodiments, the constant domain of TCRβ is murine. In some embodiments, the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain comprise or consist of the constant domain of TCR gamma. In some embodiments, the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain comprise or consist of the constant domain of TCR delta.

[0041] In some embodiments, the antigen binding domain is a camelid antibody or binding fragment thereof. In some embodiments, the antigen binding domain is a murine antibody or binding fragment thereof. In some embodiments, the antigen binding domain is a human antibody or a humanized antibody or binding fragment thereof. In some embodiments, the antigen binding domain is a single chain variable fragment (scFv) domain or a single domain antibody (sdAb) domain. In some embodiments, the antigen binding domain is a single domain antibody (sdAb). In some embodiments, an sdAb is a V HHIn some embodiments, the antigen binding domain is selected from the group consisting of an anti-CD19 binding domain, an anti-B cell maturation antigen (BCMA) binding domain, an anti-mesothelin (MSLN) binding domain, an anti-CD20 binding domain, an anti-CD70 binding domain, an anti-MUC16 binding domain, an anti-nectin-4 binding domain, an anti-GPC3 binding domain, and an anti-TROP-2 binding domain.

[0042] In some embodiments, the survival time of the cell is increased compared to a cell that does not contain (i) a nucleic acid sequence encoding an interleukin-15 (IL-15) polypeptide or a fragment thereof, or (ii) a nucleic acid sequence encoding an interleukin-15 receptor alpha (IL-15Rα) polypeptide or a fragment thereof. In some embodiments, the persistence of the cell is increased compared to a cell that does not contain (i) a nucleic acid sequence encoding an interleukin-15 (IL-15) polypeptide or a fragment thereof, or (ii) a nucleic acid sequence encoding an interleukin-15 receptor alpha (IL-15Rα) polypeptide or a fragment thereof. In some embodiments, the cytotoxicity of the cell is increased compared to a cell that does not contain (i) a nucleic acid sequence encoding an interleukin-15 (IL-15) polypeptide or a fragment thereof, or (ii) a nucleic acid sequence encoding an interleukin-15 receptor alpha (IL-15Rα) polypeptide or a fragment thereof. In some embodiments, the cells have increased cytokine production compared to a cell that does not contain (i) a nucleic acid sequence encoding an interleukin-15 (IL-15) polypeptide or fragment thereof, or (ii) a nucleic acid sequence encoding an interleukin-15 receptor alpha (IL-15Rα) polypeptide or fragment thereof. In some embodiments, the cells retain a naive and / or central memory phenotype. In some embodiments, the cells do not differentiate into terminal effector cells.

[0043] In some embodiments, proliferation of the cells is increased compared to a cell that does not contain (i) a nucleic acid sequence encoding an interleukin-15 (IL-15) polypeptide or fragment thereof, or (ii) a nucleic acid sequence encoding an interleukin-15 receptor alpha (IL-15Rα) polypeptide or fragment thereof. In some embodiments, proliferation of the cells is increased by at least about 5%. In some embodiments, IL-15 is operably linked to IL-15Rα.

[0044] In some embodiments, expression of a cellular exhaustion marker is reduced compared to a cell that does not contain (i) a nucleic acid sequence encoding an interleukin-15 (IL-15) polypeptide or fragment thereof, or (ii) a nucleic acid sequence encoding an interleukin-15 receptor alpha (IL-15Rα) polypeptide or fragment thereof. In some embodiments, IL-15 is operably linked to IL-15Rα. In some embodiments, expression of a cellular exhaustion marker is reduced by at least about 5%. In some embodiments, the exhaustion marker is PD-1, TIM-3, or LAG-3.

[0045] In some embodiments, tumor infiltration of the cell is increased compared to a cell that does not contain (i) a nucleic acid sequence encoding an interleukin-15 (IL-15) polypeptide or fragment thereof, or (ii) a nucleic acid sequence encoding an interleukin-15 receptor alpha (IL-15Rα) polypeptide or fragment thereof. In some embodiments, IL-15 is operably linked to IL-15Rα. In some embodiments, tumor infiltration of the cell is increased by at least about two-fold.

[0046] In some embodiments, the expression of TCF-1 in the cell is increased compared to a cell that does not contain (i) a nucleic acid sequence encoding an interleukin-15 (IL-15) polypeptide or a fragment thereof, or (ii) a nucleic acid sequence encoding an interleukin-15 receptor alpha (IL-15Rα) polypeptide or a fragment thereof. In some embodiments, IL-15 is operably linked to IL-15Rα. In some embodiments, the expression of TCF-1 in the cell is increased by at least about 5%.

[0047] In some aspects, provided herein is a cell population comprising the cells disclosed herein. In some embodiments, the cell population has an increased proportion of cells having a central memory phenotype compared to a cell population that does not contain (i) a nucleic acid sequence encoding an interleukin-15 (IL-15) polypeptide or a fragment thereof, or (ii) a nucleic acid sequence encoding an interleukin-15 receptor alpha (IL-15Rα) polypeptide or a fragment thereof. In some embodiments, the cell population has an increased proportion of cells having a naive phenotype compared to a cell population that does not contain (i) a nucleic acid sequence encoding an interleukin-15 (IL-15) polypeptide or a fragment thereof, or (ii) a nucleic acid sequence encoding an interleukin-15 receptor alpha (IL-15Rα) polypeptide or a fragment thereof. In some embodiments, the cell population has a decreased proportion of cells having an end effector phenotype compared to a cell population that does not contain (i) a nucleic acid sequence encoding an interleukin-15 (IL-15) polypeptide or a fragment thereof, or (ii) a nucleic acid sequence encoding an interleukin-15 receptor alpha (IL-15Rα) polypeptide or a fragment thereof. In some embodiments, the cell population is enriched for the proportion of cells that express TCF-1.

[0048] In some aspects, provided herein is a method of increasing the activity or persistence of a cell expressing a recombinant nucleic acid molecule comprising a sequence encoding a T cell receptor (TCR) fusion protein (TFP), comprising expressing an interleukin 15 (IL-15) polypeptide or a fragment thereof in the cell, the TFP comprising a TCR subunit comprising at least a portion of the TCR extracellular domain and the TCR transmembrane domain, and an antigen binding domain, wherein the TCR subunit and the antigen binding domain are operably linked. In some embodiments, the cell is any one of the cells disclosed herein.

[0049] In some aspects, provided herein is a method of increasing the activity or persistence of a cell expressing a recombinant nucleic acid molecule comprising a sequence encoding a T cell receptor (TCR) fusion protein (TFP), comprising expressing an interleukin-15 receptor alpha (IL-15Rα) polypeptide or fragment thereof in the cell, the TFP comprising a TCR subunit comprising at least a portion of the TCR extracellular domain and the TCR transmembrane domain, and an antigen binding domain, wherein the TCR subunit and the antigen binding domain are operably linked. In some embodiments, the cell is any one of the cells disclosed herein.

[0050] In some aspects, provided herein is a method of increasing proliferation of a cell expressing a recombinant nucleic acid molecule comprising a sequence encoding a T cell receptor (TCR) fusion protein (TFP), comprising expressing an interleukin 15 (IL-15) polypeptide or fragment thereof in the cell, the TFP comprising (a) a TCR subunit comprising (i) at least a portion of a TCR extracellular domain and (ii) a TCR transmembrane domain, and (b) an antigen binding domain, wherein the TCR subunit and the antigen binding domain are operably linked. In some embodiments, the IL-15 is operably linked to IL-15Rα. In some embodiments, the cell is any one of the cells described herein.

[0051] In some aspects, provided herein is a method of increasing proliferation of a cell expressing a recombinant nucleic acid molecule comprising a sequence encoding a T cell receptor (TCR) fusion protein (TFP), comprising expressing an interleukin-15 receptor alpha (IL-15Rα) polypeptide or fragment thereof in the cell, the TFP comprising (a) a TCR subunit comprising (i) at least a portion of the TCR extracellular domain and (ii) a TCR transmembrane domain, and (b) an antigen binding domain, wherein the TCR subunit and the antigen binding domain are operably linked. In some embodiments, the cell is any one of the cells described herein.

[0052]

[0052] In some aspects, provided herein is a method of increasing persistence or decreasing expression of one or more exhaustion markers in a cell expressing a recombinant nucleic acid molecule comprising a sequence encoding a T cell receptor (TCR) fusion protein (TFP), comprising expressing an interleukin 15 (IL-15) polypeptide or fragment thereof in the cell, the TFP comprising (a) a TCR subunit comprising (i) at least a portion of the TCR extracellular domain and (ii) a TCR transmembrane domain, and (b) an antigen binding domain, wherein the TCR subunit and the antigen binding domain are operably linked. In some embodiments, the IL-15 is operably linked to IL-15Rα. In some embodiments, the cell is any one of the cells described herein.

[0053]

[0053] In some aspects, provided herein is a method of reducing expression of one or more exhaustion markers in a cell expressing a recombinant nucleic acid molecule comprising a sequence encoding a T cell receptor (TCR) fusion protein (TFP), the method comprising expressing an interleukin-15 receptor alpha (IL-15Rα) polypeptide or fragment thereof in the cell, the TFP comprising (a) a TCR subunit comprising (i) at least a portion of the TCR extracellular domain and (ii) a TCR transmembrane domain, and (b) an antigen binding domain, wherein the TCR subunit and the antigen binding domain are operably linked. In some embodiments, the cell is any one of the cells described herein.

[0054] In some embodiments, TCF-1 is detected in a population of cells expressing a recombinant nucleic acid molecule comprising a sequence encoding a T cell receptor (TCR) fusion protein (TFP). + Provided herein is a method of expanding a T cell population, comprising expressing an interleukin 15 (IL-15) polypeptide or fragment thereof in a cell, wherein the TFP comprises (a) a TCR subunit comprising (i) at least a portion of a TCR extracellular domain and (ii) a TCR transmembrane domain, and (b) an antigen binding domain, wherein the TCR subunit and the antigen binding domain are operably linked. In some embodiments, the IL-15 is operably linked to IL-15Rα. In some embodiments, the cell is any one of the cells described herein.

[0055] In some embodiments, TCF-1 is detected in a population of cells expressing a recombinant nucleic acid molecule comprising a sequence encoding a T cell receptor (TCR) fusion protein (TFP). +Provided herein is a method of expanding a T cell population, comprising expressing an interleukin-15 receptor alpha (IL-15Rα) polypeptide or a fragment thereof in a cell, wherein the TFP comprises (a) a TCR subunit comprising (i) at least a portion of a TCR extracellular domain and (ii) a TCR transmembrane domain, and (b) an antigen binding domain, wherein the TCR subunit and the antigen binding domain are operably linked. In some embodiments, the cell is any one of the cells described herein.

[0056]

[0056] In some aspects, provided herein is a method of increasing tumor invasion of a cell expressing a recombinant nucleic acid molecule comprising a sequence encoding a T cell receptor (TCR) fusion protein (TFP), comprising expressing an interleukin 15 (IL-15) polypeptide or fragment thereof in the cell, the TFP comprising (a) a TCR subunit comprising (i) at least a portion of a TCR extracellular domain and (ii) a TCR transmembrane domain, and (b) an antigen binding domain, wherein the TCR subunit and the antigen binding domain are operably linked. In some embodiments, the cell is any one of the cells described herein. In some embodiments, the IL-15 is operably linked to IL-15Rα.

[0057] In some aspects, provided herein is a method of increasing tumor invasion of a cell expressing a recombinant nucleic acid molecule comprising a sequence encoding a T cell receptor (TCR) fusion protein (TFP), comprising expressing an interleukin-15 receptor alpha (IL-15Rα) polypeptide or fragment thereof in the cell, the TFP comprising (a) a TCR subunit comprising (i) at least a portion of the TCR extracellular domain and (ii) a TCR transmembrane domain, and (b) an antigen binding domain, wherein the TCR subunit and the antigen binding domain are operably linked. In some embodiments, the cell is any one of the cells described herein.

[0058] In some aspects, provided herein is a pharmaceutical composition comprising a cell(s) disclosed herein and a pharma- ceutically acceptable carrier.In some aspects, provided herein is a method of treating a disease or condition in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition disclosed herein.

[0059]

[0059] In some embodiments, the disease or condition is cancer or a disease or condition associated with expression of CD19, B-cell maturation antigen (BCMA), mesothelin (MSLN), CD20, CD70, MUC16, Trop-2, Nectin-4, or GPC3. In some embodiments, the cancer is a hematological cancer selected from the group consisting of B-cell acute lymphocytic leukemia (B-ALL), T-cell acute lymphocytic leukemia (T-ALL), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), B-cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell follicular lymphoma, large cell follicular lymphoma, malignant lymphoproliferative disorders, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplasia, myelodysplastic syndromes, non-Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom's macroglobulinemia, and preleukemia. In some embodiments, the subject is a human.

[0060] Incorporation by Reference

[0060] All publications, patents, and patent applications mentioned in this specification are incorporated by reference into this specification to the same extent as if each individual publication, patent, or patent application was specifically and individually incorporated by reference into this specification. [Brief description of the drawings]

[0061] [Figure 1]

[0061] A schematic diagram of the construct described in Example 1 is shown. [Diagram 2]

[0062] 1 is a series of graphs showing the proliferation of T cells harboring the indicated TFP constructs generated according to the methods described in Example 2. [Diagram 3]

[0063] 1 is a series of plots generated according to the methods described in Example 2 and showing the percentage of T cells harboring the indicated TFP constructs that have cell surface expression of IL-15-Rα, PD-1, and VHHs after 10 days of expansion. [Figure 4]

[0064] 1 is a series of plots showing the memory phenotype of T cells harboring the indicated TFP constructs after 10 days of expansion generated according to the methods described in Example 2. [Diagram 5]

[0065] FIG. 1 is a schematic diagram of the experiment described in Example 3. [Figure 6A]

[0066] 1 is a series of graphs showing the results of a CSFE assay of T cells carrying TFP constructs as depicted in the assay described in Example 3. FIG. 1 shows a 7 day in vitro persistence assay. [Figure 6B] 1 is a series of graphs showing the results of a CSFE assay of T cells carrying TFP constructs as depicted in the assay described in Example 3. FIG. 1 shows a 7 day in vitro persistence assay. [Figure 6C] 1 is a series of graphs showing the results of a CSFE assay of T cells carrying TFP constructs as depicted in the assay described in Example 3. FIG. 1 shows a 21 day in vitro persistence assay. [Figure 7A]

[0067] 1 is a series of graphs showing proliferation of T cells bearing the TFP constructs shown in the assay described in Example 3. FIG. 1 shows proliferation of unstimulated T cells. [Figure 7B] 1 is a series of graphs showing proliferation of T cells bearing TFP constructs as indicated in the assay described in Example 3. FIG. 1 shows proliferation of T cells with suboptimal TCR stimulation. [Figure 7C]1 is a series of graphs showing proliferation of T cells bearing the TFP constructs shown in the assay described in Example 3. Shown is proliferation of T cells at day 21 under various conditions (e.g., no stimulation, suboptimal CD3 / 28 transactivation, or optimal CD3 / 28 dynabeads). [Figure 8]

[0068] FIG. 1 is a schematic diagram of the experiment described in Example 4. [Figure 9]

[0069] 1 is a series of graphs showing the proliferation of T cells harboring TFP constructs as shown in the assay described in Example 4. [Figure 10]

[0070] 1 is a series of graphs showing the results of a CSFE assay of T cells bearing the indicated TFP constructs at day 7 of the assay described in Example 4. [Figure 11A]

[0071] 1 is a series of graphs showing the number of VHH+ T cells harboring the indicated TFP constructs at day 7, 14, and 21 of the assay described in Example 4. [Figure 11B] 1 is a series of graphs showing the number of CD3+ T cells bearing the indicated TFP constructs at day 7, 14, and 21 of the assay described in Example 4. [Figure 12]

[0072] FIG. 1 is a series of graphs showing the number of VHH+ T cells harboring the indicated TFP constructs at day 7, 14, and 21 of the assay described in Example 4 compared to the number of VHH+ T cells expressing only MSLN TFP. [Figure 13A]

[0073] 1 is a series of graphs showing the memory phenotype of T cells bearing the indicated TFP constructs at day 7 of the assay described in Example 4. Memory phenotype at day 7 is shown. [Figure 13B] 1 is a series of graphs showing the memory phenotype of T cells bearing the indicated TFP constructs at day 21 of the assay described in Example 4. Memory phenotype at day 21 is shown. [Figure 14A]

[0074] 1 is a series of graphs showing target lysis by T cells bearing the indicated TFP constructs at day 8, 15, and 22 time points of the assay described in Example 4. [Figure 14B] 1 is a series of graphs showing target lysis by T cells bearing the indicated TFP constructs at day 8, 15, and 22 time points of the assay described in Example 4. [Figure 15]

[0075] 1 is a series of graphs showing cytokine secretion by T cells harboring the indicated TFP constructs at day 3 of the assay described in Example 4. [Figure 16]

[0076] 1 is a series of graphs showing the in vivo efficacy of T cells bearing the indicated TFP constructs in reducing tumor volume in a mouse xenograft model described in Example 5. [Figure 17]

[0077] Schematic diagram of the construct described in Example 8. [Figure 18]

[0078] 1 is a series of graphs showing T cell proliferation, transduction efficiency, and memory phenotype after transduction with TRuC constructs. A shows T cell proliferation. B shows representative co-expression of CD70 TRuC and mbIL-15fu proteins. C shows a transduction summary of three donors. D shows the CD4+ / CD8+ ratio of normal transduced T cells (TRuC+). [Figure 19]

[0079] 1 is a series of graphs showing the T cell differentiation phenotype of transduced cells. A shows the characterization of T cell differentiation phenotype by flow cytometry in a representative donor. B shows the proportion of each T cell differentiation phenotype in TRuC+ / CD4+ cells. C shows the proportion of each T cell differentiation phenotype in TRuC+ / CD8+ cells. [Figure 20]

[0080] 1 is a series of graphs showing cytotoxicity and cytokine production in a co-culture assay using TRuC- T cells. A shows cytotoxicity against CD70 high target cells 786-O at 24 hours. B shows cytokine production against CD70 high target cells 786-O at 24 hours. C shows cytotoxicity against CD70 medium target cells ACHN at 24 hours. D shows cytokine production against CD70 medium target cells ACHN at 24 hours. E shows cytotoxicity against CD70- target cells K562 at 24 hours. [Figure 21]

[0081] 1 is a series of graphs showing the results of a series of persistence and proliferation assays. A shows T cell persistence in the absence of stimulation. B shows T cell proliferation after a single stimulation with CD70 high target cells 786-O. C shows T cell proliferation after repeated stimulation with CD70 high target cells 786-O. [Figure 22A]

[0082] 1 is a series of graphs showing the results of in vivo efficacy studies in mouse tumor models, showing anti-tumor activity of T cells as measured by BLI. [Figure 22B] 1 is a series of graphs showing the results of an in vivo efficacy study in a mouse tumor model, showing tumor volume measured by caliper. [Figure 22C] 1 is a series of graphs showing the results of in vivo efficacy studies in mouse tumor models, including flow cytometry data for T cell accumulation in tumor and blood samples from representative mice. [Figure 22D] 1 is a series of graphs showing the results of an in vivo efficacy study in a mouse tumor model, depicting the percentage of human CD45+ cells in the tumor. [Figure 22E] 1 is a series of graphs showing the results of an in vivo efficacy study in a mouse tumor model, depicting the percentage of human CD45+ cells in the blood. [Figure 22F] 1 is a series of graphs showing the results of an in vivo efficacy study in a mouse tumor model, showing the number of human CD45+ cells per tumor. [Figure 22G]1 is a series of graphs showing the results of an in vivo efficacy study in a mouse tumor model, showing the number of human CD45+ cells per μL of blood. [Fig. 22H] 1 is a series of graphs showing the results of an in vivo efficacy study in a mouse tumor model, showing the CD4+ / CD8+ ratio in TRuC+ cells in the tumor. [Figure 22I] 1 is a series of graphs showing the results of an in vivo efficacy study in a mouse tumor model, showing the CD4+ / CD8+ ratio in TRuC+ cells in blood. [Figure 22J] 1 is a series of graphs showing the results of an in vivo efficacy study in a mouse tumor model, showing the CD4+ / CD8+ ratio in the first infusion of TRuC+ cells. [Figure 23]

[0083] 1 is a series of graphs showing the results of an in vivo efficacy study in a mouse tumor model. A shows the tumor volume measured by caliper. B shows the percentage of human CD45+ cells in the tumor. C shows the percentage of human CD45+ cells in the blood. D shows the number of human CD45+ cells per tumor. E shows the number of human CD45+ cells per μL of blood. F shows the CD4+ / CD8+ ratio in TRuC+ cells in the tumor. G shows the CD4+ / CD8+ ratio in TRuC+ cells in the blood. H shows the CD4+ / CD8+ ratio in TRuC+ cells at the first infusion. [Figure 24]

[0084] A: Quantitative graph of T cell proliferation of T cells transduced with various TFP and / or IL-15 constructs. B: Quantitative graph of CD4 / CD8 ratio of T cells transduced with various TFP and / or IL-15 constructs. C: Quantitative graph of transduction efficiency (round 1) of T cells transduced with various TFP and / or IL-15 constructs. D: Quantitative graph of transduction efficiency (round 2) of T cells transduced with various TFP and / or IL-15 constructs. [Diagram 25]

[0085] Surface expression of the indicated constructs on transduced T cells as determined by flow cytometry is shown. [Figure 26]

[0086] Surface expression of the indicated constructs on transduced T cells as determined by flow cytometry is shown. [Figure 27]

[0087] Quantification of the differentiation status (A, Temra, B, naive, C, Tcm, D, Tem) of CD4+ and CD8+ T cells transduced with the indicated constructs 10 days after expansion. E shows a slight decrease in the Temra phenotype in transduced T cells expressing IL-15. F shows a slight increase in the Tcm phenotype in transduced T cells expressing IL-15. [Figure 28]

[0088] AC show quantification of IL-15 production by transduced T cells across three donors (A, B, and C are from different donors). The dotted line indicates the detection limit of the assay. [Figure 29]

[0089] (A) shows the results of a cytotoxicity assay when transduced T cells were co-cultured with MSTO-MSLN cells, and (B) shows the results of a cytotoxicity assay when transduced T cells were co-cultured with MSTO-MSLN-PDL1 cells. [Diagram 30]

[0090] A shows the results of a cytokine response assay in MSTO-MSLN cells as measured by IFNγ. B shows the results of a cytokine response assay in MSTO-MSLN-PDL1 cells as measured by IFNγ. C shows the results of a cytokine response assay in MSTO-MSLN cells as measured by IL-2. D shows the results of a cytokine response assay in MSTO-MSLN-PDL1 cells as measured by IL-2. [Diagram 31]

[0091] A shows quantification of the number of cells determined by CD45+ by FAC in repeated stimulation assays performed with transduced T cells and MSTO-MSLN cells. B shows quantification of the number of cells determined by VHH+ by FAC in repeated stimulation assays performed with transduced T cells and MSTO-MSLN cells. C shows quantification of the number of cells determined by CD45+ by FAC in repeated stimulation assays performed with transduced T cells and MSTO-MSLN-PDL1 cells. D shows quantification of the number of cells determined by VHH+ by FAC in repeated stimulation assays performed with transduced T cells and MSTO-MSLN-PDL1 cells. [Diagram 32]

[0092] Cytokine release data from repeated stimulation assays are shown. [Diagram 33]

[0093] Differentiation status of transduced T cells from repeated stimulation assays is shown. Flow cytometry plots are representative images from day 4. [Diagram 34]

[0094] A shows PD1 expression from a repeated stimulation assay performed on MSTO-MSLN cells. B shows PD1 expression from a repeated stimulation assay performed on MSTO-MSLN-PDL1 cells. [Diagram 35]

[0095] Data from an antigen-independent proliferation (persistence) assay are shown. A shows cell counts over time. B shows cell counts on the last day of the experiment (day 10). [Diagram 36]

[0096] Data from an antigen-independent proliferation (persistence) assay are shown. A shows the percentage of VHH+ cells in culture over time. B shows the percentage of VHH+ cells in culture on the last day of the experiment (day 10). [Figure 37]

[0097] Quantification of the memory phenotype of transduced T cells from antigen-independent proliferation (persistence) assays. [Figure 38]

[0098] 1 shows data from an antigen-independent proliferation assay using PDL1-Fc to coat the bottom of the assay plate. A shows cell counts over time. B shows cell counts on day 10. [Figure 39]

[0099] A shows cell count data from antigen-independent proliferation assays upon addition of exogenous cytokine IL-2.B shows cell number data from antigen-independent proliferation assays upon addition of exogenous cytokine IL-15. [Diagram 40]

[0100] A and B show data from an antigen-independent proliferation assay with the addition of exogenous cytokine IL-2, while C and D show data from an antigen-independent proliferation assay with the addition of exogenous cytokine IL-15. [Diagram 41]

[0101] FIG. 1 shows a schematic and associated data presenting a hypothesis regarding the decreased proliferation of T cells co-expressing IL-15 in the presence of exogenous cytokines in an antigen-independent proliferation assay. [Diagram 42]

[0102] Flow cytometry plots of CD122 surface expression from transduced T cells at day 4 of an antigen-independent proliferation assay are shown. [Diagram 43]

[0103] Quantification of tumor volume over time in an in vivo efficacy study. [Diagram 44]

[0104] Quantification of tumor volume over time in an in vivo efficacy study, split by treatment, is shown. [Diagram 45]

[0105] Data from an in vivo efficacy study at 65 days and after rechallenge (at 65 days) are shown. [Figure 46]

[0106] Quantitation of tumor volume over time after rechallenge (day 65), split by treatment, is shown. [Figure 47]

[0107] Quantification of TCF7 across experimental conditions for transduced T cells derived from a single donor. [Figure 48]

[0108] Quantification of TCF7 across experimental conditions for transduced T cells derived from a second donor is shown. [Figure 49]

[0109] Flow cytometry plots of CD8+ TCF7 (TCF-1) vs. T-bet across experimental conditions for transduced T cells derived from a single donor are shown. [Figure 50]

[0110] Flow cytometry plots of CD8+ TCF7 (TCF-1) vs. T-bet across experimental conditions for transduced T cells from a second donor are shown. [Figure 51]

[0111] Flow cytometry plots of CD8- TCF7 (TCF-1) vs. T-bet across experimental conditions for transduced T cells derived from a single donor are shown. [Figure 52]

[0112] Flow cytometry plots of CD8+ TCF7 (TCF-1) vs. T-bet across experimental conditions for transduced T cells from a second donor are shown. [Figure 53]

[0113] Flow cytometry plots of CD8+ TCF7 (TCF-1) versus Granzyme B across experimental conditions for transduced T cells derived from a single donor. [Figure 54]

[0114] Flow cytometry plots of CD8+ TCF7 (TCF-1) versus Granzyme B across experimental conditions for transduced T cells from a second donor are shown. [Figure 55]

[0115] Flow cytometry plots of CD8- TCF7 (TCF-1) versus Granzyme B across experimental conditions for transduced T cells derived from a single donor are shown. [Figure 56]

[0116] Flow cytometry plots of CD8- TCF7 (TCF-1) versus Granzyme B across experimental conditions for transduced T cells from a second donor are shown. [Figure 57]

[0117] Data from an in vivo efficacy study are shown: Tumors harvested from mice treated with transduced T cells were assessed for CD45 expression and cell counts. [Figure 58]

[0118] Figure 1 shows data from an in vivo efficacy study. Flow cytometry plots showing surface expression of VHHs in tumor tissue from mice treated with transduced T cells are shown. [Figure 59]

[0119] 1 shows data from an in vivo efficacy study evaluating Ki67 expression in tumor tissue as a measure of transduced T cell proliferation. [Figure 60]

[0120] 1 shows data from an in vivo efficacy study evaluating Ki67 expression in tumor tissue as a measure of CD8+ or CD4+ transduced T cell proliferation. [Figure 61]

[0121] Shown is data from an in vivo efficacy study in which CD4+ and CD8+ cell populations were measured and quantified by flow cytometry and plotted as ratios in histograms. [Figure 62]

[0122] Flow cytometry plots of inhibitory marker (PD-1 and LAG-3) expression in tumor tissues from mice treated with transduced T cells are shown. [Figure 63]

[0123] Flow cytometry plots of inhibitory marker (PD-1 and TIGIT) expression in tumor tissues from mice treated with transduced T cells are shown. [Fig. 64A]

[0124] 1 shows in vitro data of transduced T cells, showing T cell proliferation over 10 days. [Fig. 64B] Figure 1 shows in vitro data of transduced T cells.Flow cytometry plots measuring surface expression of TC-210 and IL15Ra on transduced T cells. [Fig. 64C]Figure 1 shows in vitro data of transduced T cells.Flow cytometry plots assessing memory phenotype by measuring surface expression of CD45Ra and CCR7 on transduced T cells. [Fig.64D] Figure 1 shows in vitro data of transduced T cells. Quantification of memory phenotype in CD4+ or CD8+ transduced T cells. [Figure 65A]

[0125] 1 shows data collected from in vitro studies of transduced T cells, showing cytotoxicity and cytokine production after 24 hours of co-culture with MSTO-MSLN cells. [Figure 65B] 1 shows data collected from in vitro studies of transduced T cells. Flow cytometry plots of surface expression of CD27 and TCF-1 after a 96 hour activation assay are shown. [Figure 65C] 1 shows data collected from in vitro studies of transduced T cells. Flow cytometry plots of TCF-1 and Granzyme B surface expression after a 96 hour activation assay are shown. [Figure 66]

[0126] 1 shows the results of a persistence assay of transduced T cells grown under culture conditions without cytokines or supplemented with cytokines (IL-2 or IL-15). [Figure 67]

[0127] 1 shows the results of a repeated stimulation assay using transduced T cells. [Figure 68]

[0128] 1 shows data from an in vivo efficacy study of transduced T cells. [Figure 69]

[0129] 1 shows data from tumor and blood samples taken during in vivo efficacy studies of transduced T cells. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0062]

[0130] In some embodiments, disclosed herein is a recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a T cell receptor (TCR) fusion protein (TFP), the TFP comprising (a) a TCR subunit comprising (i) at least a portion of a TCR extracellular domain and (ii) a TCR transmembrane domain, and (b) an antigen binding domain, wherein the TCR subunit and the antigen binding domain are operably linked, and a second nucleic acid sequence encoding an interleukin-15 (IL-15) polypeptide or a fragment thereof.

[0063]

[0131] In some embodiments, disclosed herein is a recombinant nucleic acid comprising a first nucleic acid sequence encoding a T cell receptor (TCR) fusion protein (TFP), the TFP comprising (a) a TCR subunit comprising (i) at least a portion of a TCR extracellular domain and (ii) a TCR transmembrane domain, and (b) an antigen binding domain, wherein the TCR subunit and the antigen binding domain are operably linked, and a second nucleic acid sequence encoding an interleukin-15 receptor alpha (IL-15Rα) polypeptide or a fragment thereof.

[0064]

[0132] In some embodiments, disclosed herein is a cell comprising: a first nucleic acid sequence encoding a T cell receptor (TCR) fusion protein (TFP), the TFP comprising: (a) a TCR subunit comprising (i) at least a portion of a TCR extracellular domain and (ii) a TCR transmembrane domain, and (b) an antigen binding domain, wherein the TCR subunit and the antigen binding domain are operably linked; and a second nucleic acid sequence encoding an interleukin-15 (IL-15) polypeptide or a fragment thereof.

[0065]

[0133] In some embodiments, disclosed herein is a cell comprising: a first nucleic acid sequence encoding a T cell receptor (TCR) fusion protein (TFP), the TFP comprising: (a) a TCR subunit comprising (i) at least a portion of a TCR extracellular domain and (ii) a TCR transmembrane domain, and (b) an antigen binding domain, wherein the TCR subunit and the antigen binding domain are operably linked; and a second nucleic acid sequence encoding an interleukin-15 receptor alpha (IL-15Rα) polypeptide or a fragment thereof.

[0066]

[0134] In some embodiments, disclosed herein is a method of increasing the activity or persistence of a cell expressing a recombinant nucleic acid molecule comprising a sequence encoding a T cell receptor (TCR) fusion protein (TFP), comprising expressing an interleukin-15 (IL-15) polypeptide or a fragment thereof in the cell, wherein the TFP comprises: (a) a TCR subunit comprising (i) at least a portion of the TCR extracellular domain and (ii) a TCR transmembrane domain; and (b) an antigen-binding domain, wherein the TCR subunit and the antigen-binding domain are operably linked.

[0067]

[0135] In some embodiments, disclosed herein is a method of increasing the activity or persistence of a cell expressing a recombinant nucleic acid molecule comprising a sequence encoding a T cell receptor (TCR) fusion protein (TFP), comprising expressing an interleukin-15 receptor alpha (IL-15Rα) polypeptide or a fragment thereof in the cell, wherein the TFP comprises: (a) a TCR subunit comprising (i) at least a portion of the TCR extracellular domain and (ii) a TCR transmembrane domain; and (b) an antigen-binding domain, wherein the TCR subunit and the antigen-binding domain are operably linked.

[0068]

[0136] In some embodiments, disclosed herein is a polypeptide encoded by a recombinant nucleic acid molecule described herein. In some embodiments, disclosed herein is a vector comprising a recombinant nucleic acid molecule described herein. In some embodiments, disclosed herein is a cell comprising a recombinant nucleic acid molecule described herein, a polypeptide described herein, or a vector described herein. In some embodiments, disclosed herein is a cell population comprising a cell described herein. In some embodiments, disclosed herein is a pharmaceutical composition comprising a cell described herein and a pharma- ceutically acceptable carrier. In some embodiments, disclosed herein is a method of treating a disease or condition in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition described herein.

[0069] specific term

[0137] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0138] The articles "a" and "an" refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

[0070]

[0139] As used herein, "about" can mean a decrease or increase of less than 1%, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, or more than 30%, depending on the context and what is known or known to one of ordinary skill in the art.

[0071]

[0140] As used herein, a "subject" (singular or plural) or "individual" can include, but is not limited to, a mammal, such as a human or a non-human mammal, such as a domestic, agricultural or wild animal, as well as birds and aquatic animals. A "patient" is a subject suffering from or at risk of developing a disease, disorder, or condition, or otherwise in need of the compositions and methods provided herein.

[0072]

[0141] As used herein, "treating" or "treatment" refers to any indication of success in treating or ameliorating a disease or condition. Treating may include, for example, reducing, delaying, or alleviating the severity of one or more symptoms of a disease or condition, or reducing the frequency with which a symptom of a disease, disorder, disorder, or adverse condition, etc., appears in a patient. As used herein, "treating or preventing" may be used herein to refer to a method that results in some degree of treatment or amelioration of a disease or condition, and contemplates a range of results for that purpose, including, but not limited to, complete prevention of the condition.

[0073]

[0142] As used herein, "preventing" refers to the prevention of a disease or condition, such as tumor formation, in a patient. For example, if an individual at risk of developing a tumor or other form of cancer is treated with the methods disclosed herein and does not thereafter develop a tumor or other form of cancer, the disease has been prevented in that individual, at least for some period of time.

[0074]

[0143] As used herein, a "therapeutically effective amount" is an amount of a composition or its active ingredients sufficient to provide a beneficial effect or reduce otherwise adverse non-beneficial events to an individual to whom the composition is administered. As used herein, a "therapeutically effective dose" refers to a dose administered to produce one or more desired or desirable (e.g., beneficial) effects, such administration occurring one or more times over a given period of time. The exact dose depends on the purpose of the treatment and can be ascertained by one of ordinary skill in the art using known techniques (see, for example, Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999), and Pickar, Dosage Calculations (1999)).

[0075]

[0144] As used herein, "T cell receptor (TCR) fusion protein" or "TFP" includes recombinant polypeptides derived from various polypeptides that contain a TCR, which generally is capable of i) binding to a surface antigen on a target cell, and ii) interacting with other polypeptide components of the intact TCR complex, typically when co-localized within or on the surface of a T cell. In this disclosure, "TFP" and "TRuC" may be used interchangeably.

[0076]

[0145] The term "stimulation" refers to a primary response induced by a stimulatory domain or molecule (e.g., the TCR / CD3 complex) binding to its cognate ligand and thereby mediating a signaling event, including, but not limited to, signaling through the TCR / CD3 complex. Stimulation can mediate, for example, changes in expression of certain molecules and / or rearrangements of cytoskeletal structure.

[0077]

[0146] The term "stimulatory molecule" or "stimulatory domain" refers to a molecule or portion thereof expressed by a T cell that provides at least some aspects of the T cell's signaling pathway with a primary cytoplasmic signaling sequence(s) that stimulatorily regulates primary activation of the TCR complex. In one embodiment, the primary signal is initiated by, for example, binding of a peptide-loaded MHC molecule to the TCR / CD3 complex, resulting in mediation of a T cell response, including, but not limited to, proliferation, activation, differentiation, and the like. A stimulatory primary cytoplasmic signaling sequence (also referred to as a "primary signaling domain") may contain a signaling motif known as an immunoreceptor tyrosine-based activation motif, or "ITAM." Examples of primary cytoplasmic signaling sequences containing ITAMs that are particularly useful in the present invention include, but are not limited to, those derived from TCR zeta, FcR gamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, CD278 (also referred to as "ICOS"), and CD66d.

[0078]

[0147] The term "antigen-presenting cell" or "APC" refers to immune system cells such as accessory cells (e.g., B cells, dendritic cells, etc.) that present foreign antigens complexed with major histocompatibility complexes (MHC) on their surface. T cells can recognize these complexes using the T cell receptor (TCR). APCs process antigens and present them to T cells.

[0079]

[0148] "A major histocompatibility complex (MHC) molecule is typically bound by the TCR as part of a peptide:MHC complex. The MHC molecule may be an MHC class I or II molecule. The complex may be present on the surface of an antigen-presenting cell, such as a dendritic cell or B cell, or any other cell, including a cancer cell, or may be immobilized, for example by coating on a bead or plate.

[0080]

[0149] Human leukocyte antigen system (HLA) is the name for the gene complex that encodes the human major histocompatibility complex (MHC) and includes the HLA class I antigens (A, B, and C) and the HLA class II antigens (DP, DQ, and DR). HLA alleles A, B, and C present peptides derived primarily from intracellular proteins, e.g., proteins expressed intracellularly.

[0081]

[0150] During T cell development in vivo, T cells undergo a positive selection step that ensures they recognize self-MHC, followed by a negative step that removes T cells that bind too tightly to MHC presenting self antigens. As a result, a given T cell and the TCR it expresses will only recognize peptides presented by a particular type of MHC molecule, i.e., one encoded by a particular HLA allele. This is known as HLA restriction.

[0082]

[0151] One HLA allele of interest is HLA-A, which is expressed in the majority (>50%) of the Caucasian population. * 0201. Therefore, HLA-A * 0201 (i.e., HLA-A * TCRs that bind to WT1 peptides presented by MHC (restricted by 0201) are advantageous because immunotherapy utilizing such TCRs is suitable for treating a large portion of the Caucasian population.

[0083]

[0152] Other HLA-A alleles of interest are HLA-A * 0101, HLA-A * 2402 and HLA-A * It's 0301.

[0153] The broadly expressed HLA-B alleles of interest are HLA-B * 3501, HLA-B * 0702 and HLA-B * The number is 3502.

[0084]

[0154] The term "intracellular signaling domain" as used herein refers to the intracellular portion of a molecule. The intracellular signaling domain generates a signal that promotes immune effector function of a TFP-containing cell, e.g., a modified TT cell. Examples of immune effector function, e.g., in modified TT cells, include cytolytic activity and T helper cell activity, including secretion of cytokines. In an embodiment, the intracellular signaling domain may include a primary intracellular signaling domain. Exemplary primary intracellular signaling domains include those derived from molecules involved in primary or antigen-dependent stimulation. In an embodiment, the intracellular signaling domain may include a costimulatory intracellular domain. Exemplary costimulatory intracellular signaling domains include those derived from molecules involved in costimulatory signals or antigen-independent stimulation.

[0085]

[0155] The primary intracellular signaling domain may comprise an ITAM ("immunoreceptor tyrosine-based activation motif"). Examples of primary cytoplasmic signaling sequences containing ITAMs include, but are not limited to, those derived from CD3zeta, FcRgamma, FcRbeta, CD3gamma, CD3delta, CD3epsilon, CD5, CD22, CD79a, CD79b, and CD66d DAP10 and DAP12.

[0086]

[0156] The term "costimulatory molecule" refers to a cognate binding partner on a T cell that specifically binds to a costimulatory ligand, thereby mediating a costimulatory response, such as, but not limited to, proliferation by the T cell. A costimulatory molecule is a cell surface molecule other than an antigen receptor or its ligand that is required for an efficient immune response. Costimulatory molecules include, but are not limited to, MHC class 1 molecules, BTLA, and Toll ligand receptors, as well as OX40, CD2, CD27, CD28, CDS, ICAM-1, LFA-1 (CD11a / CD18), and 4-1BB (CD137). A costimulatory intracellular signaling domain can be the intracellular portion of a costimulatory molecule. Costimulatory molecules can appear in the following protein families: TNF receptor proteins, immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocyte activation molecules (SLAM proteins), and activating NK cell receptors. Examples of such molecules include ligands that specifically bind to CD27, CD28, 4-1BB (CD137), OX40, GITR, CD30, CD40, ICOS, BAFFR, HVEM, lymphocyte function associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3, and CD83, etc. The intracellular signaling domain can include the entire intracellular portion or entire native intracellular signaling domain of the molecule from which it is derived, or a functional fragment thereof. The term "4-1BB" refers to a member of the TNFR superfamily having the amino acid sequence assigned GenBank Accession No. AAA62478.2, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape, etc., and the "4-1BB costimulatory domain" is defined as amino acid residues 214 to 255 of GenBank Accession No. AAA62478.2, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape, etc.

[0087]

[0157] As used herein, the term "antibody" refers to a protein or polypeptide sequence derived from an immunoglobulin molecule that specifically binds to an antigen. Antibodies may be intact immunoglobulins, or fragments thereof, of polyclonal or monoclonal origin, and may be derived from natural or recombinant sources.

[0088]

[0158] The term "antibody fragment" refers to at least a portion of an antibody, or a recombinant variant thereof, that contains the antigen-binding domain, i.e., the antigen-determining variable region of an intact antibody, sufficient to confer recognition and specific binding of the antibody fragment to a target, e.g., an antigen and its defined epitope. Examples of antibody fragments include Fab, Fab', F(ab') and Fab'. 2 and single domain antibodies (V), such as Fv fragments, single chain (sc) Fv ("scFv") antibody fragments, linear antibodies, and sdAbs. L Or V H Camelidae V HH These include, but are not limited to, multispecific antibodies formed from antibody domains, as well as antibody fragments.

[0089]

[0159] The term "scFv" refers to a fusion protein comprising at least one antibody fragment comprising the variable region of a light chain and at least one antibody fragment comprising the variable region of a heavy chain, wherein the light and heavy chain variable regions are contiguously linked via a short flexible polypeptide linker and can be expressed as a single polypeptide chain, and the scFv retains the specificity of the intact antibody from which it is derived.

[0090]

[0160] The "heavy chain variable region" or "V H " refers to a fragment of a heavy chain containing the three CDRs located between adjacent stretches known as framework regions, which are generally more highly conserved than the CDRs and form a scaffold supporting the CDRs. HH A " domain is a heavy chain that contains a single variable antibody domain.

[0091]

[0161] Unless otherwise specified, as used herein, an scFv can refer to a VFv fragment in any order, e.g., relative to the N-terminus and C-terminus of the polypeptide. L and V H and the scFv may have a variable region of L -Linker-V H or V H -Linker-V L In some embodiments, the linker may comprise SEQ ID NO:401.

[0092]

[0162] The portion of the TFP composition of the present disclosure that includes an antibody or antibody fragment thereof may exist in various forms, with the antigen-binding domain being expressed as part of a continuous polypeptide chain, including, for example, single domain antibody fragments (sdAbs), single chain antibodies (scFvs) derived from mouse, humanized, or human antibodies (Harlow et al., 1999, In:Using Antibodies:A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989, In:Antibodies:A Laboratory Manual, Cold Spring Harbor, NY; Houston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science 242:423-426). In some embodiments, the antigen-binding domain of the TFP composition of the present disclosure includes an antibody fragment. In further embodiments, the TFP includes an antibody fragment that includes an scFv or an sdAb.

[0093]

[0163] The term "recombinant antibody" refers to antibodies made using recombinant DNA techniques, such as antibodies expressed by bacteriophage or yeast expression systems. The term should also be taken to mean antibodies made by synthesis of a DNA molecule encoding the antibody, which DNA molecule expresses an antibody protein or an amino acid sequence that specifies the antibody, which DNA or amino acid sequence is obtained using recombinant DNA or amino acid sequence techniques that are available and well known in the art.

[0094]

[0164] The term "antigen" or "Ag" refers to a molecule capable of being specifically bound by an antibody or otherwise eliciting an immune response that may involve either antibody production, or activation of specific immunologically competent cells, or both.

[0095]

[0165] Those skilled in the art will understand that any macromolecule, including virtually any protein or peptide, can serve as an antigen. Furthermore, antigens can be derived from recombinant or genomic DNA. Thus, those skilled in the art will understand that any DNA that contains a nucleotide sequence or a partial nucleotide sequence that encodes a protein that elicits an immune response will encode an "antigen" as that term is used herein. Furthermore, those skilled in the art will understand that an antigen need not be encoded solely by the full-length nucleotide sequence of a gene. It will be appreciated that the present disclosure includes, but is not limited to, the use of partial nucleotide sequences of multiple genes, which are arranged in various combinations to encode a polypeptide that elicits a desired immune response. Furthermore, those skilled in the art will understand that an antigen need not be encoded by a "gene" at all. It will be appreciated that an antigen may be synthetically produced or may be derived from a biological sample, or may be a macromolecule other than a polypeptide. Such biological samples may include, but are not limited to, tissue samples, tumor samples, cells, or liquids containing other biological components.

[0096]

[0166] As used herein, the term "CD19" refers to the cluster of differentiation 19 protein, an antigenic determinant detectable on B cell leukemia progenitor cells, other malignant B cells, and most cells of the normal B cell lineage.

[0097]

[0167] As used herein, the term "BCMA" refers to B-cell maturation antigen, also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), cluster of differentiation 269 protein (CD269), which in humans is encoded by the TNFRSF17 gene. TNFRSF17 is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF) (see, e.g., Laabi et al., EMBO 11(11):3897-904 (1992)). This receptor is expressed on mature B lymphocytes and may be important in B-cell development and autoimmune responses.

[0098]

[0168] As used herein, the term "CD16" (also known as FcγRIII) refers to a cluster of differentiation molecule found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes, and macrophages. CD16 has been identified as an Fc receptor, FcγRIIIa (CD16a) and FcγRIIIb (CD16b), involved in signal transduction. CD16 is a molecule of the immunoglobulin superfamily (IgSF) involved in antibody-dependent cellular cytotoxicity (ADCC).

[0099]

[0169] As used herein, "NKG2D" refers to a transmembrane protein that belongs to the CD94 / NKG2 family of C-type lectin-like receptors. In humans, NKG2D is involved in the expression of NK cells, γδ T cells, and CD8 + Expressed by αβ T cells, NKG2D recognizes inducible self-proteins of the MIC and RAET1 / ULBP families that appear on the surface of stressed, malignantly transformed, and infected cells.

[0100]

[0170] Mesothelin (MSLN) refers to a tumor differentiation antigen normally present in mesothelial cells lining the pleura, peritoneum, and pericardium. Mesothelin is overexpressed in several human tumors, including mesothelioma, ovarian adenocarcinoma, and pancreatic adenocarcinoma.

[0101]

[0171] The tyrosine protein kinase transmembrane receptor ROR1, also known as neurotrophic tyrosine kinase receptor-related 1 (NTRKR1), is a member of the receptor tyrosine kinase-like orphan receptor (ROR) family, which is involved in cancer metastasis.

[0102]

[0172] The term "MUC16", also known as "mucin 16, cell surface associated" or "ovarian cancer-associated tumor marker CA125", is a membrane-anchored mucin that contains a transmembrane domain with an amino-terminal extracellular domain, a large tandem repeat domain, and a short cytoplasmic domain. The product of this gene has been used as a marker for various cancers, and increased expression levels are associated with poorer outcome.

[0103]

[0173] The term "CD22," also known as sialic acid-binding Ig-like lectin 2, SIGLEC-2, T cell surface antigen leu-14, and B cell receptor CD22, is a protein that mediates B cell / B cell interactions, is believed to be involved in the localization of B cells within lymphoid tissues, and has been linked to diseases including refractory hematological cancers and hairy cell leukemia. A fully human anti-CD22 monoclonal antibody ("M971") suitable for use in the methods disclosed herein is described, for example, in Xiao et al., MAbs. 2009 May-Jun;1(3):297-303.

[0104]

[0174] Programmed cell death protein 1 (also known as "PD-1") and CD279 (cluster of differentiation 279) are cell surface proteins that play a role in controlling the immune system's response to the body's cells by suppressing the inflammatory activity of T cells, thereby downregulating the immune system and promoting self-tolerance. This prevents autoimmune diseases, but may also prevent the immune system from killing cancer cells. PD-1 is an immune checkpoint that prevents autoimmunity through two mechanisms. First, it promotes apoptosis (programmed cell death) of antigen-specific T cells in lymph nodes. Second, it reduces apoptosis of regulatory T cells (anti-inflammatory, suppressive T cells). PD-1 is a cell surface receptor that belongs to the immunoglobulin superfamily and is expressed on T cells and pro-B cells. PD-1 binds to two ligands, PD-L1 and PD-L2.

[0105]

[0175] Programmed death-ligand 1 ("PD-L1") is a 40 kDa type 1 transmembrane protein that is speculated to play a key role in suppressing the adaptive immune system during certain events such as pregnancy, tissue allografts, autoimmune diseases, and other diseases such as hepatitis. Normally, the adaptive immune system responds to antigens that are associated with immune system activation by exogenous or endogenous danger signals. In turn, antigen-specific CD8 + T cells and / or CD4 + Expands the clonal expansion of helper cells. Binding of PD-L1 to the inhibitory checkpoint molecule PD-1 transmits an inhibitory signal based on interaction with phosphatases (SHP-1 or SHP-2) via the immunoreceptor tyrosine-dependent switch motif (ITSM) motif. This reduces the proliferation of antigen-specific T cells in lymph nodes, while simultaneously reducing the apoptosis of regulatory T cells (anti-inflammatory, inhibitory T cells) mediated by downregulation of the gene Bcl-2.

[0106]

[0176] The "CD79α" and "CD79β" genes code for proteins that make up the B lymphocyte antigen receptor, a multimeric complex that contains the antigen-specific component, surface immunoglobulin (Ig). Surface Ig is non-covalently associated with two other proteins, Ig-α and Ig-β (encoded by CD79α and its paralog, CD79β, respectively), that are necessary for the expression and function of the B cell antigen receptor. Functional disruption of this complex can cause, for example, human B cell chronic lymphocytic leukemia.

[0107]

[0177] B-cell activating factor, or "BAFF," is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This cytokine is a ligand for the receptors TNFRSF13B / TACI, TNFRSF17 / BCMA, and TNFRSF13C / BAFF-R. This cytokine is expressed in cells of the B-cell lineage and functions as a potent B-cell activator. It has also been shown to play an important role in B-cell proliferation and differentiation.

[0108]

[0178] The term "Interleukin 15" or "IL-15" refers to a pleiotropic cytokine that plays an important role in the maintenance and homeostatic proliferation of various immune cells. IL-15 plays a key role in the development of the NK lineage, as well as the survival, proliferation, and function of NK cells. Local secretion of pleiotropic cytokines such as IL-15 in the tumor microenvironment (TME) contributes to improved antitumor immunity. IL-15 also plays a role in lymphocyte homeostasis, as lymphocytes are dependent on IL-15 for survival or proliferation. IL-15 also plays multiple roles in the function of peripheral innate and adaptive immune cells. IL-15 is trans-presented by antigen-presenting cells and plays a key role in the induction of central memory T cell subsets and the enhancement of cytolytic effectors. It supports T cell survival by reducing activation-induced cell death (AICD). Human IL-15 precursor protein has two known isoforms based on the signal peptide length. IL-15 (also referred to as IL-15-S48AA, or IL-15LSP for "long signal peptide") has a 48 amino acid signal peptide and propeptide, whereas IL-15-S21AA or IL-15SSP (for "short signal peptide"), which is expressed from an alternatively spliced ​​mRNA, has a 21 amino acid signal peptide and propeptide. IL-15SSP has been shown to be not secreted, but rather stored intracellularly in the cytoplasm.

[0109]

[0179] In some embodiments, the IL-15 signal peptide comprises amino acids 1-29 of the IL-15 protein sequence. In some embodiments, the IL-15 signal peptide comprises the sequence of SEQ ID NO: 374. In some embodiments, the IL-15 comprises amino acids 30-162 of the IL-15 protein sequence. In some embodiments, the IL-15 comprises the sequence of SEQ ID NO: 375.

[0110]

[0180] SEQ ID NO: 385 (IL-15 protein sequence) MRISKPHLRSISIQCYCLLLNSHFLTEAGIHVFILGCFSAGLPKTEANWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTMKCFLLELQVISLESGDASIHDTVENLIILANNSLSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS

[0111]

[0181] The term "interleukin-15 receptor" or "IL-15R" refers to the receptor complex through which IL-15 binds and signals. IL-15R is composed of three subunits: the IL-15 receptor alpha chain ("IL-15Rα" or CD215), the IL-2 receptor beta chain ("IL-2Rβ" or CD122), and the IL-2 receptor gamma / common gamma chain ("IL-2Rγ / γc" or CD132). The human IL-15Rα precursor protein has a 30 amino acid signal peptide, a 175 amino acid extracellular domain, a 23 amino acid single membrane-spanning transmembrane stretch, and a 39 amino acid cytoplasmic (or intracellular) domain, containing N- and O-linked glycosylation sites. IL-15Rα contains a Sushi domain (amino acids 31-95) that is essential for IL-15 binding. IL-15Rα also exists in a soluble form (sIL-15Rα). sIL-15Rα is constitutively generated from the transmembrane receptor through a defined proteolytic cleavage, and this process can be enhanced by certain chemicals such as PMA. Human sIL-15Rα, with a size of approximately 42 kDa, can extend the half-life of IL-15 or enhance IL-15 signaling through IL-15 binding and IL-2Rβ / γc heterodimerization. Although IL-15R shares subunits with IL-2R that contain cytoplasmic motifs required for signaling, IL-15 signaling has distinct biological effects in vivo apart from the many biological activities that overlap with IL-2 signaling. This is due to the IL-15Rα subunit, the availability and concentration of IL-15, and the kinetics and affinity of IL-15-IL-15Rα binding, which are unique to IL-15R. IL-15 binds specifically with high affinity to IL-15Rα and then associates with a complex composed of IL-2Rβ and IL-2Rγ / γc subunits expressed on the same cell ("cis presentation") or on different cells ("trans presentation"). The interaction of IL-15 with IL-15Rα is independent of the complex composed of IL-2Rβ and IL-2Rγ / γc subunits.Binding of IL-15 to the IL-2Rβ / γc heterodimeric receptor induces activation of JAK1, which phosphorylates STAT3 through its β chain, and JAK3, which phosphorylates STAT5 through its γ chain. IL-15 / IL-15R interaction not only regulates T cell development and homeostasis, but also memory CD8. + It also regulates the development, maintenance, proliferation, and activity of T cells and NK cells.

[0112]

[0182] In some embodiments, the cytoplasmic (or intracellular) domain of IL-15Rα comprises amino acids 229-267 of the IL-15Rα protein. In some embodiments, the cytoplasmic (or intracellular) domain of IL-15Rα comprises the sequence of SEQ ID NO: 372. In some embodiments, the Sushi domain of IL-15Rα comprises amino acids 31-95 of the IL-15Rα protein. In some embodiments, the Sushi domain of IL-15Rα comprises the sequence of SEQ ID NO: 382. In some embodiments, IL-15Rα comprises the transmembrane domain and the cytoplasmic (intracellular) domain of the IL-15Rα protein. In some embodiments, IL-15Rα comprises amino acids 96-267 of the IL-15Rα protein. In some embodiments, IL-15Rα comprises the sequence of SEQ ID NO: 383. In some embodiments, sIL-15Rα comprises amino acids 21-205 of the IL-15Rα protein. In some embodiments, sIL-15Rα comprises the sequence of SEQ ID NO: 379. In some embodiments, the IL-15Rα comprises the sequence of SEQ ID NO:403.

[0113]

[0183] SEQ ID NO: 386 (IL-15Rα protein sequence) MAPRRARGCRTLGLPALLLLLLRPPATRGITCPPPMSVEHADIWVKSYSLYSRERYICNSGFKRKAGTSSLTECVLNKATNVAHWTTPSLKCIRDPALVHQRPAPPSTVTTAGVTPQPESLSPSGKEPAASS PSSNNTAATTAAIVPGSQLMPSKSPSTGTTEISSHESSHGTPSQTTAKNWELTASASHQPPGVYPQGHSDTTVAISTSTVLLCGLSAVSLLACYLKSRQTPPLASVEMEAMEALPVTWGTSSRDEDLENCSHHL

[0114]

[0184] The term "anti-tumor effect" refers to a biological effect that may be manifested in a variety of ways, including, but not limited to, a reduction in tumor volume, a reduction in tumor cell number, a reduction in the number of metastases, an increase in life expectancy, a reduction in tumor cell proliferation, a decrease in tumor cell viability, or an improvement in various physiological symptoms associated with a cancer pathology. An "anti-tumor effect" may also be manifested by the ability of the peptides, polynucleotides, cells, and antibodies of the present disclosure to prevent the development of tumors in the first place.

[0115]

[0185] The term "autologous" refers to any material that originates from the same individual and is later reintroduced into that individual.

[0186] The term "allogeneic" or alternatively "similar" refers to any material derived from a different animal or patient of the same species as the individual to whom the material is introduced. Two or more individuals are said to be allogeneic to one another when the genes at one or more loci are not identical. In some embodiments, allogeneic material from individuals of the same species may be sufficiently genetically distinct to interact antigenically.

[0116]

[0187] The term "xenogeneic" refers to a graft derived from an animal of a different species.

[0188] The term "cancer" refers to a disease characterized by the rapid and uncontrollable growth of abnormal cells. Cancer cells may be distributed locally or may spread to other parts of the body via the bloodstream and lymphatic system. Examples of various cancers are described herein, including, but not limited to, breast cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colon cancer, kidney cancer, liver cancer, malignant brain tumors, lymphoma, leukemia, lung cancer, etc.

[0117]

[0189] The term "encode" refers to the inherent property of a particular nucleotide sequence in a polynucleotide, such as a gene, cDNA, or mRNA, to serve as a template for the synthesis of other polymers and macromolecules in biological processes, either with a defined nucleotide sequence (e.g., rRNA, tRNA, and mRNA) or with a defined amino acid sequence and the biological properties attributed thereto. Thus, a gene, cDNA, or RNA encodes a protein if the protein is produced in a cell or other biological system by transcription and translation of the mRNA corresponding to that gene. Both the coding strand, whose nucleotide sequence is identical to the mRNA sequence and is usually depicted in a sequence listing, and the non-coding strand, which is used as a template for transcription of a gene or cDNA, can be referred to as encoding a protein or other product of that gene or cDNA.

[0118]

[0190] Unless otherwise specified, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. Also, a reference to a nucleotide sequence encoding a protein or RNA can include introns to the extent that the nucleotide sequence encoding the protein may, in some versions, contain one or more introns.

[0119]

[0191] The terms "effective amount" or "therapeutically effective amount" are used interchangeably herein and refer to an amount of a compound, formulation, material, or composition described herein that is effective to achieve a particular biological or therapeutic effect.

[0120]

[0192] The term "endogenous" refers to any substance that is derived from or produced within an organism, cell, tissue, or system.

[0193] The term "exogenous" refers to any substance introduced or produced from outside an organism, cell, tissue, or system.

[0194] The term "expression" refers to the transcription and / or translation of a particular nucleotide sequence driven by a promoter.

[0121]

[0195] The term "functional disruption" refers to a physical or biochemical change to a particular (e.g., target) nucleic acid (e.g., a gene, an RNA transcript, and the protein encoded thereby) that prevents normal expression and / or behavior in a cell. In one embodiment, a functional disruption refers to the modification of a gene by gene editing. In one embodiment, a functional disruption prevents expression of a target gene (e.g., an endogenous gene).

[0122]

[0196] The term "transcription vector" refers to a composition that contains an isolated nucleic acid and can be used to deliver the isolated nucleic acid to the inside of a cell. Numerous vectors are known in the art, including, but not limited to, linear polynucleotides, polynucleotides associated with ionic or amphiphilic compounds, plasmids, and viruses. Thus, the term "transcription vector" includes self-replicating plasmids or viruses. This term should also be construed to further include non-plasmid and non-viral compounds that facilitate the transfer of nucleic acid into cells, such as polylysine compounds, liposomes, and the like. Examples of viral transcription vectors include, but are not limited to, adenoviral vectors, adeno-associated viral vectors, retroviral vectors, lentiviral vectors, and the like.

[0123]

[0197] The term "expression vector" refers to a vector that contains a recombinant polynucleotide that includes an expression control sequence operably linked to a nucleotide sequence to be expressed. An expression vector contains sufficient cis-acting elements for expression; other elements for expression can be supplied by the host cell or in an in vitro expression system. Expression vectors include all those known in the art, including cosmids, plasmids (e.g., naked plasmids or contained in liposomes), and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) that incorporate a recombinant polynucleotide.

[0124]

[0198] The term "lentivirus" refers to a genus of the Retroviridae family.Lentivirus is unique among retroviruses in that it can infect non-dividing cells, and can deliver a significant amount of genetic information into the DNA of host cells, making it one of the most efficient methods of gene delivery vectors.HIV, SIV, and FIV are all examples of lentiviruses.

[0125]

[0199] The term "lentiviral vector" refers to a vector derived from at least a portion of the lentiviral genome, including, in particular, the self-inactivating lentiviral vectors described in Milone et al., Mol. Ther. 17(8):1453-1464 (2009). Other examples of lentiviral vectors that can be used clinically include, but are not limited to, Oxford BioMedica's LENTIVECTOR™ gene delivery technology, Lentigen's LENTIMAX™ vector system, and the like. Non-clinical lentiviral vectors are also available and known to those skilled in the art.

[0126]

[0200] The term "homologous" or "identity" refers to the identity of subunit sequences between two polymeric molecules, e.g., between two nucleic acid molecules such as two DNA molecules or two RNA molecules, or between two polypeptide molecules. Two sequences are homologous or identical at a subunit position if the same monomeric subunit occupies that position in both sequences, e.g., adenine occupies each position in two DNA molecules. The homology between two sequences is a direct function of the number of matching or homologous positions, e.g., if half the positions in two sequences (e.g., 5 positions in a polymer 10 subunits long) are homologous, the two sequences are 50% homologous, and if 90% of the positions (e.g., 9 out of 10) are matched or homologous, the two sequences are 90% homologous.

[0127]

[0201] "Humanized" forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (e.g., Fv, Fab, Fab', F(ab')) that have minimal sequence derived from the non-human immunoglobulin. 2, or other antigen-binding subsequences of antibodies). Primarily, humanized antibodies and antibody fragments thereof are human immunoglobulins (recipient antibody or antibody fragment) in which residues from a complementarity determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some cases, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies / antibody fragments may comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. Such modifications can further refine and optimize antibody or antibody fragment performance. In general, a humanized antibody or antibody fragment thereof will comprise substantially all of at least one, and usually two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or a substantial portion of the FR regions are those of a human immunoglobulin sequence. A humanized antibody or antibody fragment can also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature, 321:522-525, 1986; Reichmann et al., Nature, 332:323-329, 1988; Presta, Curr. Op. Struct. Biol., 2:593-596, 1992.

[0128]

[0202] "Human" or "fully human" refers to an immunoglobulin, such as an antibody or antibody fragment, where the entire molecule is of human origin or consists of an amino acid sequence identical to a human form of an antibody or immunoglobulin.

[0129]

[0203] The term "isolated" means altered or removed from the natural state. For example, a nucleic acid or peptide that is naturally present in a living animal is not "isolated," but the same nucleic acid or peptide that is partially or completely separated from the coexisting materials in its natural state is "isolated." An isolated nucleic acid or protein can exist in a substantially purified form, or can exist in a non-native environment, such as, for example, a host cell.

[0130]

[0204] In the context of this disclosure, the following abbreviations are used for commonly occurring nucleobases: "A" refers to adenosine, "C" refers to cytosine, "G" refers to guanosine, "T" refers to thymidine, and "U" refers to uridine.

[0131]

[0205] The term "conservative sequence modifications" refers to amino acid modifications that do not significantly affect or alter the binding characteristics of the antibody or antibody fragment containing the amino acid sequence. Such conservative modifications include amino acid substitutions, additions, and deletions. Modifications can be introduced into the antibodies or antibody fragments of the present disclosure by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are those in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues within the TFPs of the present disclosure can be substituted with other amino acid residues from the same side chain family, and the altered TFPs can be tested using the functional assays described herein.

[0132]

[0206] The term "operably linked" or "transcriptional control" refers to a functional linkage between a regulatory sequence and a heterologous nucleic acid sequence that results in expression of the heterologous nucleic acid sequence. For example, a first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is in a functional relationship with the second nucleic acid sequence. For example, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Functionally linked DNA sequences may be contiguous with each other and, for example, in the same reading frame as required for the joining of two protein coding regions.

[0133]

[0207] The term "parenteral" administration of an immunogenic composition includes, for example, subcutaneous (sc), intravenous (iv), intramuscular (im), or intrasternal injection, intratumor, or infusion techniques.

[0208] The term "nucleic acid" or "polynucleotide" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and polymers thereof in either single- or double-stranded form. Unless otherwise limited, the term encompasses nucleic acids containing known analogs of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise specified, a particular nucleic acid sequence also implicitly encompasses the sequence explicitly stated, as well as conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences. Specifically, degenerate codon substitutions can be obtained by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).

[0134]

[0209] The terms "peptide", "polypeptide" and "protein" are used interchangeably and refer to compounds composed of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and there is no limit to the maximum number of amino acids that may make up a protein or peptide sequence. A polypeptide includes any peptide or protein that contains two or more amino acids linked together by peptide bonds. As used herein, the term refers to both short chains, e.g., also commonly referred to in the art as peptides, oligopeptides, and oligomers, and to longer chains, of which there are many varieties, commonly referred to in the art as proteins. "Polypeptide" specifically includes, e.g., biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, and fusion proteins. A polypeptide includes a natural peptide, a recombinant peptide, or a combination thereof.

[0135]

[0210] The term "promoter" refers to a DNA sequence recognized by the transcriptional machinery of a cell or introduced synthetic machinery required to initiate the specific transcription of a polynucleotide sequence.

[0136]

[0211] The term "promoter / regulatory sequence" refers to a nucleic acid sequence required for expression of a gene product operably linked to the promoter / regulatory sequence. In some cases, this sequence may be the core promoter sequence, and in other cases, this sequence may include enhancer sequences and other regulatory elements required for expression of the gene product. The promoter / regulatory sequence may, for example, be one that directs expression of the gene product in a tissue-specific manner.

[0137]

[0212] The term "constitutive" promoter refers to a nucleotide sequence that, when operably linked to a polynucleotide encoding or specifying a gene product, causes that gene product to be produced in a cell under most or all physiological conditions of the cell.

[0138]

[0213] The term "inducible" promoter refers to a nucleotide sequence that, when operably linked to a polynucleotide encoding or specifying a gene product, causes that gene product to be produced in a cell only when an inducer corresponding to that promoter is present in the cell.

[0139]

[0214] The term "tissue-specific" promoter refers to a nucleotide sequence that, when operably linked to a polynucleotide that encodes or specifies a gene product, causes that gene product to be produced in a cell substantially only if the cell is a cell of the tissue type corresponding to the promoter.

[0140]

[0215] The terms "linker" and "flexible polypeptide linker" as used in the context of scFvs refer to a peptide linker consisting of amino acids such as glycine and / or serine residues used alone or in combination to link the variable heavy and variable light chain regions together. In one embodiment, the flexible polypeptide linker is a Gly / Ser linker and has the amino acid sequence (Gly-Gly-Gly-Ser). n where n is a positive integer equal to or greater than 1. For example, n=1, n=2, n=3, n=4, n=5, n=6, n=7, n=8, n=9, and n=10. In one embodiment, the flexible polypeptide linker comprises (Gly 4 Ser) 4 or (Gly 4 Ser) 3 In another embodiment, the linker includes, but is not limited to, (Gly 2 Ser), (GlySer), or (Gly 3 The scope of the present disclosure also includes linkers described in WO2012 / 138475, which is incorporated herein by reference. In some cases, the linker sequence may be 4 S) n (wherein n=2 to 5). In some cases, the linker sequence includes (G 4 S) n (wherein n = 1 to 3).

[0141]

[0216] As used herein, the 5' cap (also referred to as RNA cap, RNA 7-methylguanosine cap, or RNA m7G cap) is a modified guanine nucleotide that is added to the "head" or 5' end of eukaryotic messenger RNA shortly after transcription initiation. The 5' cap consists of a terminal group linked to the first transcribed nucleotide. Its presence is essential for recognition by ribosomes and protection from RNases. The addition of the cap is coupled to transcription and occurs co-transcriptionally, with each step affecting the other. Shortly after transcription initiation, a cap synthesis complex associated with RNA polymerase binds to the 5' end of the mRNA being synthesized. This enzyme complex catalyzes the chemical reactions required to cap the mRNA. Synthesis proceeds as a multi-step biochemical reaction. The cap moiety can be modified to modulate mRNA functions, such as translation stability or efficiency.

[0142]

[0217] As used herein, "in vitro transcribed RNA" refers to RNA, preferably mRNA, synthesized in vitro. Generally, in vitro transcribed RNA is generated from an in vitro transcription vector. The in vitro transcription vector contains a template used to generate the in vitro transcribed RNA.

[0143]

[0218] As used herein, "poly(A)" is a series of adenosines attached to an mRNA by polyadenylation. In preferred embodiments of constructs for transient expression, the polyA is 50-5000, preferably more than 64, more preferably more than 100, and most preferably more than 300 or 400. The poly(A) sequence can be modified chemically or enzymatically to modulate mRNA function such as localization, stability, or efficiency of translation.

[0144]

[0219] As used herein, "polyadenylation" refers to the covalent attachment of a polyadenylyl moiety or modified variants thereof to a messenger RNA molecule. In eukaryotes, most messenger RNA (mRNA) molecules are polyadenylated at the 3' end. The 3' poly(A) tail is a long sequence of adenine nucleotides (often hundreds) that is added to pre-mRNA by the action of the enzyme polyadenylate polymerase. In higher eukaryotes, poly(A) tails are added to transcripts that contain a specific sequence, the polyadenylation signal. The poly(A) tail and the proteins bound to it help protect the mRNA from degradation by exonucleases. Polyadenylation is also important for transcription termination, nuclear export of mRNA, and translation. Polyadenylation occurs in the nucleus immediately after transcription of DNA into RNA, but can also occur later in the cytoplasm. After transcription is terminated, the mRNA strand is cleaved by the action of an endonuclease complex associated with RNA polymerase. The cleavage site is usually characterized by the presence of the base sequence AAUAAA near the cleavage site. After the mRNA is cleaved, an adenosine residue is added to the free 3' end of the cleavage site.

[0145]

[0220] As used herein, "transient" refers to expression of a non-integrated transgene for a period of hours, days, or weeks that is shorter than the period of expression of a gene when the gene is integrated into the genome or contained within a stable plasmid replicon in a host cell.

[0146]

[0221] The term "signal transduction pathway" refers to the biochemical relationships between various signal transduction molecules that play a role in the transmission of a signal from one part of a cell to another part of the cell. The expression "cell surface receptor" includes molecules and complexes of molecules that are capable of receiving a signal and transmitting the signal across a cell membrane.

[0147]

[0222] The term "subject" is intended to include organisms in which an immune response can be elicited (eg, mammals, humans).

[0223] The term "substantially purified" cells refers to cells that are essentially free of other cell types. Substantially purified cells also refer to cells that are separated from other cell types with which they are normally associated in their naturally occurring state. In some cases, a population of substantially purified cells refers to a homogenous cell population. In other cases, the term simply refers to cells that have been separated from the cells with which they are naturally associated in their natural state. In some embodiments, the cells are cultured in vitro. In other embodiments, the cells are not cultured in vitro.

[0148]

[0224] As used herein, the term "therapeutic" means treatment. The therapeutic effect is achieved by reducing, suppressing, ameliorating, or eradicating a disease condition.

[0225] As used herein, the term "prophylaxis" means the prevention or protective treatment of a disease or condition.

[0149]

[0226] In the context of the present disclosure, "tumor antigen" or "hyperproliferative disease antigen" or "antigen associated with a hyperproliferative disease" refers to an antigen common to a particular hyperproliferative disease. In certain aspects, the hyperproliferative disease antigens of the present disclosure are derived from cancers including, but not limited to, primary or metastatic melanoma, thymoma, lymphoma, sarcoma, lung cancer, liver cancer, NHL, leukemia, uterine cancer, cervical cancer, bladder cancer, kidney cancer, and adenocarcinomas such as breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, and the like.

[0150]

[0227] The terms "transfected" or "transformed" or "transduced" refer to the process by which exogenous nucleic acid is transferred or introduced into a host cell. A "transfected" or "transformed" or "transduced" cell is one that has been transfected, transformed or transduced with exogenous nucleic acid. This includes the primary subject cell and its progeny.

[0151]

[0228] The term "specifically binds" refers to an antibody, antibody fragment, or specific ligand that recognizes and binds to its cognate binding partner (e.g., CD19) present in a sample, but does not necessarily substantially recognize or bind to other molecules in the sample.

[0152]

[0229] As used herein, the term "meganuclease" refers to an endonuclease that binds to double-stranded DNA, the recognition sequence of which is greater than 12 base pairs. Preferably, the recognition sequence of the meganuclease of the present disclosure is 22 base pairs. Meganucleases may be endonucleases derived from I-Crel, and may also refer to modified variants of I-Crel that are modified, for example, with respect to DNA-binding specificity, DNA-cleavage activity, DNA-binding affinity, or dimerization properties, compared to native I-Crel. Methods for making such modified variants of I-Crel are known in the art (e.g., WO2007 / 047859). Meganucleases as used herein bind to double-stranded DNA as heterodimers or as "single-stranded meganucleases" in which a pair of DNA-binding domains are linked to a single polypeptide using a peptide linker. The term "homing endonuclease" is synonymous with the term "meganuclease". The meganucleases of the present disclosure are substantially non-toxic when expressed in cells, particularly human T cells, such that the cells can be transfected and maintained at 37°C, with no adverse effects on cell viability or significant reduction in meganuclease cleavage activity as measured using the methods described herein.

[0153]

[0230] As used herein, the term "single-chain meganuclease" refers to a polypeptide comprising a pair of nuclease subunits linked by a linker. The structure of a single-chain meganuclease is N-terminal subunit-linker-C-terminal subunit. These two meganuclease subunits generally do not have identical amino acid sequences and recognize non-identical DNA sequences. Thus, single-chain meganucleases usually cleave pseudopalindromic or non-palindromic recognition sequences. Single-chain meganucleases are sometimes referred to as "single-chain heterodimers" or "single-chain heterodimeric meganucleases", even though they are not actually dimers. For clarity, unless otherwise specified, the term "meganuclease" can refer to either dimeric meganucleases or single-chain meganucleases.

[0154]

[0231] As used herein, the term "TALEN" refers to an endonuclease that contains a DNA-binding domain, comprising 16-22 TAL domain repeats fused to any portion of a Fok1 nuclease domain.

[0155]

[0232] As used herein, the term "mini TALEN" refers to an endonuclease that contains a DNA-binding domain with 16-22 TAL domain repeats fused in any orientation to any catalytically active portion of the nuclease domain of the I-Tev1 homing endonuclease.

[0156]

[0233] As used herein, the term "CRISPR" refers to a caspase-based endonuclease that includes a caspase, such as Cas9, and a guide RNA that hybridizes to a recognition site in genomic DNA, thereby directing the caspase to cleave DNA.

[0157]

[0234] As used herein, the term "megaTAL" refers to a single-stranded nuclease comprising a transcription activator-like effector (TALE) DNA-binding domain and an engineered sequence-specific homing endonuclease.

[0158]

[0235] As used herein, the terms "T cell receptor" and "T cell receptor complex" are used interchangeably to refer to a molecule found on the surface of a T cell that is generally involved in antigen recognition. In 95% of T cells, the TCR comprises a heterodimer consisting of a TCRα chain and a TCRβ chain, while 5% of T cells have a TCR consisting of a TCRγ chain and a TCRδ chain. The TCR further comprises one or more of CD3ε, CD3γ, and CD3δ. In some embodiments, the TCR comprises CD3ε. In some embodiments, the TCR comprises CD3γ. In some embodiments, the TCR comprises CD3δ. In some embodiments, the TCR comprises CD3ζ. Engagement of the TCR with an antigen, e.g., antigen and MHC, results in activation of the T cell through a series of biological events mediated by associated enzymes, co-receptors, and specialized co-receptor molecules. In some embodiments, the constant domain of human TCRα has the sequence of SEQ ID NO: 142. In some embodiments, the constant domain of human TCR alpha has an IgC domain having the sequence of SEQ ID NO: 143, a transmembrane domain having the sequence of SEQ ID NO: 144, and an intracellular domain having the sequence of SS. In some embodiments, the constant domain of mouse TCR alpha has a sequence of SEQ ID NO: 147. In some embodiments, the constant domain of mouse TCR alpha has a transmembrane domain having the sequence of SEQ ID NO: 144, and an intracellular domain having the sequence of SS. In some embodiments, the constant domain of human TCR beta has a sequence of SEQ ID NO: 148. In some embodiments, the constant domain of human TCR beta has an IgC domain having the sequence of SEQ ID NO: 149, a transmembrane domain having the sequence of SEQ ID NO: 150, and an intracellular domain having the sequence of SEQ ID NO: 151. In some embodiments, the constant domain of mouse TCR beta has a sequence of SEQ ID NO: 152. In some embodiments, the constant domain of mouse TCR beta has a transmembrane domain having the sequence of SEQ ID NO: 152, and an intracellular domain having the sequence of SEQ ID NO: 153. In some embodiments, the constant domain of human TCR delta has a sequence of SEQ ID NO: 243.In some embodiments the constant domain of human TCR delta has an IgC domain having the sequence of SEQ ID NO: 265, a transmembrane domain having the sequence of SEQ ID NO: 158, and an intracellular domain having the sequence of L. In some embodiments the constant domain of human TCR gamma has the sequence of SEQ ID NO: 21. In some embodiments the constant domain of human TCR gamma has an IgC domain having the sequence of SEQ ID NO: 155, a transmembrane domain having the sequence of SEQ ID NO: 156, and an intracellular domain having the sequence of SEQ ID NO: 157.

[0159]

[0236] In some embodiments, human CD3ε has the sequence of SEQ ID NO: 364. In some embodiments, human CD3ε has an extracellular domain with the sequence of SEQ ID NO: 126, a transmembrane domain with the sequence of SEQ ID NO: 127, and an intracellular domain, e.g., an intracellular signaling domain, with the sequence of SEQ ID NO: 128. In some embodiments, human CD3δ has the sequence of SEQ ID NO: 136. In some embodiments, human CD3δ has an extracellular domain with the sequence of SEQ ID NO: 138, a transmembrane domain with the sequence of SEQ ID NO: 139, and an intracellular domain, e.g., an intracellular signaling domain, with the sequence of SEQ ID NO: 140. In some embodiments, human CD3γ has the sequence of SEQ ID NO: 130. In some embodiments, human CD3γ has an extracellular domain with the sequence of SEQ ID NO: 132, a transmembrane domain with the sequence of SEQ ID NO: 133, and an intracellular domain, e.g., an intracellular signaling domain, with the sequence of SEQ ID NO: 134.

[0160]

[0237] range:Throughout this disclosure, various aspects of the disclosure may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosure. Thus, the description of a range should be considered to have expressly disclosed all possible subranges within that range as well as individual numerical values. For example, the description of a range such as 1-6 should be considered to have expressly disclosed subranges such as 1-3, 1-4, 1-5, 2-4, 2-6, 3-6, as well as individual numbers within that range, such as 1, 2, 2.7, 3, 4, 5, 5.3, and 6. As another example, a range such as 95-99% identity includes those with 95%, 96%, 97%, 98%, or 99% identity, and includes subranges such as 96-99%, 96-98%, 96-97%, 97-99%, 97-98%, and 98-99% identity. This applies regardless of the width of the range.

[0161]

[0238] Provided herein are compositions and methods of use for the treatment of diseases such as cancer using engineered T cells comprising T cell receptor (TCR) fusion proteins (TFPs) in combination with IL-15 and / or IL-15Rα polypeptides. Advantageously, these IL-15 and / or IL-15-Rα proteins, when expressed in combination with TCR fusion proteins, can confer improved persistence, prolonged activity, and improved efficacy to T cells for treating malignancies as described herein. As used herein, "T cell receptor (TCR) fusion proteins" or "TFPs" include recombinant polypeptides derived from various polypeptides that comprise a TCR, which generally are capable of i) binding to surface antigens on target cells, and ii) interacting with other polypeptide components of the intact TCR complex when typically co-located within or on the surface of the T cell. As shown herein, TFPs offer significant advantages over chimeric antigen receptors. The term "chimeric antigen receptor" or alternatively "CAR" refers to a recombinant polypeptide comprising an extracellular antigen-binding domain, for example in the form of a single domain antibody or scFv, a transmembrane domain, and a cytoplasmic signaling domain (also referred to herein as "intracellular signaling domain") that comprises a functional signaling domain derived from a stimulatory molecule as defined below. Generally, the central intracellular signaling domain of a CAR is derived from the CD3ζ chain, which is normally found in association with the TCR complex. This CD3ζ signaling domain can be fused to one or more functional signaling domains derived from at least one co-stimulatory molecule, such as 4-1BB (i.e., CD137), CD27, and / or CD28.

[0162] T cell receptor (TCR) fusion proteins (TFPs)

[0239] The present disclosure encompasses recombinant DNA constructs encoding a TFP, the TFP comprising a binding domain, e.g., an antibody or antibody fragment, a ligand, or a ligand-binding protein, the sequence of the binding domain being adjacent to and in the same reading frame as a nucleic acid sequence encoding a TCR subunit or a portion thereof. The present disclosure encompasses recombinant DNA constructs encoding a TFP, the TFP comprising an antibody fragment that specifically binds to a tumor-associated antigen (TAA), the sequence of the antibody fragment being adjacent to and in the same reading frame as a nucleic acid sequence encoding a TCR subunit or a portion thereof. The present disclosure encompasses recombinant DNA constructs encoding a TFP, the TFP comprising an antibody fragment that specifically binds to CD19, e.g., human CD19, the sequence of the antibody fragment being adjacent to and in the same reading frame as a nucleic acid sequence encoding a TCR subunit or a portion thereof. The disclosure includes a recombinant DNA construct encoding a TFP, the TFP comprising an antibody fragment that specifically binds to mesothelin, e.g., human mesothelin, and the sequence of the antibody fragment is adjacent to and in the same reading frame as a nucleic acid sequence encoding a TCR subunit or portion thereof. The disclosure includes a recombinant DNA construct encoding a TFP, the TFP comprising an antibody fragment that specifically binds to MUC16, e.g., human MUC16, and the sequence of the antibody fragment is adjacent to and in the same reading frame as a nucleic acid sequence encoding a TCR subunit or portion thereof. The disclosure includes a recombinant DNA construct encoding a TFP, the TFP comprising an antibody fragment that specifically binds to CD20, e.g., human CD20, and the sequence of the antibody fragment is adjacent to and in the same reading frame as a nucleic acid sequence encoding a TCR subunit or portion thereof. The present disclosure encompasses recombinant DNA constructs encoding a TFP, the TFP comprising an antibody fragment that specifically binds to CD70, e.g., human CD70, wherein the sequence of the antibody fragment is contiguous with and in the same reading frame as a nucleic acid sequence encoding a TCR subunit or portion thereof.The present disclosure includes a recombinant DNA construct encoding a TFP, the TFP comprising an antibody fragment that specifically binds to CD79B, e.g., human CD79B, and the sequence of the antibody fragment is adjacent to and in the same reading frame as a nucleic acid sequence encoding a TCR subunit or a portion thereof. The present disclosure includes a recombinant DNA construct encoding a TFP, the TFP comprising an antibody fragment that specifically binds to HER2, e.g., human HER2, and the sequence of the antibody fragment is adjacent to and in the same reading frame as a nucleic acid sequence encoding a TCR subunit or a portion thereof. The present disclosure includes a recombinant DNA construct encoding a TFP, the TFP comprising an antibody fragment that specifically binds to PSMA, e.g., human PSMA, and the sequence of the antibody fragment is adjacent to and in the same reading frame as a nucleic acid sequence encoding a TCR subunit or a portion thereof. The present disclosure encompasses recombinant DNA constructs encoding TFP, the TFP comprising an antibody fragment that specifically binds to BCMA, e.g., human BCMA, and the sequence of the antibody fragment is adjacent to and in the same reading frame as a nucleic acid sequence encoding a TCR subunit or portion thereof. The present disclosure encompasses recombinant DNA constructs encoding TFP, the TFP comprising an antibody fragment that specifically binds to ROR1, e.g., human ROR1, and the sequence of the antibody fragment is adjacent to and in the same reading frame as a nucleic acid sequence encoding a TCR subunit or portion thereof. The present disclosure encompasses recombinant DNA constructs encoding TFP, the TFP comprising an antibody fragment that specifically binds to CD22, e.g., human CD22, and the sequence of the antibody fragment is adjacent to and in the same reading frame as a nucleic acid sequence encoding a TCR subunit or portion thereof. The disclosure encompasses recombinant DNA constructs encoding a TFP, the TFP comprising an antibody fragment that specifically binds to GPC3, e.g., human GPC3, wherein the sequence of the antibody fragment is contiguous with and in the same reading frame as a nucleic acid sequence encoding a TCR subunit or portion thereof.The present disclosure encompasses recombinant DNA constructs encoding a TFP, the TFP comprising an antibody fragment that specifically binds to Nectin-4, e.g., human Nectin-4, and the sequence of the antibody fragment is adjacent to and in the same reading frame as a nucleic acid sequence encoding a TCR subunit or portion thereof. The present disclosure encompasses recombinant DNA constructs encoding a TFP, the TFP comprising an antibody fragment that specifically binds to Trop-2, e.g., human Trop-2, and the sequence of the antibody fragment is adjacent to and in the same reading frame as a nucleic acid sequence encoding a TCR subunit or portion thereof. The TFPs provided herein can associate with one or more endogenous (or alternatively, one or more exogenous, or a combination of endogenous and exogenous) TCR subunits to form a functional TCR complex.

[0163]

[0240] In one embodiment, the TFP of the present disclosure comprises a target-specific binding element, otherwise referred to as an antigen-binding domain. The selection of the moiety depends on the type and number of target antigens that define the surface of the target cell. For example, the antigen-binding domain can be selected to recognize a target antigen that acts as a cell surface marker for target cells associated with a particular disease state. Thus, examples of cell surface markers that can act as target antigens for the antigen-binding domain of the TFP of the present disclosure include those associated with viral, bacterial, and parasitic infections, autoimmune diseases, and cancer diseases (e.g., malignant tumor diseases).

[0164]

[0241] In one embodiment, a TFP-mediated T cell response can be directed to an antigen of interest by engineering the antigen-binding domain into a TFP that specifically binds to a desired antigen.

[0242] Antigen binding domains include, but are not limited to, monoclonal antibodies, polyclonal antibodies, recombinant antibodies, human antibodies, humanized antibodies, and heavy chain variable domains (V H ), light chain variable domain (V L ), and the heavy chain variable domain of a camelid-derived nanobody (V HHThe antigen-binding domain may be any domain that binds to an antigen, including but not limited to single domain antibodies such as IgG, IgG1, IgG2, IgG3, IgG4, IgG5, IgG6, IgG7, IgG8, IgG9, IgG10, IgG11, IgG12, IgG13, IgG14, IgG15, IgG16, IgG17, IgG18, IgG19, IgG20, IgG21, IgG22, IgG23, IgG24, IgG25, IgG30, IgG41, IgG42, IgG43, IgG44, IgG45, IgG45, IgG46, IgG47, IgG48, IgG49, IgG41, IgG48, IgG49, IgG41, IgG45, IgG48, IgG49, IgG41, IgG41, IgG41, IgG42, IgG43, IgG44, IgG45, IgG46, IgG47, IgG48, IgG49, IgG41, IgG45, IgG47, IgG48, IgG49, IgG41, IgG41, IgG41, IgG42, IgG43, IgG44, IgG45, IgG45, IgG46, IgG47, IgG48, IgG49, IgG41 ...1, IgG41, IgG41, IgG41, IgG41, IgG41, IgG41, IgG41, IgG41, IgG41,

[0165]

[0243] Thus, in one aspect, the antigen binding domain comprises a murine, humanized, or human antibody or antibody fragment, or a murine antibody or antibody fragment. In one embodiment, the murine, humanized, or human anti-TAA binding domain comprises one or more (e.g., all three) of the light chain complementarity determining region 1 (LC CDR1), light chain complementarity determining region 2 (LC CDR2), and light chain complementarity determining region 3 (LC CDR3) of a murine, humanized, or human anti-TAA binding domain described herein, and / or one or more (e.g., all three) of the heavy chain complementarity determining region 1 (HC CDR1), heavy chain complementarity determining region 2 (HC CDR2), and heavy chain complementarity determining region 3 (HC CDR3) of a murine, humanized, or human anti-CD19 binding domain described herein, e.g., a murine, humanized, or human anti-TAA binding domain comprising one or more, e.g., all three LC CDRs and one or more, e.g., all three HC CDRs. In one embodiment, the murine, humanized, or human anti-CD19 binding domain comprises one or more (e.g., all three) of the heavy chain complementarity determining region 1 (HC CDR1), heavy chain complementarity determining region 2 (HC CDR2), and heavy chain complementarity determining region 3 (HC CDR3) of the murine, humanized, or human anti-TAA binding domain described herein, e.g., the murine, humanized, or human anti-TAA binding domain has two variable heavy chain regions, each comprising the HC CDR1, HC CDR2, and HC CDR3 described herein. In one embodiment, the murine, humanized, or human anti-TAA binding domain comprises a humanized or human light chain variable region described herein and / or a murine, humanized, or human heavy chain variable region described herein. In one embodiment, the murine, humanized, or human anti-TAA binding domain comprises a murine, humanized, or human heavy chain variable region described herein, e.g., at least two murine, humanized, or human heavy chain variable regions described herein. In one embodiment, the anti-TAA binding domain is an scFv comprising a light chain and a heavy chain of the amino acid sequences provided herein.In certain embodiments, the anti-TAA binding domain (e.g., scFv) comprises a light chain variable region comprising an amino acid sequence having at least one, two, or three modifications (e.g., substitutions), but not more than 30, 20, or 10 modifications (e.g., substitutions), of the amino acid sequence of a light chain variable region provided herein, or a sequence having 95-99% identity to an amino acid sequence provided herein, and / or a heavy chain variable region comprising an amino acid sequence having at least one, two, or three modifications (e.g., substitutions), but not more than 30, 20, or 10 modifications (e.g., substitutions), of the amino acid sequence of a heavy chain variable region provided herein, or a sequence having 95-99% identity to an amino acid sequence provided herein. In one embodiment, the murine, humanized, or human anti-TAA binding domain is an scFv, in which a light chain variable region comprising an amino acid sequence described herein is linked via a linker, e.g., a linker described herein, to a heavy chain variable region comprising an amino acid sequence described herein. In one embodiment, the murine, humanized, or human anti-TAA binding domain comprises a light chain variable region comprising an amino acid sequence described herein, but not more than 30, 20, or 10 modifications (e.g., substitutions), but not more than 95, 99% identity to an amino acid sequence provided herein. 4 -Ser) n and a linker, where n is 1, 2, 3, 4, 5, or 6, preferably 3 or 4. The light chain variable region and the heavy chain variable region of the scFv may be arranged, for example, as light chain variable region-linker-heavy chain variable region, or heavy chain variable region-linker-light chain variable region. In some cases, the linker sequence comprises a long linker (LL) sequence. In some cases, the long linker sequence may be arranged as follows: (G 4 S) n (wherein n=2-4). In some cases, the linker sequence comprises a short linker (SL) sequence. In some cases, the short linker sequence comprises a short linker (SL) sequence, such as (G 4 S) n (wherein n = 1 to 3).

[0166]

[0244] In some embodiments, the antigen binding domain comprises an anti-CD19 murine, humanized, or human antibody or antibody fragment, or a murine antibody or antibody fragment, having a light chain CDR1 of SEQ ID NO: 73, a CDR2 of SEQ ID NO: 75, and a CDR3 of SEQ ID NO: 77, and a heavy chain CDR1 of SEQ ID NO: 79, a CDR2 of SEQ ID NO: 81, and a CDR3 of SEQ ID NO: 83. In some embodiments, the anti-CD19 antibody is a murine scFv. In some embodiments, the anti-CD19 antibody comprises a VL of SEQ ID NO: 85 and a VH of SEQ ID NO: 87.

[0167]

[0245] In some embodiments, the antigen binding domain comprises an anti-mesothelin murine, humanized, or human single domain antibody or antibody fragment having a CDR1 of SEQ ID NO: 60, a CDR2 of SEQ ID NO: 61, and a CDR3 of SEQ ID NO: 62, or a CDR1 of SEQ ID NO: 63, a CDR2 of SEQ ID NO: 64, and a CDR3 of SEQ ID NO: 65, or a CDR1 of SEQ ID NO: 66, a CDR2 of SEQ ID NO: 67, and a CDR3 of SEQ ID NO: 68. In some embodiments, the anti-mesothelin antibody has a variable domain of SEQ ID NO: 69, SEQ ID NO: 70, or SEQ ID NO: 71.

[0168]

[0246] In some embodiments, the antigen binding domain comprises CDR1 of SEQ ID NO:88, CDR2 of SEQ ID NO:89, and CDR3 of SEQ ID NO:90, or CDR1 of SEQ ID NO:92, CDR2 of SEQ ID NO:93, and CDR3 of SEQ ID NO:94, or CDR1 of SEQ ID NO:96, CDR2 of SEQ ID NO:97, and CDR3 of SEQ ID NO:98, or CDR1 of SEQ ID NO:100, CDR2 of SEQ ID NO:101, and CDR3 of SEQ ID NO:102, CDR1 of SEQ ID NO:104, CDR2 of SEQ ID NO:105, and CDR3 of SEQ ID NO:106. or CDR1 of SEQ ID NO: 108, CDR2 of SEQ ID NO: 109, and CDR3 of SEQ ID NO: 110, or CDR1 of SEQ ID NO: 112, CDR2 of SEQ ID NO: 113, and CDR3 of SEQ ID NO: 114, or CDR1 of SEQ ID NO: 116, CDR2 of SEQ ID NO: 117, and CDR3 of SEQ ID NO: 118, or CDR1 of SEQ ID NO: 120, CDR2 of SEQ ID NO: 121, and CDR3 of SEQ ID NO: 122.

[0169]

[0247] In some embodiments, the antigen binding domain comprises an anti-CD70 murine, humanized, or human single domain antibody or antibody fragment having CDR1 of SEQ ID NO: 392, CDR2 of SEQ ID NO: 393, CDR3 of SEQ ID NO: 394, or CDR1 of SEQ ID NO: 396, CDR2 of SEQ ID NO: 397, and CDR3 of SEQ ID NO: 398. In some embodiments, the antigen binding domain comprises a CDR sequence selected from the group consisting of SEQ ID NOs: 392-394 and 396-398. In some embodiments, the antigen binding domain comprises SEQ ID NOs: 392-394 and 396-398. In some embodiments, the antigen binding domain comprises an anti-CD70 heavy chain variable domain region comprising SEQ ID NO: 392 as CDR1, SEQ ID NO: 393 as CDR2, and SEQ ID NO: 394 as CDR3. In some embodiments, the antigen binding domain comprises an anti-CD70 light chain variable domain region comprising SEQ ID NO: 396 as CDR1, SEQ ID NO: 397 as CDR2, and SEQ ID NO: 398 as CDR3. In some embodiments, the antigen binding domain comprises an anti-CD70 heavy chain variable domain region comprising SEQ ID NO: 392 as CDR1, SEQ ID NO: 393 as CDR2, and SEQ ID NO: 394 as CDR3, and a light chain variable domain region comprising SEQ ID NO: 396 as CDR1, SEQ ID NO: 397 as CDR2, and SEQ ID NO: 398 as CDR3. In some embodiments, the antigen binding domain comprises SEQ ID NO: 395. In some embodiments, the antigen binding domain comprises SEQ ID NO: 399. In some embodiments, the antigen binding domain comprises SEQ ID NO: 395 and SEQ ID NO: 399. In some embodiments, the antigen binding domain comprises a linker sequence. In some embodiments, the linker sequence of the antigen binding domain comprises SEQ ID NO: 401. In some embodiments, the antigen binding domain comprises SEQ ID NOs: 399, 401, and 395. In some embodiments, the antigen binding domain comprises SEQ ID NOs: 399, 401, and 395, when read in the 5' to 3' direction.

[0170]

[0248] In some embodiments, a non-human antibody is humanized, where certain sequences or regions of the antibody have been modified to increase similarity to antibodies or fragments thereof that are naturally produced in humans, hi one embodiment, the antigen-binding domain is humanized.

[0171]

[0249] Humanized antibodies can be produced using a variety of techniques known in the art, such as CDR grafting (see, e.g., European Patent No. EP 239,400, International Publication No. WO 91 / 09967, and U.S. Pat. Nos. 5,225,539, 5,530,101, and 5,585,089, each of which is incorporated herein by reference in its entirety), veneering or resurfacing (see, e.g., European Patent Nos. EP 592,106 and EP 519,596, Padlan, 1991, Molecular Immunology, 28(4 / 5):489-498; Studnicka et al., 1994, Protein Engineering, 7(6):805-814; and Roguska et al., 1997, Protein Engineering, 7(6):805-814, each of which is incorporated herein by reference in its entirety), and / or other techniques. al., 1994, PNAS, 91:969-973), chain shuffling (see, e.g., U.S. Pat. No. 5,565,332, which is incorporated by reference in its entirety), e.g., U.S. Patent Application Publication No. US2005 / 0042664, U.S. Patent Application Publication No. US2005 / 0048617, U.S. Pat. No. 6,407,213, U.S. Pat. No. 5,766,886, International Publication No. WO9317105, Tan et al., J. Immunol., 169:1119-25 (2002), Caldas et al., Protein Eng., 13(5):353-60 (2000), Morea et al., Methods, 20(3):267-79 (2000), Baca et al., Protein Eng., 13(5):353-60 (2000), Morea et al., Methods, 20(3):267-79 (2000), Baca et al., Protein Eng., 13(5):353-60 (2000), al., J.Biol.Chem.,272(16):10678-84(1997), Roguska et al.,Protein Eng.,9(10):895-904(1996), Couto et al.,Cancer Res.,55(23 Supp):5973s-5977s(1995), Couto et al.,Cancer Res.,55(8):1717-22(1995), Sandhu JS, Gene,150(2):409-10(1994), and Pedersen et al., J.Mol.Biol., 235(3):959-73 (1994). Often, framework residues in the framework regions are replaced with corresponding residues from the CDR donor antibody to alter, e.g., improve, antigen binding. Such framework replacements are identified by methods well known in the art, for example, by modeling the interactions of the CDRs with framework residues to identify framework residues important for antigen binding and sequence comparison to identify unique framework residues at particular positions (see, e.g., Queen et al., U.S. Pat. No. 5,585,089, and Riechmann et al., 1988, Nature, 332:323, which are incorporated herein by reference in their entireties).

[0172]

[0250] A humanized antibody or antibody fragment has one or more amino acid residues remaining from a source that is non-human. These non-human amino acid residues are often referred to as "import" residues, and are usually taken from an "import" variable domain. As provided herein, a humanized antibody or antibody fragment comprises one or more CDRs and framework regions from a non-human immunoglobulin molecule, in which the amino acid residues comprising the framework are derived entirely or mostly from human germline. Many techniques for humanizing antibodies or antibody fragments are known in the art and are described by Winter and coworkers (Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science Humanization can essentially be performed by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody, i.e., CDR grafting, according to the method of Roberts, J. Clin. Sci. 239:1534-1536 (1988) (EP 239,400, PCT Publication No. WO 91 / 09967, and U.S. Pat. Nos. 4,816,567, 6,331,415, 5,225,539, 5,530,101, 5,585,089, and 6,548,640, the contents of which are incorporated herein by reference in their entireties). In such humanized antibodies and antibody fragments, the substitution of corresponding sequences from a non-human species is significantly less than in intact human variable domains. Humanized antibodies are often human antibodies in which some CDR residues and possibly some framework (FR) residues are substituted by residues from analogous sites in rodent antibodies.Humanization of antibodies and antibody fragments can also be achieved by veneering or resurfacing (EP 592,106; EP 519,596; Padlan, 1991, Molecular Immunology, 28(4 / 5):489-498; Studnicka et al., Protein Engineering, 7(6):805-814(1994)); and Roguska et al., Proc. Natl. Acad. Sci. USA, 91:969-973(1994)), and chain shuffling (U.S. Pat. No. 5,565,332), the entire contents of which are incorporated herein by reference.

[0173]

[0251] The choice of human variable domains (both light and heavy chains) used to generate humanized antibodies is to reduce antigenicity. According to the so-called "best fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable domain sequences. The human sequence that is most similar to that of the rodent is then accepted as the human framework (FR) for the humanized antibody (Sims et al., J. Immunol., 151:2296 (1993); Chothia et al., J. Mol. Biol., 196:901 (1987), the entire contents of which are incorporated herein by reference). Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies (see, e.g., Nicholson et al., Mol. Immun. 34(16-17):1157-1165 (1997); Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285 (1992); Presta et al., J. Immunol., 151:2623 (1993), the contents of which are incorporated herein by reference in their entireties). In some embodiments, the framework regions, e.g., all four framework regions of the heavy chain variable region, are H4-4-59 germline sequence. In one embodiment, the framework regions may contain, for example, one, two, three, four, or five modifications, e.g., substitutions, from the amino acids in the corresponding murine sequence. In one embodiment, the framework regions, e.g., all four framework regions of the light chain variable region, are derived from the VK3-1.25 germline sequence. In one embodiment, the framework regions may contain, for example, one, two, three, four, or five modifications, e.g., substitutions, from the amino acids in the corresponding murine sequence.

[0174]

[0252] In some embodiments, some of the TFP compositions of the present disclosure, including antibody fragments, are humanized while retaining high affinity for the target antigen and other favorable biological properties. According to one embodiment of the present disclosure, humanized antibodies and antibody fragments are generated by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are publicly available and are familiar to those skilled in the art. Computer programs are available that illustrate and display probable three-dimensional conformations of selected candidate immunoglobulin sequences. Inspection of these displays allows analysis of the likely role of residues in the functionality of the candidate immunoglobulin sequence, for example, analysis of residues that affect the ability of the candidate immunoglobulin to bind to the target antigen. In this way, FR residues from the recipient and import sequences can be selected and combined to achieve the desired antibody or antibody fragment property, for example, increased affinity for the target antigen. In general, the CDR residues are directly and most significantly involved in influencing antigen binding.

[0175]

[0253] A humanized antibody or antibody fragment can retain similar antigen specificity as the original antibody, e.g., in the present disclosure, the ability to bind to a human tumor-associated antigen (TAA). In some embodiments, a humanized antibody or antibody fragment can have improved affinity and / or specificity of binding, e.g., to human CD19, human BCMA, or another tumor-associated antigen.

[0176]

[0254] In one embodiment, the binding domain is characterized by a particular functional feature or characteristic of an antibody or antibody fragment. For example, in one embodiment, a portion of the TFP composition of the present disclosure that includes an antigen binding domain specifically binds to human CD19. In one embodiment, the antigen binding domain has the same or similar binding specificity for human CD19 as the FMC63 scFv described in Nicholson et al., Mol.Immun.34(16-17):1157-1165 (1997). In one embodiment, the present disclosure relates to an antigen binding domain that includes an antibody or antibody fragment, which specifically binds to a CD19 or BCMA protein or a fragment thereof, and which antibody or antibody fragment includes a variable light chain and / or a variable heavy chain that includes an amino acid sequence provided herein. In certain embodiments, the scFv is adjacent to and in the same reading frame as a leader sequence.

[0177]

[0255] In one embodiment, the anti-tumor associated antigen binding domain is a fragment, such as a single chain variable fragment (scFv). In one embodiment, the anti-TAA binding domain is an Fv, Fab, (Fab') 2 , or a bifunctional (e.g., bispecific) hybrid antibody (e.g., Lanzavecchia et al., Eur. J. Immunol. 17, 105 (1987)). In one embodiment, the antibodies and fragments thereof of the present disclosure bind to the CD19 protein with wild-type or enhanced affinity. In another embodiment, the anti-TAA binding domain is a single domain antibody (sdAb or V HH ).

[0178]

[0256] Also provided herein are methods for obtaining an antibody antigen-binding domain specific for a target antigen (e.g., CD19, BCMA, or any of the target antigens described elsewhere herein for targets of fusion moiety binding domains), which methods comprise the V-binding domains described herein. H The addition, deletion, substitution, or insertion of one or more amino acids in the amino acid sequence of the domain results in a V H Domain amino acid sequence variant V HProviding the domain, if any, so provided H A domain can be one or more V L Combined with the domain, this V H Domain or V H / V L to identify a specific binding member or antibody antigen-binding domain that is specific for a target antigen of interest (e.g., MSLN, CD79B, etc.) and optionally has one or more desired properties.

[0179]

[0257] In some cases, V H Domains and scFvs can be produced according to methods known in the art (see, e.g., Bird et al., (1988) Science 242:423-426 and Huston et al., (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). scFv molecules are H and V L The variable regions can be generated by linking them together using a flexible polypeptide linker. The scFv molecules comprise a linker (e.g., a Ser-Gly linker) that is optimized in length and / or amino acid composition. The length of this linker can greatly affect how the variable regions of the scFv fold and interact. Indeed, when short polypeptide linkers are used (e.g., 5-10 amino acids), intrachain folding is prevented. Also, interchain folding is required to bring the two variable regions together to form a functional epitope binding site. In some cases, the linker sequence comprises one linker sequence. In some cases, a long linker sequence is used (e.g., a Gly linker). 4 S) n (wherein n=2 to 4). In some cases, the linker sequence includes (G 4 S) n(wherein n=1-3). For examples of linker configurations and sizes, see, e.g., Hollinger et al., 1993 Proc Natl Acad.Sci.USA 90:6444-6448, U.S. Patent Application Publication Nos. 2005 / 0100543, 2005 / 0175606, 2007 / 0014794, and PCT Publication Nos. WO2006 / 020258 and WO2007 / 024715, each of which is incorporated herein by reference.

[0180]

[0258] scFv is a V L and V H There may be a linker between the regions of about 10, 11, 12, 13, 14, 15, or more than 15 residues. The linker sequence may comprise any naturally occurring amino acid. In some embodiments, the linker sequence comprises the amino acids glycine and serine. In another embodiment, the linker sequence comprises (Gly 4 Ser) n In one embodiment, the linker comprises repeats of a set of glycines and serines such as (Gly 4 Ser) 4 or (Gly 4 Ser) 3 Variation of the linker length can maintain or enhance activity, resulting in superior efficacy in activity testing. In some cases, the linker sequence can be (G 4 S) n (wherein n=2 to 4). In some cases, the linker sequence includes (G 4 S) n (wherein n=1 to 3). In some embodiments, the linker sequence may comprise SEQ ID NO:401.

[0181] Stability and Mutation

[0259] The stability of a tumor-associated antigen binding domain, such as an scFv molecule (e.g., a soluble scFv), can be assessed relative to the biophysical properties (e.g., thermal stability) of a conventional control scFv molecule or a full-length antibody. In one embodiment, the humanized or human scFv has a thermal stability of about 0.1°C, about 0.25°C, about 0.5°C, about 0.75°C, about 1°C, about 1.25°C, about 1.5°C, about 1.75°C, about 2°C, about 2.5°C, about 3°C, about 3.5°C, about 4°C, about 4.5°C, about 5°C, about 5.5°C, about 6°C, about 6.5°C, about 7°C, about 7.5°C, about 8°C, about 8.5°C, about 9°C, about 9.5°C, about 10°C, about 11°C, about 12°C, about 13°C, about 14°C, or about 15°C higher than the parent scFv in the assays described.

[0182]

[0260] The improved thermal stability of the anti-TAA binding domain, e.g., scFv, is subsequently imparted to the overall TAA-TFP construct, leading to improved therapeutic properties of the anti-TAA TFP construct. The thermal stability of the binding domain, e.g., scFv or sdAb, can be improved by at least about 2°C or 3°C compared to a conventional antibody. In one embodiment, the binding domain has a 1°C improvement in thermal stability compared to a conventional antibody. In another embodiment, the binding domain has a 2°C improvement in thermal stability compared to a conventional antibody. In another embodiment, the scFv has a 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, 10°C, 11°C, 12°C, 13°C, 14°C, or 15°C improvement in thermal stability compared to a conventional antibody. Comparisons can be made, for example, between scFv molecules disclosed herein and the V of the scFv. H and V L The thermal stability can be measured using methods known in the art. For example, in one embodiment, T M It is possible to measure T M Methods for measuring and other methods for determining protein stability are detailed below.

[0183]

[0261] Mutations in the antibody sequence (occurring through humanization of the soluble scFv or through direct mutagenesis) alter the stability of the antibody or fragment thereof and improve the overall stability of the antibody and TFP construct. M Measurements such as temperature denaturation, temperature aggregation, and the like are used to compare the stability of the humanized antibody or fragment thereof to the murine antibody or fragment thereof. In one embodiment, the binding domain, e.g., scFv or sdAb, contains at least one mutation resulting from the humanization process, whereby the mutant scFv confers improved stability to the anti-TAA TFP construct. In another embodiment, the anti-TAA binding domain, e.g., scFv or sdAb, contains at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 mutations resulting from the humanization process, whereby the mutant scFv or sdAb confers improved stability to the TAA-TFP construct.

[0184]

[0262] In one embodiment, the antigen-binding domain of the TFP comprises an amino acid sequence that is homologous to the amino acid sequence of the antigen-binding domain described herein, and the antigen-binding domain retains the desired functional properties of the anti-tumor associated antigen antibody fragment described herein. In a specific embodiment, the TFP composition of the present disclosure comprises an antibody fragment. In a further embodiment, the antibody fragment comprises an scFv.

[0185]

[0263] In various embodiments, the antigen-binding domain of TFP comprises one or both variable regions (e.g., V H and / or V L ), for example, by modifying one or more amino acids within one or more CDR regions and / or one or more framework regions. In a specific embodiment, the TFP composition of the present disclosure comprises an antibody fragment. In a further embodiment, the antibody fragment comprises an scFv.

[0186]

[0264] It is understood by those skilled in the art that the antibodies or antibody fragments of the present disclosure can be further modified to differ (e.g., from wild type) in terms of amino acid sequence, but not in terms of the desired activity. For example, additional nucleotide substitutions can be made to the protein that result in amino acid substitutions at "non-essential" amino acid residues. For example, a non-essential amino acid residue in the molecule can be replaced with another amino acid residue from the same side chain family. In another embodiment, a chain of amino acids can be replaced with a structurally similar chain that differs in the order and / or composition of the side chain family members. For example, conservative substitutions can be made in which an amino acid residue is replaced with an amino acid residue having a similar side chain.

[0187]

[0265] Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

[0188]

[0266] In the context of two or more nucleic acid or polypeptide sequences, percent identity refers to the fact that the two or more sequences are identical. Two sequences are "substantially identical" if they have a specified percentage of amino acid residues or nucleotides that are identical (e.g., 60% identity, optionally 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity over a designated region, or if not specified, over the entire sequence), when compared and aligned for maximum correspondence over a comparison window or designated region, as measured using any of the following sequence comparison algorithms or by manual alignment and visual inspection. Optionally, the identity exists over a region that is at least about 50 nucleotides (or 10 amino acids) in length, or more preferably over a region that is 100-500 or 1000 or more nucleotides (or 20, 50, 200, or more amino acids) in length.

[0189]

[0267] To compare sequences, one sequence is usually used as a reference sequence, and test sequences are compared to the reference sequence. When using sequence comparison algorithms, test and reference sequences are input into a computer, partial coordinates are designated as necessary, and parameters of sequence algorithm programs are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identity of the test sequence to the reference sequence based on the program parameters. Methods of sequence alignment for comparison are well known in the art. Optimal alignment for sequence comparison can be performed, for example, by the local homology algorithm of Smith and Waterman, (1970) Adv. Appl. Math. 2:482c, by the homology alignment algorithm of Needleman and Wunsch, (1970) J. Mol. Biol. 48:443, by the similarity search method of Pearson and Lipman, (1988) Proc. Natl. Acad. Sci. USA 85:2444, by computer implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by manual alignment and visual inspection (see, for example, Brent et al., (2003) Current Protocols in Molecular Biology). Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., (1977) Nuc. Acids Res. 25:3389-3402, and Altschul et al., (1990) J. Mol. Biol. 215:403-410, respectively. Software for performing BLAST analyses is publicly available from the National Center for Biotechnology Information.

[0190]

[0268] In one embodiment, the present disclosure contemplates modifications of the amino acid sequence of a starting antibody or fragment (e.g., scFv) that will generate a functionally equivalent molecule. For example, the binding domain contained in the TFP, e.g., the V of an scFv, H Or V L is the starting V of an anti-CD19 binding domain, e.g., an scFv. H Or V L Modifications can be made to retain at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity of the framework regions. The present disclosure contemplates modification of the entire TFP construct, e.g., modification of the amino acid sequence of one or more of the various domains of the TFP construct to generate functionally equivalent molecules. The TFP construct can be modified to retain at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to the starting TFP construct.

[0191] Extracellular domain

[0269] The extracellular domain may be derived from either natural or recombinant sources. If the source is natural, the domain may be derived from any protein, particularly a domain other than a membrane-bound or transmembrane protein. In one aspect, the extracellular domain may be associated with a transmembrane domain. An extracellular domain specifically used in the present disclosure may include, for example, at least the extracellular region(s) of the α, β, or ζ chain of the T cell receptor, or CD3ε, CD3γ, or CD3δ, or in another embodiment, CD28, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, or CD154. In some embodiments, the extracellular domain is a TCR extracellular domain. In some cases, the TCR extracellular domain comprises the extracellular domain of a protein or a portion thereof selected from the group consisting of a TCR alpha chain, a TCR beta chain, a TCR gamma chain, a TCR delta chain, a CD3 epsilon TCR subunit, a CD3 gamma TCR subunit, a CD3 delta TCR subunit, functional fragments thereof, and amino acid sequences thereof having at least one but not more than 20 modifications.

[0192]

[0270] In some embodiments, the TCR extracellular domain comprises the extracellular domain or a portion thereof of a TCR alpha, beta, delta, or gamma chain, hi some embodiments, the TCR extracellular domain comprises the IgC domain of a TCR alpha, beta, delta, or gamma chain.

[0193]

[0271] In some embodiments, the extracellular domain is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 109, 110, 111, 112, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more consecutive amino acid residues. In some embodiments, the extracellular domain comprises a sequence having at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or more sequence identity to a sequence encoding the extracellular domain of a TCR alpha, beta, delta or gamma chain. In some embodiments, the extracellular domain comprises a sequence encoding the extracellular domain of a TCR alpha, beta, delta or gamma chain having a truncation of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more amino acids at the N-terminus or C-terminus, or at both the N-terminus and C-terminus.

[0194]

[0272] In some embodiments, the extracellular domain is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 109, 110, 111, 112, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 , 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more consecutive amino acid residues. In some embodiments, the extracellular domain comprises a sequence having at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or more sequence identity to a sequence encoding an IgC domain of TCR alpha, TCR beta, TCR delta, or TCR gamma, in some embodiments, the extracellular domain comprises a sequence encoding an IgC domain of TCR alpha, TCR beta, TCR delta, or TCR gamma, with a truncation of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more amino acids at the N-terminus or C-terminus, or at both the N-terminus and C-terminus.

[0195]

[0273] In some embodiments, the extracellular domain is selected from the group consisting of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 102, 104, 105, 106, 107, 108, 109, 109, 109, 102, 103, 104, or at least 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more consecutive amino acid residues. In some embodiments, the extracellular domain comprises a sequence having at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or more sequence identity to a sequence encoding the extracellular domain of a CD3ε, CD3γ, or CD3δ TCR subunit. In some embodiments, the extracellular domain comprises a sequence encoding the extracellular domain of a CD3ε, CD3γ, or CD3δ TCR subunit with a truncation of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more amino acids at the N-terminus or C-terminus, or at both the N-terminus and C-terminus.

[0196]

[0274] The extracellular domain may be a TCR extracellular domain. The TCR extracellular domain may be derived from a TCR alpha chain, a TCR beta chain, a TCR gamma chain, a TCR delta chain, a CD3 epsilon TCR subunit, a CD3 gamma TCR subunit, or a CD3 delta TCR subunit. The extracellular domain may be a full-length TCR extracellular domain or a fragment (e.g., a functional fragment) thereof. The extracellular domain may comprise a variable domain of a TCR alpha chain, a TCR beta chain, a TCR gamma chain, or a TCR delta chain. The extracellular domain may comprise a variable domain and a constant domain of a TCR alpha chain, a TCR beta chain, a TCR gamma chain, or a TCR delta chain. In some cases, the extracellular domain may not comprise a variable domain.

[0197]

[0275] The extracellular domain may comprise a constant domain of a TCR alpha, beta, gamma, or delta chain. The extracellular domain may comprise a full-length constant domain of a TCR alpha, beta, gamma, or delta chain. The extracellular domain may comprise a fragment (e.g., a functional fragment) of a full-length constant domain of a TCR alpha, beta, gamma, or delta chain. For example, the extracellular domain may comprise at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, or more amino acid residues of a constant domain of a TCR alpha, beta, gamma, or delta chain.

[0198]

[0276] The TCR alpha, beta, gamma, or delta chains described herein may be derived from various species. The TCR chains may be murine or human TCR chains. For example, the extracellular domain may comprise the constant domain of a murine TCR alpha, murine TCR beta, human TCR gamma, or human TCR delta chain.

[0199] Transmembrane domain

[0277] Generally, a TFP sequence includes an extracellular domain and a transmembrane domain encoded by a single genomic sequence. In alternative embodiments, a TFP can be engineered to include a transmembrane domain that is heterologous to the extracellular domain of the TFP. A transmembrane domain can include one or more additional amino acids adjacent to the transmembrane region, e.g., one or more amino acids associated with an extracellular region of the protein from which the transmembrane is derived (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more amino acids of the extracellular region), and / or one or more additional amino acids associated with an intracellular region of the protein from which the transmembrane is derived (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more amino acids of the intracellular region). In some cases, the transmembrane domain may comprise at least 30, 35, 40, 45, 50, 55, 60 or more amino acids of the extracellular region. In some cases, the transmembrane domain may comprise at least 30, 35, 40, 45, 50, 55, 60 or more amino acids of the intracellular region. In one embodiment, the transmembrane domain is one that associates with one of the other domains of the TFP used. In some cases, the transmembrane domain can be selected or modified by amino acid substitution to avoid binding of such domains to transmembrane domains of the same or different surface membrane proteins, e.g., to minimize interactions with other members of the receptor complex. In one embodiment, the transmembrane domain is capable of homodimerization with another TFP on the surface of the TFP-T cell. In a different embodiment, the amino acid sequence of the transmembrane domain can be modified or substituted to minimize interactions with binding domains of natural binding partners present on the same TFP.

[0200]

[0278] The transmembrane domain may be derived from either natural or recombinant sources. If the source is natural, the domain may be derived from any membrane-bound or transmembrane protein. In one embodiment, whenever the TFP is bound to the target, the transmembrane domain is capable of signaling to the intracellular domain(s). In some cases, the TCR integral subunit comprises a transmembrane domain comprising a transmembrane domain of a protein selected from the group consisting of TCR alpha chain, TCR beta chain, TCR gamma chain, TCR delta chain, TCR zeta chain, CD3 epsilon TCR subunit, CD3 gamma TCR subunit, CD3 delta TCR subunit, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD28, CD37, CD64, CD80, CD86, CD134, CD137, CD154, functional fragments thereof, and amino acid sequences thereof having at least one but not more than 20 modifications.

[0201]

[0279] In some embodiments the transmembrane domain comprises, or at least comprises, at least about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 or more contiguous amino acid residues of the transmembrane domain of a TCR alpha chain, a TCR beta chain, a TCR gamma chain, a TCR delta chain, a CD3 epsilon TCR subunit, a CD3 gamma TCR subunit, or a CD3 delta TCR subunit. In some embodiments, the transmembrane domain comprises a sequence having at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or more sequence identity to a sequence encoding a transmembrane domain of a TCR alpha chain, a TCR beta chain, a TCR gamma chain, a TCR delta chain, a CD3 epsilon TCR subunit, a CD3 gamma TCR subunit, or a CD3 delta TCR subunit. In some embodiments, the transmembrane domain comprises a sequence encoding a transmembrane domain of a TCR alpha chain, a TCR beta chain, a TCR gamma chain, a TCR delta chain, a CD3 epsilon TCR subunit, a CD3 gamma TCR subunit, or a CD3 delta TCR subunit with a truncation of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more amino acids at the N-terminus or C-terminus, or at both the N-terminus and C-terminus.

[0202]

[0280] In some cases, the transmembrane domain can be attached to the extracellular region of the TFP, e.g., the antigen-binding domain of the TFP, via a hinge, e.g., a hinge derived from a human protein. For example, in one embodiment, the hinge can be a human immunoglobulin (Ig) hinge, e.g., an IgG4 hinge, or a CD8a hinge.

[0203] Linker

[0281] Optionally, the link between the binding element and the TCR extracellular domain of TFP may be formed by a short oligopeptide or polypeptide linker, 2-10 amino acids in length. A glycine-serine doublet is a particularly suitable linker. In some cases, the linker may be at least about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more in length. For example, in one embodiment, the linker has the amino acid sequence GGGGSGGGGS, or the sequence (GGGGS) x Or (G 4 S) n (wherein X or n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more). In some embodiments, X or n is an integer from 1 to 10. In some embodiments, X or n is an integer from 1 to 4. In some embodiments, X or n is 2. In some embodiments, X or n is 4. In some embodiments, the linker is encoded by the nucleotide sequence GGTGGCGGAGGTTCTGGAGGTGGAGGTTCC.

[0204]

[0282] In some embodiments, the linker sequence may comprise SEQ ID NO: 387. In some embodiments, the linker sequence may comprise SEQ ID NO: 388. In some embodiments, the linker sequence may comprise SEQ ID NO: 378. In some embodiments, the linker sequence may comprise SEQ ID NO: 405. In some embodiments, the linker sequence may comprise SEQ ID NO: 23. In some embodiments, the linker sequence may comprise SEQ ID NO: 365. In some embodiments, the linker sequence may comprise SEQ ID NO: 401.

[0205] Cytoplasmic domain

[0283] The cytoplasmic domain of the TFP may include an intracellular domain. In some embodiments, the intracellular domain is derived from CD3γ, CD3δ, CD3ε, TCRα, TCRβ, TCRγ, or TCRδ. In some embodiments, when the TFP includes a CD3γ, δ, or ε polypeptide, the intracellular domain includes a signaling domain. TCRα, TCRβ, TCRγ, and TCRδ subunits generally have short (e.g., 1-19 amino acids in length) intracellular domains and generally are not present in the signaling domain. The intracellular signaling domain generally participates in the activation of at least one normal effector function of the immune cell into which the TFP is introduced. The intracellular domains of TCRα, TCRβ, TCRγ, and TCRδ do not have a signaling domain, but can recruit proteins having a primary intracellular signaling domain, e.g., CD3ζ, as described herein, that function as an intracellular signaling domain. The term "effector function" refers to a special function of a cell. The effector function of a T cell can be, for example, cytolytic activity, or helper activity, including secretion of cytokines. Thus, the term "intracellular signaling domain" refers to a portion of a protein that transmits an effector function signal to induce a cell to perform a particular function. Usually, the entire intracellular signaling domain can be utilized, but in many cases it is not necessary to use the entire chain. When a truncated portion of an intracellular signaling domain is used, it may be used in place of the intact chain, so long as such truncated portion transmits the effector function signal. Thus, the term intracellular signaling domain is intended to include any truncated portion of an intracellular signaling domain that is sufficient to transmit an effector function signal.

[0206]

[0284] Examples of intracellular domains used in the TFPs of the present disclosure include cytoplasmic sequences of T cell receptors (TCRs) and co-receptors that can act in concert to initiate signal transduction following antigen receptor binding, as well as any derivative or variant of the sequences, and any recombinant sequences with the same functional capabilities. In some embodiments, the intracellular domain comprises the intracellular domain of a TCR alpha chain, a TCR beta chain, a TCR gamma chain, a TCR delta chain, a CD3 epsilon TCR subunit, a CD3 gamma TCR subunit, or a CD3 delta TCR subunit. In some embodiments, the intracellular domain comprises or at least comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 or more consecutive amino acid residues of the intracellular domain of a TCR alpha chain, a TCR beta chain, a TCR gamma chain, or a TCR delta chain. In some embodiments, the intracellular domain comprises a sequence having at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or more sequence identity to a sequence encoding the intracellular domain of a TCR alpha, beta, gamma or delta chain. In some embodiments, the transmembrane domain comprises a sequence encoding the intracellular domain of a TCR alpha, beta, gamma or delta chain with a truncation of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more amino acids at the N-terminus or C-terminus, or at both the N-terminus and C-terminus.

[0207]

[0285] In some embodiments the intracellular domain comprises, or at least comprises, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, or 62 or more contiguous amino acid residues of the intracellular domain of a CD3ε TCR subunit, a CD3γ TCR subunit, or a CD3δ TCR subunit. In some embodiments, the intracellular domain comprises a sequence having at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or more sequence identity to a sequence encoding the intracellular domain of a CD3ε, CD3γ or CD3δ TCR subunit. In some embodiments, the intracellular domain comprises a sequence encoding the intracellular domain of a CD3ε, CD3γ or CD3δ TCR subunit with a truncation of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more amino acids at the N-terminus or C-terminus, or at both the N-terminus and C-terminus.

[0208]

[0286] It is known that signals generated by the TCR alone are insufficient for the complete activation of naive T cells, and secondary and / or costimulatory signals are required. Thus, T cell activation may be mediated by two distinct classes of cytoplasmic signaling sequences, namely, those that initiate antigen-dependent primary activation via the TCR (primary intracellular signaling sequences) and those that act antigen-independently to provide secondary or costimulatory signals (secondary cytoplasmic domains, e.g., costimulatory domains).

[0209]

[0287] The primary signaling domain regulates the primary activation of the TCR complex in either a stimulatory or inhibitory manner. Primary intracellular signaling domains that act in a stimulatory manner may contain signaling motifs known as immunoreceptor tyrosine-based activation motifs (ITAMs).

[0210]

[0288] Examples of ITAMs comprising a primary intracellular signaling domain that are particularly useful in the present disclosure include those of CD3zeta, FcRgamma, FcRbeta, CD3gamma, CD3delta, CD3epsilon, CD5, CD22, CD79a, CD79b, and CD66d. In one embodiment, a TFP of the present disclosure comprises an intracellular signaling domain, e.g., a primary signaling domain of CD3epsilon. In one embodiment, the primary signaling domain comprises a modified ITAM domain, e.g., a mutated ITAM domain that has altered (e.g., increased or decreased) activity compared to the naturally occurring ITAM domain. In one embodiment, the primary signaling domain comprises a modified ITAM-comprising primary intracellular signaling domain, e.g., a primary intracellular signaling domain that comprises an optimized and / or truncated ITAM. In one embodiment, the primary signaling domain comprises one, two, three, four, or more ITAM motifs.

[0211]

[0289] The intracellular signaling domain of TFP may comprise a CD3 signaling domain, e.g., CD3ε, CD3δ, CD3γ, or CD3ζ, alone or in combination with any other desired intracellular signaling domain(s) useful in the context of the TFP of the present disclosure. For example, the intracellular signaling domain of TFP may comprise a CD3ε chain portion and a costimulatory signaling domain. Costimulatory signaling domain refers to a portion of TFP that comprises the intracellular domain of a costimulatory molecule. A costimulatory molecule is a cell surface molecule other than an antigen receptor or its ligand that is required for an efficient response of lymphocytes to an antigen. Examples of such molecules include CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and a ligand that specifically binds to CD83. For example, CD27 costimulation has been demonstrated to enhance the proliferation, effector function, and survival of human TFP-T cells in vitro, and to increase the persistence and antitumor activity of human T cells in vivo (Song et al., Blood. 2012;119(3):696-706).

[0212]

[0290] The intracellular signaling sequences within the cytoplasmic portion of the TFP of the present disclosure can be linked to each other in a random order or in a specified order. Optionally, the linkages between the intracellular signaling sequences can be formed by short oligo- or polypeptide linkers, e.g., 2-10 amino acids in length (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids).

[0213]

[0291] In one embodiment, a suitable linker may be a glycine-serine doublet. In one embodiment, a suitable linker may be a single amino acid, such as alanine, glycine.

[0214]

[0292] In one aspect, the TFP described herein may comprise a TCR extracellular domain, a TCR transmembrane domain, and a TCR intracellular domain, wherein at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain are derived from the same TCR subunit. In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain may be derived from TCR alpha. In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain may be derived from TCR beta. In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain may be derived from TCR gamma. In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain may be derived from TCR delta. In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain may be derived from CD3 epsilon. In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain may be derived from CD3 delta. In some embodiments, at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain may be derived from CD3 gamma.

[0215]

[0293] In one aspect, the TFP described herein may comprise a TCR extracellular domain, a TCR transmembrane domain, and a TCR intracellular domain, and all three of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain may be derived from the same TCR subunit. In some embodiments, the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain may be derived from CD3ε. In some embodiments, the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain may be derived from CD3δ. In some embodiments, the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain may be derived from CD3γ. In some embodiments, the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain may comprise the constant domain of TCRα. In some embodiments, the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain may comprise the constant domain of TCRβ. In some embodiments, the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain may comprise the constant domain of TCRγ. In some embodiments, the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular domain may comprise a constant domain of TCR δ. In some embodiments, the constant domain of TCR α or the constant domain of TCR β may be murine.

[0216]

[0294] In one aspect, the TFP-expressing cells described herein may further comprise a second TFP, e.g., against the same target (e.g., MSLN) or a different target (e.g., CD70, CD19, or MUC16), e.g., a second TFP comprising a different antigen-binding domain. In one embodiment, when the TFP-expressing cells comprise two or more different TFPs, the antigen-binding domains of the different TFPs may be such that the respective antigen-binding domains do not interact with each other. For example, a cell expressing a first and a second TFP may have the antigen-binding domain of the first TFP, e.g., as a fragment, e.g., an scFv, that does not form an association with the antigen-binding domain of the second TFP, e.g., the antigen-binding domain of the second TFP may be a VFv. HH It is.

[0217] IL-15 and IL-15 receptor alpha polypeptides

[0295] In some aspects, the TFP-expressing cells described herein can further express another agent, for example, an agent that can enhance the survival or activity of the TFP-expressing cells described herein. In some embodiments, the agent is a cytokine, such as a pleiotropic cytokine that plays an important role in the maintenance and homeostatic proliferation of immune cells. In some embodiments, local secretion of pleiotropic cytokines in the tumor microenvironment (TME) can contribute to enhanced anti-tumor immunity. In some embodiments, the agent activates cytokine signaling. In some embodiments, the agent activates interleukin 15 (IL-15) signaling. In some embodiments, the agent comprises interleukin 15 (IL-15) and / or interleukin 15 receptor (IL-15R). In some embodiments, the IL-15R is the IL-15Rα (IL-15Rα) subunit.

[0218]

[0296] The present disclosure provides compositions and methods for enhancing the persistence of TFP-T cells by manipulating constitutive IL-15 signaling. Improved persistence of TFP may lead to a longer duration of response (DOR) in patients. IL-15 inhibits naive and central memory CD8 + It may play an important role in maintaining T cells and promoting survival by reducing activation-induced cell death (AICD). TFP-T cells expressing IL-15 can in some cases show increased persistence in vitro and in vivo. IL-15 or its variants can be T cell specific enhancers and thus can be used in TFP targeting various tumor types. As described herein, various constructs containing IL-15 or IL-15Rα or fragments thereof can be referred to as enhancers.

[0219]

[0297] T cells engineered with a TFP described herein (e.g., a TFP containing an antigen binding domain that targets a TAA) and an IL-15 enhancer can exhibit high transduction efficiency and co-expression. For example, in some cases, T cells engineered with an anti-mesothelin TFP and an IL-15 enhancer described herein can exhibit high transduction efficiency and co-expression. As another example, in some cases, T cells engineered with an anti-CD70 TFP and an IL-15 enhancer described herein can exhibit high transduction efficiency and co-expression. In various embodiments, the cells described herein (e.g., TFP-T cells or transduced T cells) can constitutively express an IL-15 polypeptide or fragment thereof, or an IL-15R subunit or fragment thereof.

[0220]

[0298] The present disclosure encompasses recombinant nucleic acid molecules encoding interleukin 15 (IL-15) polypeptides or fragments thereof. In some embodiments, the IL-15 polypeptide or fragment thereof is selected from the group consisting of IL-15 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 108, 109, 109, 110, 9, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84 , 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 1 22, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150 or more contiguous amino acid residues. In some embodiments, the IL-15 polypeptide or fragment thereof comprises a sequence having at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or more sequence identity to a sequence encoding IL-15. In some embodiments, an IL-15 polypeptide or fragment thereof comprises a sequence encoding IL-15 with a truncation of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more amino acids at the N-terminus or C-terminus, or at both the N-terminus and C-terminus.

[0221]

[0299] In some embodiments, the IL-15 polypeptide or fragment thereof may comprise an IL-15 signal peptide. In some embodiments, the IL-15 polypeptide or fragment thereof may comprise amino acids 1-29 of IL-15. In some embodiments, the IL-15 polypeptide or fragment thereof may comprise amino acids 1-29 of SEQ ID NO:385. In some embodiments, the IL-15 polypeptide or fragment thereof may comprise the sequence of SEQ ID NO:374. In some embodiments, the IL-15 polypeptide or fragment thereof may comprise amino acids 30-162 of IL-15. In some embodiments, the IL-15 polypeptide or fragment thereof may comprise amino acids 30-162 of SEQ ID NO:385. In some embodiments, the IL-15 polypeptide or fragment thereof may comprise the sequence of SEQ ID NO:375. In some embodiments, the IL-15 polypeptide or fragment thereof may comprise amino acids 1-162 of SEQ ID NO:385. In some embodiments, the IL-15 polypeptide or fragment thereof may comprise the sequence of SEQ ID NO:374 and the sequence of SEQ ID NO:375. In some embodiments, the IL-15 polypeptide or fragment thereof may comprise the sequence of SEQ ID NO: 380. In some embodiments, the IL-15 polypeptide is secreted upon expression in a cell, such as a T cell.

[0222]

[0300] The present disclosure further encompasses recombinant nucleic acid molecules encoding interleukin-15 receptor (IL-15R) subunit polypeptides or fragments thereof. For example, the IL-15R subunit can be the IL-15 receptor alpha chain ("IL-15Rα" or CD215), the IL-2 receptor beta chain ("IL-2Rβ" or CD122), and the IL-2 receptor gamma / common gamma chain ("IL-2Rγ / γc" or CD132). In some embodiments, the IL-15R subunit is IL-15Rα or a fragment thereof.In some embodiments, the IL-15Rα polypeptide or fragment thereof is selected from the group consisting of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 , 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250 or more consecutive amino acid residues.In some embodiments, an IL-15Rα polypeptide or fragment thereof comprises a sequence having at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or more sequence identity to a sequence encoding IL-15Rα. In some embodiments, the IL-15Rα polypeptide or fragment thereof has at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 109, 109, 108, 110, 111, 112, 113, 114, 115, 116, 117, and sequences encoding IL-15Rα having a truncation of 8, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more amino acids.

[0223]

[0301] In some embodiments, the IL-15Rα polypeptide or fragment thereof may comprise an IL-15Rα signal peptide. In some embodiments, the IL-15Rα polypeptide or fragment thereof may comprise amino acids 1-30 of IL-15Rα. In some embodiments, the IL-15Rα polypeptide or fragment thereof may comprise amino acids 1-30 of SEQ ID NO:386. In some embodiments, the IL-15Rα polypeptide or fragment thereof does not comprise an IL-15Rα signal peptide. In some embodiments, the IL-15Rα polypeptide or fragment thereof does not comprise amino acids 1-30 of IL-15Rα. In some embodiments, the IL-15Rα polypeptide or fragment thereof does not comprise amino acids 1-30 of SEQ ID NO:386.

[0224]

[0302] In some embodiments, an IL-15Rα polypeptide or fragment thereof may comprise an IL-15Rα Sushi domain. In some embodiments, an IL-15Rα polypeptide or fragment thereof may comprise amino acids 31-95 of IL-15Rα. In some embodiments, an IL-15Rα polypeptide or fragment thereof may comprise amino acids 31-95 of SEQ ID NO: 386. In some embodiments, an IL-15Rα polypeptide or fragment thereof may comprise the sequence of SEQ ID NO: 382.

[0225]

[0303] In some embodiments, an IL-15Rα polypeptide or fragment thereof may comprise the intracellular domain of IL-15Rα. In some embodiments, an IL-15Rα polypeptide or fragment thereof may comprise amino acids 229-267 of IL-15Rα. In some embodiments, an IL-15Rα polypeptide or fragment thereof may comprise amino acids 229-267 of SEQ ID NO: 386. In some embodiments, an IL-15Rα polypeptide or fragment thereof may comprise the sequence of SEQ ID NO: 372.

[0226]

[0304] In some embodiments, the IL-15Rα polypeptide or fragment thereof may comprise an IL-15Rα Sushi domain, a transmembrane domain, and an intracellular domain. In some embodiments, the IL-15Rα polypeptide or fragment thereof may comprise amino acids 31-267 of IL-15Rα. In some embodiments, the IL-15Rα polypeptide or fragment thereof may comprise amino acids 31-267 of SEQ ID NO:386. In some embodiments, the IL-15Rα polypeptide or fragment thereof may comprise the sequence of SEQ ID NO:382. In some embodiments, the IL-15Rα polypeptide or fragment thereof may comprise the sequence of SEQ ID NO:383. In some embodiments, the IL-15Rα polypeptide or fragment thereof may comprise amino acids 96-267 of SEQ ID NO:386. In some embodiments, the IL-15Rα polypeptide or fragment thereof may comprise the sequence of SEQ ID NO:382 and the sequence of SEQ ID NO:383. In some embodiments, the IL-15Rα polypeptide or fragment thereof may comprise the sequence of SEQ ID NO:403.

[0227]

[0305] In some embodiments, the IL-15Rα polypeptide or fragment thereof may be soluble IL-15Rα (sIL-15Rα). In some embodiments, the IL-15Rα polypeptide or fragment thereof may comprise amino acids 21-205 of IL-15Rα. In some embodiments, the IL-15Rα polypeptide or fragment thereof may comprise amino acids 21-205 of SEQ ID NO: 386. In some embodiments, the IL-15Rα polypeptide or fragment thereof may comprise the sequence of SEQ ID NO: 379.

[0228]

[0306] The present disclosure encompasses recombinant nucleic acid molecules that encode a fusion protein comprising an IL-15 polypeptide linked to an IL-15R subunit. In some embodiments, the IL-15 and IL-15R subunit are operably linked by a linker. In some embodiments, the IL-15R subunit is IL-15Rα (IL-15Rα). For example, the IL-15 polypeptide can be linked to the N-terminus of the IL-15Rα subunit. For example, the IL-15 polypeptide can be linked to the C-terminus of the IL-15Rα subunit. In some embodiments, the IL-15 and IL-15Rα are operably linked by a linker. In some embodiments, the linker is not a cleavable linker. For example, the linker is a (G 4 S) n where G is glycine, S is serine, and n is an integer from 1 to 10. In some embodiments, n is an integer from 1 to 4. In some embodiments, n is 3. In some embodiments, the linker comprises the sequence of SEQ ID NO: 378. In some embodiments, the linker comprises the sequence of SEQ ID NO: 405.

[0229]

[0307] In some embodiments, the fusion protein may comprise amino acids 30-162 of IL-15. In some embodiments, the fusion protein may comprise amino acids 30-162 of the sequence of SEQ ID NO: 385. In some embodiments, the fusion protein may comprise the sequence of SEQ ID NO: 375. In some embodiments, the fusion protein does not comprise the IL-15 signal peptide. In some embodiments, the fusion protein does not comprise amino acids 1-29 of IL-15. In some embodiments, the fusion protein does not comprise amino acids 1-29 of the sequence of SEQ ID NO: 385. In some embodiments, the fusion protein does not comprise the sequence of SEQ ID NO: 374.

[0230]

[0308] In some embodiments, the fusion protein may comprise a Sushi domain. In some embodiments, the fusion protein may comprise amino acids 31-95 of IL-15Rα. In some embodiments, the fusion protein may comprise amino acids 31-95 of the sequence of SEQ ID NO: 386. In some embodiments, the fusion protein may comprise the sequence of SEQ ID NO: 382.

[0231]

[0309] In some embodiments, the fusion protein may comprise the intracellular domain of IL-15Rα. In some embodiments, the fusion protein may comprise amino acids 229-267 of IL-15Rα. In some embodiments, the fusion protein may comprise amino acids 229-267 of the sequence of SEQ ID NO: 386. In some embodiments, the fusion protein may comprise the sequence of SEQ ID NO: 372.

[0232]

[0310] In some embodiments, the fusion protein may comprise soluble IL-15Rα (sIL-15Rα). In some embodiments, the fusion protein may comprise amino acids 21-205 of IL-15Rα. In some embodiments, the fusion protein may comprise amino acids 21-205 of the sequence of SEQ ID NO: 386. In some embodiments, the fusion protein may comprise the sequence of SEQ ID NO: 379.

[0233]

[0311] In some embodiments, the fusion protein may comprise the transmembrane and intracellular domains of IL-15Rα. In some embodiments, the fusion protein may comprise amino acids 96-267 of IL-15Rα. In some embodiments, the fusion protein may comprise amino acids 96-267 of the sequence of SEQ ID NO: 386. In some embodiments, the fusion protein may comprise the sequence of SEQ ID NO: 383.

[0234]

[0312] In some embodiments, the fusion protein may comprise the Sushi domain, the transmembrane domain, and the intracellular domain of IL-15Rα. In some embodiments, the fusion protein may comprise amino acids 31-267 of IL-15Rα. In some embodiments, the fusion protein may comprise amino acids 31-267 of the sequence of SEQ ID NO: 386. In some embodiments, the fusion protein may comprise the sequence of SEQ ID NO: 382 and the sequence of SEQ ID NO: 383. In some embodiments, the IL-15Rα comprises the sequence of SEQ ID NO: 403.

[0235]

[0313] In some embodiments, the fusion protein further comprises an epitope tag. The epitope tag described herein can be a peptide epitope tag or a protein epitope tag. Examples of peptide epitope tags include, but are not limited to, 6xHis (also known as His tag or hexahistidine tag), FLAG (e.g., 3xFLAG), HA, Myc, and V5. Examples of protein epitope tags include, but are not limited to, green fluorescent protein (GFP), glutathione-S-transferase (GST), β-galactosidase (β-GAL), luciferase, maltose binding protein (MBP), red fluorescent protein (RFP), and vesicular stomatitis virus glycoprotein (VSV-G). In some embodiments, the fusion protein further comprises a FLAG tag. In some embodiments, the fusion protein further comprises a 3xFLAG tag. In some embodiments, the fusion protein further comprises the sequence of SEQ ID NO: 384.

[0236]

[0314] In some embodiments, the fusion protein comprises the sequence of SEQ ID NO: 377. In some embodiments, the fusion protein comprises the sequence of SEQ ID NO: 381. In some embodiments, the fusion protein is expressed on the cell surface when expressed in T cells. In some embodiments, the fusion protein is secreted when expressed in T cells.

[0237]

[0315] In some aspects, a cell expressing TFP, an IL-15 polypeptide or fragment thereof, an IL-15Rα polypeptide or fragment thereof, and / or a fusion protein comprising an IL-15 polypeptide and an IL-15Rα polypeptide as described herein can still further express another agent capable of enhancing the activity of an engineered T cell expressing TFP. For example, in one embodiment, the agent capable of enhancing the activity of an engineered T cell can be a PD-1 polypeptide. In these embodiments, the PD-1 polypeptide can be operably linked to the N-terminus of the intracellular domain of a costimulatory polypeptide through the C-terminus of the PD-1 polypeptide. For example, in another embodiment, the agent capable of enhancing the activity of an engineered T cell expressing TFP can be an anti-PD-1 antibody, or an antigen-binding fragment thereof. In this embodiment, the anti-PD-1 antibody, or an antigen-binding fragment thereof, can be operably linked to the N-terminus of the intracellular domain of a costimulatory polypeptide through the C-terminus of the anti-PD-1 antibody, or an antigen-binding fragment thereof. In some embodiments, the PD-1 polypeptide or anti-PD-1 antibody is linked to the intracellular domain of a costimulatory polypeptide through the transmembrane domain of PD-1. In some embodiments, the costimulatory polypeptide is selected from the group consisting of OX40, CD2, CD27, CDS, ICAM-1, ICOS (CD278), 4-1BB (CD137), GITR, CD28, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, CD226, FcγRI, FcγRII, and FcγRIII.

[0238]

[0316] In some aspects, an agent capable of enhancing the activity of modified T cells expressing TFP can be linked to an IL-15Rα polypeptide or fragment thereof. For example, the agent can be an agent capable of inhibiting an inhibitory molecule that can reduce the ability of T cells expressing TFP to mount an immune effector response. In some embodiments, the agent that inhibits an inhibitory molecule comprises a first polypeptide, e.g., an inhibitory molecule, that is associated with a second polypeptide that provides a positive signal to the cell, e.g., an intracellular signaling domain as described herein. In one embodiment, the agent may comprise a first polypeptide, e.g., a polypeptide of an inhibitory molecule such as PD-1, LAG3, CTLA4, CD160, BTLA, LAIR1, TIM3, 2B4, and TIGIT, or a fragment of any of these (e.g., at least a portion of the extracellular domain of any of these), and a second polypeptide that is an intracellular signaling domain as described herein (e.g., including a costimulatory domain (e.g., 4-1BB, CD27, or CD28 as described herein)) and / or a primary signaling domain (e.g., IL-15Rα as described herein). In some embodiments, the agent may be PD-1 or a fragment thereof. For example, the agent may comprise the extracellular domain of PD-1. In some embodiments, the agent may comprise the extracellular domain and transmembrane domain of PD-1. In some embodiments, the agent may further comprise CD28 or a fragment thereof. In some embodiments, the agent may comprise the intracellular domain of CD28. In some embodiments, the agent may comprise a fusion protein comprising the PD-1 extracellular domain and transmembrane domain linked to a CD28 intracellular domain linked to IL-15Rα, hi some embodiments, the CD28 intracellular domain is linked to the intracellular domain of IL-15Rα.

[0239]

[0317] In some embodiments, PD-1 or a fragment thereof may comprise the sequence of SEQ ID NO: 366. In some embodiments, PD-1 or a fragment thereof may comprise the sequence of SEQ ID NO: 367. In some embodiments, PD-1 or a fragment thereof may comprise the sequence of SEQ ID NO: 368. In some embodiments, PD-1 or a fragment thereof may comprise the sequence of SEQ ID NO: 369. In some embodiments, the transmembrane domain of PD-1 may comprise the sequence of SEQ ID NO: 370. In some embodiments, the intracellular domain of CD28 may comprise the sequence of SEQ ID NO: 371. In some embodiments, the intracellular domain of IL-15Rα comprises amino acids 229-267 of IL-15Rα. In some embodiments, the intracellular domain of IL-15Rα comprises amino acids 229-267 of the sequence of SEQ ID NO: 386. In some embodiments, the fusion protein comprises the sequence of SEQ ID NO: 372. In some embodiments, the fusion protein comprises the sequence of SEQ ID NO: 376.

[0240]

[0318] In some aspects, an agent capable of enhancing the activity of engineered T cells expressing a TFP can be linked to a fusion protein comprising an IL-15 polypeptide and an IL-15Rα polypeptide. In some embodiments, the agent can be PD-1 or a fragment thereof. For example, the agent can include the extracellular domain of PD-1. In some embodiments, the agent can include the extracellular domain and transmembrane domain of PD-1. In some embodiments, the agent can further include CD28 or a fragment thereof. In some embodiments, the agent can include the intracellular domain of CD28. In some embodiments, the agent can include a fusion protein comprising a PD-1 extracellular domain and a transmembrane domain linked to a CD28 intracellular domain linked to a fusion protein comprising an IL-15 polypeptide and an IL-15Rα polypeptide. In some embodiments, the CD28 intracellular domain is linked to the intracellular domain of IL-15Rα. In some embodiments, the intracellular domain of IL-15Rα is linked to the IL-15 polypeptide by a linker as described herein. In some embodiments, the linker comprises a cleavage site. The cleavage site may be a self-cleaving peptide, such as a T2A, P2A, E2A, or F2A cleavage site. In some embodiments, the cleavage site may comprise the sequence of SEQ ID NO: 373. In some embodiments, the cleavage site may comprise SEQ ID NO: 23. In some embodiments, the cleavage site may comprise SEQ ID NO: 365.

[0241]

[0319] In some embodiments, the fusion protein may comprise PD-1 or a fragment thereof comprising the sequence of SEQ ID NO:366. In some embodiments, the fusion protein may comprise PD-1 or a fragment thereof comprising the sequence of SEQ ID NO:367. In some embodiments, the fusion protein may comprise PD-1 or a fragment thereof comprising the sequence of SEQ ID NO:368. In some embodiments, the fusion protein may comprise PD-1 or a fragment thereof comprising the sequence of SEQ ID NO:369. In some embodiments, the fusion protein may comprise PD-1 or a fragment thereof comprising the transmembrane domain of PD-1 comprising the sequence of SEQ ID NO:370. In some embodiments, the fusion protein may comprise CD28 or a fragment thereof comprising the intracellular domain of CD28 comprising the sequence of SEQ ID NO:371. In some embodiments, the intracellular domain of IL-15Rα comprises amino acids 229-267 of IL-15Rα. In some embodiments, the intracellular domain of IL-15Rα comprises amino acids 229-267 of the sequence of SEQ ID NO:386. In some embodiments, the fusion protein comprises the sequence of SEQ ID NO:372. In some embodiments, the IL-15 polypeptide comprises an IL-15 signal peptide. In some embodiments, the IL-15 polypeptide comprises amino acids 1-29 of IL-15. In some embodiments, the IL-15 polypeptide comprises amino acids 1-29 of the sequence of SEQ ID NO: 385. In some embodiments, the IL-15 polypeptide comprises the sequence of SEQ ID NO: 374. In some embodiments, the IL-15 polypeptide comprises amino acids 30-162 of IL-15. In some embodiments, the IL-15 polypeptide comprises amino acids 30-162 of the sequence of SEQ ID NO: 385. In some embodiments, the IL-15 polypeptide comprises the sequence of SEQ ID NO: 375. In some embodiments, the fusion protein comprises the sequence of SEQ ID NO: 361.

[0242]

[0320] In some embodiments, disclosed herein is a polypeptide encoded by any of the recombinant nucleic acid molecules described herein.

[0243] Other agents

[0321] In another aspect, the cells expressing TFP, IL-15, and / or IL-15Rα described herein can further express another agent, e.g., an agent that enhances the activity of the engineered T cell. For example, in one embodiment, the agent can be an agent that inhibits an inhibitory molecule. An inhibitory molecule, e.g., PD-1, can in some embodiments reduce the ability of the engineered T cell to mount an immune effector response. Examples of inhibitory molecules include PD-1, PD-L1, CTLA4, TIM3, LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, and TGFRβ. In one embodiment, the agent that inhibits an inhibitory molecule includes a first polypeptide, e.g., an inhibitory molecule, that is associated with a second polypeptide that provides a positive signal to the cell, e.g., an intracellular signaling domain described herein. In one embodiment, the agent comprises a first polypeptide, e.g., a polypeptide of an inhibitory molecule such as PD-1, LAG3, CTLA4, CD160, BTLA, LAIR1, TIM3, 2B4, and TIGIT, or a fragment of any of these (e.g., at least a portion of the extracellular domain of any of these), and a second polypeptide which is an intracellular signaling domain described herein (e.g., including a costimulatory domain (e.g., 4-1BB, CD27, or CD28, e.g., as described herein)) and / or a primary signaling domain (e.g., a CD3 zeta signaling domain described herein). In one embodiment, the agent comprises a first polypeptide which is PD-1 or a fragment thereof (e.g., at least a portion of the extracellular domain of PD-1), and a second polypeptide which is an intracellular signaling domain described herein (e.g., a CD28 signaling domain described herein and / or a CD3 zeta signaling domain described herein). PD-1 is an inhibitory member of the CD28 receptor family, which also includes CD28, CTLA-4, ICOS, and BTLA. PD-1 is expressed on activated B cells, T cells, and myeloid cells (Agata et al., 1996, Int. Immunol 8:765-75).Two ligands for PD-1, PD-L1 and PD-L2, have been shown to downregulate T cell activation upon binding to PD-1 (Freeman et al., 2000 J. Exp. Med. 192:1027-34; Latchman et al., 2001 Nat. Immunol. 2:261-8; Carter et al., 2002 Eur. J. Immunol. 32:634-43). PD-L1 is abundant in human cancers (Dong et al., 2003 J. Mol. Med. 81:281-7; Blank et al., 2005 Cancer Immunol. Immunother. 54:307-314; Konishi et al., 2004 Clin. Cancer Res. 10:5094). Blocking the local interaction of PD-1 with PD-L1 can reverse immune suppression.

[0244]

[0322] In one embodiment, the agent comprises the extracellular domain (ECD) of an inhibitory molecule, for example, programmed cell death 1 (PD-1), which can be fused to a transmembrane domain and optionally an intracellular signaling domain such as 41BB and CD3ζ (also referred to herein as PD-1 TFP). In one embodiment, the PD-1 TFP improves T cell persistence when used in combination with an anti-TAA TFP as described herein. In one embodiment, the TFP is a PD-1 TFP that comprises the extracellular domain of PD-1. Alternatively, a TFP is provided that comprises an antibody or antibody fragment, such as an scFv, that specifically binds to programmed death ligand 1 (PD-L1) or programmed death ligand 2 (PD-L2).

[0245]

[0323] In another aspect, the present disclosure provides a population of TFP-expressing T cells, e.g., TFP-T cells. In some embodiments, the population of TFP-expressing T cells comprises a mixture of cells expressing different TFPs. For example, in one embodiment, the population of TFP-T cells may comprise a first cell expressing a TFP with a binding domain as described herein and a second cell expressing a TFP with a different anti-TAA binding domain, e.g., a binding domain as described herein that is different from the binding domain in the TFP expressed by the first cell. As another example, the population of TFP-expressing cells may comprise a first cell expressing a TFP with a first binding domain, e.g., as described herein, and a second cell expressing a TFP with an antigen binding domain against a target other than the binding domain of the first cell (e.g., another tumor-associated antigen).

[0246]

[0324] In another aspect, the disclosure provides a population of cells, where at least one cell in the population expresses a TFP having a domain as described herein, and a second cell expressing another agent, e.g., an agent that enhances the activity of the engineered T cell. For example, in one embodiment, the agent can be an agent that inhibits an inhibitory molecule. An inhibitory molecule, e.g., in some embodiments, can reduce the ability of the engineered T cell to mount an immune effector response. Examples of inhibitory molecules include PD1, PD-L1, PD-L2, CTLA4, TIM3, LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, and TGFRβ. In one embodiment, the agent that inhibits an inhibitory molecule comprises a first polypeptide, e.g., an inhibitory molecule, associated with a second polypeptide that provides a positive signal to the cell, e.g., an intracellular signaling domain as described herein.

[0247] Recombinant Nucleic Acid Molecules

[0325] Disclosed herein is a recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a T cell receptor (TCR) fusion protein (TFP) as described herein and a second nucleic acid sequence encoding an interleukin 15 (IL-15) polypeptide or a fragment thereof. Disclosed herein is a recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a T cell receptor (TCR) fusion protein (TFP) and a second nucleic acid sequence encoding an interleukin 15 receptor alpha (IL-15Rα) polypeptide or a fragment thereof. Also disclosed herein is a recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a T cell receptor (TCR) fusion protein (TFP) and a second nucleic acid sequence encoding a fusion protein comprising an IL-15 polypeptide or a fragment thereof linked to an IL-15Rα polypeptide or a fragment thereof. Further disclosed herein is a recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a T cell receptor (TCR) fusion protein (TFP) and a second nucleic acid sequence encoding a fusion protein, comprising a fusion protein comprising an IL-15Rα polypeptide or a fragment thereof linked to PD-1 or a fragment thereof and / or CD28 or a fragment thereof.

[0248] Recombinant nucleic acids encoding TFP and TCR constant domains

[0326] In some embodiments, disclosed herein is a recombinant nucleic acid molecule comprising a sequence encoding a T cell receptor (TCR) fusion protein (TFP). The TFP may comprise a TCR subunit comprising at least a portion of a TCR extracellular domain. The TCR subunit may further comprise a transmembrane domain. The TCR subunit may further comprise an intracellular domain comprising a stimulatory domain from an intracellular domain of TCR gamma, TCR delta, TCR alpha, or TCR beta, or an intracellular signaling domain of CD3 epsilon, CD3 gamma, or CD3 delta. The TFP may further comprise an antibody (e.g., a human antibody, a humanized antibody, or a murine antibody) comprising an antigen-binding domain. The recombinant nucleic acid molecule may further comprise a sequence encoding a TCR constant domain, the TCR constant domain being a TCR alpha constant domain, a TCR beta constant domain, a TCR alpha constant domain and a TCR beta constant domain, a TCR gamma constant domain, a TCR delta constant domain, or a TCR gamma constant domain and a TCR delta constant domain. The TCR subunit and the antibody may be operably linked. When expressed in a T cell, the TFP can functionally integrate into the TCR complex (eg, the endogenous TCR complex).

[0249]

[0327] The constant domain may comprise a constant domain of a TCR alpha, beta, gamma, or delta chain. The constant domain may comprise a full-length constant domain of a TCR alpha, beta, gamma, or delta chain. The constant domain may comprise a fragment (e.g., a functional fragment) of a full-length constant domain of a TCR alpha, beta, gamma, or delta chain. For example, the constant domain may comprise at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, or more amino acid residues of a constant domain of a TCR alpha, beta, gamma, or delta chain. The sequence encoding the TCR constant domain may further encode the transmembrane domain and / or intracellular region of the TCR alpha, beta, gamma, or delta chain. The sequence encoding the TCR constant domain may encode the full-length constant region of the TCR alpha, beta, gamma, or delta chain. The constant region of the TCR chain may include the constant domain, the transmembrane domain, and the intracellular region. The constant region of the TCR chain may also exclude the transmembrane domain and the intracellular region of the TCR alpha, beta, gamma, or delta chain.

[0250]

[0328] The TCR alpha, beta, gamma, or delta chains described herein may be derived from various species. The TCR chains may be murine or human TCR chains. For example, the constant domains may include murine or human TCR alpha, beta, gamma, or delta chain constant domains.

[0251]

[0329] The constant domain may comprise a truncation, addition, or substitution of the sequence of the constant domain described herein. For example, the constant domain may comprise a truncated constant domain described herein having at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, or more amino acid residues of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:146, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:152, SEQ ID NO:155, SEQ ID NO:207, SEQ ID NO:209, SEQ ID NO:243, or SEQ ID NO:265. For example, a constant domain can comprise a sequence of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:146, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:152, SEQ ID NO:155, SEQ ID NO:207, SEQ ID NO:209, SEQ ID NO:243, or SEQ ID NO:265, with at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, or more additional amino acid residues. For example, a constant domain can comprise a sequence with at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, or more amino acid substitutions of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:146, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:152, SEQ ID NO:155, SEQ ID NO:207, SEQ ID NO:209, SEQ ID NO:243, or SEQ ID NO:265. The constant domain may comprise the sequence of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:146, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:152, SEQ ID NO:155, SEQ ID NO:207, SEQ ID NO:209, SEQ ID NO:243, or SEQ ID NO:265 or a fragment thereof.The constant domain may comprise at least one, two, three, four, five, six, seven, eight, nine, ten or more modifications, mutations, or deletions of the sequence of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:146, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:152, SEQ ID NO:155, SEQ ID NO:207, SEQ ID NO:209, SEQ ID NO:243, or SEQ ID NO:265. The constant domain may comprise up to 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 modification, mutation, or deletion of the sequence of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:146, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:152, SEQ ID NO:155, SEQ ID NO:207, SEQ ID NO:209, SEQ ID NO:243, or SEQ ID NO:265. The constant domain may comprise a sequence having at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to the sequence of SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, or SEQ ID NO:22, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:146, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:152, SEQ ID NO:155, SEQ ID NO:207, SEQ ID NO:209, SEQ ID NO:243, or SEQ ID NO:265.

[0252]

[0330] The murine TCR alpha constant domain may comprise positions 2-137 of SEQ ID NO: 146. The murine TCR alpha constant domain may comprise truncations, additions, or substitutions of the sequences of the constant domains described herein. For example, the constant domain may comprise a truncated constant domain described herein having at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, or more amino acid residues from positions 2-137 of SEQ ID NO: 146. For example, the constant domain may comprise a sequence from positions 2-137 of SEQ ID NO: 146 with at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, or more additional amino acid residues. For example, a constant domain can comprise a sequence having at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, or more amino acid substitutions of positions 2-137 of SEQ ID NO: 146. A constant domain can comprise a sequence of positions 2-137 of SEQ ID NO: 146 or a fragment thereof. A constant domain can comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more modifications, mutations, or deletions of positions 2-137 of SEQ ID NO: 146. The constant domain can include up to 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 modifications, mutations, or deletions of the sequence of positions 2-137 of SEQ ID NO: 146. The constant domain can include a sequence having at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to the sequence of positions 2-137 of SEQ ID NO: 146.

[0253]

[0331] The murine TCR β constant domain may comprise positions 2-173 of SEQ ID NO: 152. The murine TCR β constant domain may comprise truncations, additions, or substitutions of the sequences of the constant domains described herein. For example, the constant domain may comprise a truncated constant domain described herein having at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, or more amino acid residues from positions 2-173 of SEQ ID NO: 152. For example, the constant domain may comprise a sequence having at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, or more additional amino acid residues from positions 2-173 of SEQ ID NO: 152. For example, the constant domain may comprise a sequence having at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, or more amino acid substitutions from positions 2 to 173 of SEQ ID NO: 152. The constant domain may comprise a sequence from positions 2 to 173 of SEQ ID NO: 152 or a fragment thereof. The constant domain may comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more modifications, mutations, or deletions from positions 2 to 173 of SEQ ID NO: 152. The constant domain may include up to 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 modification, mutation, or deletion of the sequence of positions 2 to 173 of SEQ ID NO: 152. The constant domain may include a sequence having at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to the sequence of positions 2 to 173 of SEQ ID NO: 152.

[0254]

[0332] In some cases, the TCR constant domain is a TCR delta constant domain. The TCR delta constant domain may comprise the amino acid sequence of SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:243, or SEQ ID NO:265, functional fragments thereof, and at least one but not more than 20 modifications thereof. In some embodiments, the TCR delta constant domain may comprise SEQ ID NO:243. The TCR delta constant domain may comprise a truncation, addition, or substitution of the sequence of the constant domain described herein. For example, the constant domain may comprise a truncated constant domain described herein having at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, or more amino acid residues of SEQ ID NO:243. For example, a constant domain may comprise a sequence of SEQ ID NO: 243 with at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, or more additional amino acid residues. For example, a constant domain may comprise a sequence of SEQ ID NO: 243 with at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, or more amino acid substitutions. A constant domain may comprise a sequence of SEQ ID NO: 243 or a fragment thereof. A constant domain may comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more modifications, mutations, or deletions of the sequence of SEQ ID NO: 243. The constant domain may comprise up to 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 modifications, mutations, or deletions of the sequence of SEQ ID NO: 243. The constant domain may comprise a sequence having at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to the sequence of SEQ ID NO: 243.

[0255]

[0333] The TCR delta constant domain may comprise the amino acid sequence of SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:243, or SEQ ID NO:265, a functional fragment thereof, or the amino acid sequence thereof having at least one but not more than 20 modifications. Optionally, the sequence encoding the TCR delta constant domain further encodes a TCR delta variable domain, thereby encoding the entire TCR delta domain. The entire TCR delta domain may be delta 2 or delta 1. The entire TCR delta constant domain may comprise SEQ ID NO:256, a functional fragment thereof, and the amino acid sequence thereof having at least one but not more than 20 modifications.

[0256]

[0334] The full TCR δ domain may comprise a truncation, addition, or substitution of the constant domain sequence described herein. For example, the δ domain may comprise a truncated δ domain as described herein having at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, or more amino acid residues of SEQ ID NO: 256. For example, the δ domain may comprise a sequence of SEQ ID NO: 256 having at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, or more additional amino acid residues. For example, a delta domain may comprise a sequence of SEQ ID NO: 256 with at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150 or more amino acid substitutions. A delta domain may comprise a sequence of SEQ ID NO: 256 or a fragment thereof. A delta domain may comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more modifications, mutations, or deletions of the sequence of SEQ ID NO: 256. A delta domain may comprise up to 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 modifications, mutations, or deletions of the sequence of SEQ ID NO: 256. The δ domain may comprise a sequence having at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to the sequence of SEQ ID NO:256.

[0257]

[0335] The TCR gamma constant domain may comprise SEQ ID NO: 21. The TCR gamma constant domain may comprise truncations, additions, or substitutions of the sequences of the constant domains described herein. For example, the constant domain may comprise a truncated constant domain described herein having at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, or more amino acid residues of SEQ ID NO: 21. For example, the constant domain may comprise a sequence of SEQ ID NO: 21 having at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, or more additional amino acid residues. For example, a constant domain may comprise a sequence of SEQ ID NO: 21 with at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, or more amino acid substitutions. A constant domain may comprise a sequence of SEQ ID NO: 21 or a fragment thereof. A constant domain may comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more modifications, mutations, or deletions of the sequence of SEQ ID NO: 21. A constant domain may comprise up to 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 modifications, mutations, or deletions of the sequence of SEQ ID NO: 21. The constant domain may comprise a sequence having at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to the sequence of SEQ ID NO:243.

[0258]

[0336] The TCR gamma constant domain may comprise the amino acid sequence of SEQ ID NO:21 or SEQ ID NO:155, functional fragments thereof, and at least one but not more than 20 modifications thereof. Optionally, the sequence encoding the TCR gamma constant domain further encodes a TCR gamma variable domain, thereby encoding the entire TCR gamma domain. The entire TCR gamma domain may be gamma9 or gamma4. The entire TCR gamma domain may comprise the amino acid sequence of SEQ ID NO:255, functional fragments thereof, and at least one but not more than 20 modifications thereof.

[0259]

[0337] The full TCR gamma domain may include truncations, additions, or substitutions of the constant domain sequences described herein. For example, the gamma domain may include a truncated gamma domain described herein having at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, or more amino acid residues of SEQ ID NO: 255. For example, the gamma domain may include a sequence of SEQ ID NO: 255 having at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, or more additional amino acid residues. For example, a gamma domain can comprise a sequence having at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, or more amino acid substitutions of SEQ ID NO: 255. A gamma domain can comprise a sequence of SEQ ID NO: 255 or a fragment thereof. A gamma domain can comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more modifications, mutations, or deletions of the sequence of SEQ ID NO: 255. A gamma domain can comprise up to 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 modifications, mutations, or deletions of the sequence of SEQ ID NO: 255. The gamma domain can comprise a sequence having at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to the sequence of SEQ ID NO:255.

[0260]

[0338] TCR β chain (Homo sapiens): VEDLNKVFPPEVAVFEPSEAEISHTQKATLVCLATGFFPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSVSYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDF (sequence number 16).

[0261]

[0339] The canonical sequence of the constant region of the mouse TCR β chain is as follows: EDLRNVTPPKVSLFEPSKAEIANKQKATLVCLARGFFPDHVELSWWVNGKEVHSGVSTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFRCQVQFHGLSEEDKWPEGSPKPVTQNISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAVLVSTLVVMAMVKRKNS (sequence number 152).

[0262]

[0340] TCR alpha constant region (Mus musculus) (or [mm]TRAC(82-137)): ATYPSSDVPCDATLTEKSFETDMNLNFQNLSVMGLRILLLKVAGFNLLMTLRLWSS (sequence number 17).

[0263]

[0341] The canonical sequence of the constant (mTRAC) region of the mouse TCR alpha chain is as follows: XIQNPEPAVYQLKDPRSQDSTLCLFTDFDSQINVPKTMESGTFITDKTVLDMKAMDSKSNGAIAWSNQTSFTCQDIFKETNATYPSSDVPCDATLTEKSFETDMNLNFQNLSVMGLRILLLKVAGFNLLMTLRLWSS (sequence number 146).

[0264]

[0342] TCRβ constant region (Mus musculus) (or [mm]TRBC1(123-173)): GRADCGITSASYQQGVLSATILYEILLGKATLYAVLVSTLVVMAMVKRKNS (sequence number 18).

[0265]

[0343] The canonical sequence of the constant region of the mouse TCR β chain is as follows: EDLRNVTPPKVSLFEPSKAEIANKQKATLVCLARGFFPDHVELSWWVNGKEVHSGVSTDPQAYKESNYSYCLSSRLRVSATFWHNPRNHFRCQVQFHGLSEEDKWPEGSPKPVTQNISAEAWGRADCGITSASYQQGVLSATILYEILLGKATLYAVLVSTLVVMAMVKRKNS (sequence number 152).

[0266]

[0344] TCR β chain (Homo sapiens): PVDSGVTQTPKHLITATGQRVTLRCSPRSGDLSVSWYQQSLDQGLQFLIQYYNGEERAKGNILERFSAQQFPDLHSELNLSSLELGDSALYFCASSPRTGLNTEAFFGQGTRLTVVEDLNKVFPPEVAVFEPSEAEISHTQKATLVCLATGFFPDHVELSWWVNGKEVHSGVSTDPQPLKEQPALNDSRYCLSSRLRVSATFWQNPRNHFRCQVQFYGLSENDEWTQDRAKPVTQIVSAEAWGRADCGFTSVSYQQGVLSATILYEILLGKATLYAVLVSALVLMAMVKRKDF (sequence number 19).

[0267]

[0345] TCR delta constant region version 1 (Homo sapiens): SQPHTKPSVFVMKNGTNVACLVKEFYPKDIRINLVSSKKITEFDPAIVISPSGKYNAVKLGKYEDSNSVTCSVQHDNKTVHSTDFEVKTDSTDHVKPKETENTKQPSKSCHKPKAIVHTEKVNMMSLTVLGLRMLFAKTVAVNFLLTAKLFF (SEQ ID NO: 20).

[0268]

[0346] TCR gamma constant region (Homo sapiens) (or [hs]TRGC(1-173)): DKQLDADVSPKPTIFLPSIAETKLQKAGTYLCLLEKFFPDVIKIHWQEKKSNTILGSQEGNTMKTNDTYMKFSWLTVPEKSLDKEHRCIVRHENNKNGVDQEIIFPPIKTDVITMDPKDNCSKDANDTLLLQLTNTSAYYMYLLLLLKSVVYFAIITCCLLRRTAFCCNGEKS (SEQ ID NO:21).

[0269]

[0347] TCR delta constant region version 2 (Homo sapiens): SQPHTKPSVFVMKNGTNVACLVKEFYPKDIRINLVSSKKITEFDPAIVISPSGKYNAVKLGKYEDSNSVTCSVQHDNKTVHSTDFEVKTDSTDHVKPKETENTKQPSKSCHKPKAIVHTEKVNMMSLTVLGLRMLFAKTVAVNFLLTAK (sequence number 22).

[0270]

[0348] In some cases, the TCR constant domain is a TCR delta constant domain. The sequence encoding the TCR delta constant domain may further encode a second antigen- or ligand-binding domain operably linked to the sequence encoding the TCR delta constant domain. The second antigen- or ligand-binding domain may be the same as or different from the antigen- or ligand-binding domain of the TFP.

[0271]

[0349] In some cases, the TCR constant domain is a TCR gamma constant domain. The sequence encoding the TCR gamma constant domain may further encode a second antigen- or ligand-binding domain operably linked to the sequence encoding the TCR gamma constant domain. The second antigen- or ligand-binding domain may be the same as or different from the antigen- or ligand-binding domain of the TFP.

[0272]

[0350] In some cases, the recombinant nucleic acid comprises a sequence encoding a TCR gamma constant domain and a TCR delta constant domain. The TCR gamma constant domain may comprise the amino acid sequence of SEQ ID NO:21 or SEQ ID NO:155, functional fragments thereof, and at least one but not more than 20 modifications thereof. The sequence encoding the TCR gamma constant domain may further encode a TCR gamma variable domain, thereby encoding the entire TCR gamma domain. The TCR gamma domain may be gamma 9 or gamma 4. The entire TCR gamma domain may comprise the amino acid sequence of SEQ ID NO:255, functional fragments thereof, and at least one but not more than 20 modifications thereof. The TCR delta constant domain may comprise the amino acid sequence of SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:243, or SEQ ID NO:265, functional fragments thereof, and at least one but not more than 20 modifications thereof. The sequence encoding the TCR delta constant domain may further encode a TCR delta variable domain, thereby encoding the entire TCR delta domain. The TCR delta domain may be delta 2 or delta 1. The entire TCR δ domain may comprise the amino acid sequence of SEQ ID NO: 256, functional fragments thereof, and any of the amino acid sequences having at least one but no more than 20 modifications.

[0273]

[0351] In some cases, the TCR constant domain is incorporated into a functional TCR complex when expressed in a T cell. In some cases, the TCR constant domain is incorporated into the same functional TCR complex that incorporates the TFP when expressed in a T cell. In some cases, the sequence encoding the TFP and the sequence encoding the TCR constant domain are contained within the same nucleic acid molecule. In some cases, the sequence encoding the TFP and the sequence encoding the TCR constant domain are contained within different nucleic acid molecules. The sequence may further encode a cleavage site (e.g., a protease cleavage site) between the encoded TFP and the TCR constant domain. The cleavage site may be a protease cleavage site. The cleavage site may be a self-cleaving peptide, such as a T2A, P2A, E2A, or F2A cleavage site. The cleavage site may comprise the sequence of SEQ ID NO: 23.

[0274]

[0352] T2A cleavage site:EGRGSLLTCGDVEENPGP (sequence number 23).

[0353] The TCR subunits and constant domains of the TFP may comprise sequences derived from the same or different TCR chains. In some cases, the TCR subunits and constant domains of the TFP are derived from different TCR chains. For example, the TCR subunits may comprise (1) at least a portion of a TCR extracellular domain, (2) a transmembrane domain, and (3) an intracellular domain, where the TCR extracellular domain, transmembrane domain, and intracellular domain are derived from a TCR alpha chain, and the constant domain may comprise a constant domain of a TCR beta chain. In another example, the TCR subunits may comprise (1) at least a portion of a TCR extracellular domain, (2) a transmembrane domain, and (3) an intracellular domain, where the TCR extracellular domain, transmembrane domain, and intracellular domain are derived from a TCR beta chain, and the constant domain may comprise a constant domain of a TCR alpha chain. In another example, a TCR subunit comprises (1) at least a portion of a TCR extracellular domain, (2) a transmembrane domain, and (3) an intracellular domain, wherein the TCR extracellular domain, transmembrane domain, and intracellular domain are derived from a TCR gamma chain, and the constant domain can comprise the constant domain of a TCR delta chain. In yet another example, a TCR subunit comprises (1) at least a portion of a TCR extracellular domain, (2) a transmembrane domain, and (3) an intracellular domain, wherein the TCR extracellular domain, transmembrane domain, and intracellular domain are derived from a TCR delta chain, and the constant domain can comprise the constant domain of a TCR gamma chain.

[0275]

[0354] In some cases, the TCR subunit and the antibody domain, antigen domain, or binding ligand, or fragments thereof, are operably linked by a linker sequence. In some cases, the linker sequence is 4 S) n (wherein n = 1 to 4).

[0276]

[0355] In some cases, the transmembrane domain is a TCR transmembrane domain from CD3ε, CD3γ, CD3δ, TCRγ, TCRδ, TCRα, or TCRβ. In some cases, the intracellular domain is derived from only CD3ε, only CD3γ, only CD3δ, only TCRγ, only TCRδ, only TCRα, or only TCRβ.

[0277]

[0356] In some cases, the TCR subunit comprises (i) at least a portion of a TCR extracellular domain, (ii) a TCR transmembrane domain, and (iii) a TCR intracellular domain, wherein at least two or all of (i), (ii), and (iii) are from the same TCR subunit.

[0278]

[0357] In some cases, the TCR extracellular domain comprises the extracellular domain of a protein or a portion thereof selected from the group consisting of a TCR alpha chain, a TCR beta chain, a TCR gamma chain, a TCR delta chain, a CD3 epsilon TCR subunit, a CD3 gamma TCR subunit, a CD3 delta TCR subunit, functional fragments thereof, and amino acid sequences thereof having at least one but not more than 20 modifications.

[0279]

[0358] In some cases, the TCR subunit comprises a transmembrane domain comprising a transmembrane domain of a protein selected from the group consisting of a TCR alpha chain, a TCR beta chain, a TCR zeta chain, a CD3 epsilon TCR subunit, a CD3 gamma TCR subunit, a CD3 delta TCR subunit, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD28, CD37, CD64, CD80, CD86, CD134, CD137, CD154, functional fragments thereof, and amino acid sequences thereof having at least one but not more than 20 modifications.

[0280]

[0359] In some cases, the TCR subunit comprises a TCR intracellular domain of a TCR alpha chain, a TCR beta chain, a TCR gamma chain, a TCR delta chain, or a fragment thereof. In some cases, the TCR subunit comprises an intracellular domain comprising a stimulatory domain of a protein selected from the intracellular signaling domains of CD3 epsilon, CD3 gamma, or CD3 delta, or an amino acid sequence having at least one modification thereto.

[0281]

[0360] In some cases, the TCR subunit may comprise (i) at least a portion of the TCR extracellular domain, (ii) a TCR transmembrane domain, and (iii) a TCR intracellular domain of a TCR gamma or TCR delta chain. The TCR extracellular domain may comprise the extracellular portion of the constant domain of the TCR gamma or TCR delta chain, a functional fragment thereof, and an amino acid sequence thereof having at least one but not more than 20 modifications. In some embodiments, the TCR subunit comprising (i) at least a portion of the TCR extracellular domain, (ii) a TCR transmembrane domain, and (iii) a TCR intracellular domain is or comprises a delta constant domain or a fragment thereof, e.g., a delta constant domain as described herein. The delta constant domain may have the sequence of SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:243, or SEQ ID NO:265, a functional fragment thereof, and an amino acid sequence thereof having at least one but not more than 20 modifications. In some embodiments, the TCR subunit comprising (i) at least a portion of the TCR extracellular domain, (ii) the TCR transmembrane domain, and (iii) the TCR intracellular domain is or comprises a gamma constant domain, e.g., a gamma constant domain as described herein. The gamma constant domain may have the amino acid sequence of SEQ ID NO: 21 or SEQ ID NO: 155, functional fragments thereof, and at least one but not more than 20 modifications thereof. The extracellular domain of TFP may not comprise the variable domain of the gamma or delta chain.

[0282]

[0361] The TCR subunit of the TFP may comprise the extracellular, transmembrane, and intracellular domains of CD3ε, CD3γ, or CD3δ. In some embodiments, the recombinant nucleic acid comprises a TFP comprising the extracellular, transmembrane, and intracellular domains of CD3ε, CD3γ, or CD3δ, and the constant domains of TCRβ and TCRα. In some embodiments, the recombinant nucleic acid comprises a TFP comprising the extracellular, transmembrane, and intracellular domains of CD3ε, and the constant domains of TCRγ and TCRδ. In some embodiments, the recombinant nucleic acid comprises a TFP comprising the extracellular, transmembrane, and intracellular domains of CD3ε, and the full-length TCFγ and full-length TCRδ. In some embodiments, the TCR subunit of the TFP comprises CD3ε. The TCR subunit of CD3ε may comprise the amino acid sequence of SEQ ID NO: 364, functional fragments thereof, and at least one but not more than 20 modifications thereof.

[0283]

[0362] In some cases, the TCR subunit comprising at least a portion of the extracellular domain of mouse TCR alpha or mouse TCR beta and the transmembrane domain of mouse TCR alpha or mouse TCR beta is or comprises a TCR alpha constant domain or a TCR beta constant domain. The TCR subunit may comprise the intracellular domain of mouse TCR alpha or mouse TCR beta. The TCR constant domain may be a TCR alpha constant domain, e.g., a TCR alpha constant domain as described herein. The TCR alpha constant domain may comprise the amino acid sequence of SEQ ID NO: 17, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 146, or SEQ ID NO: 207, functional fragments thereof, and at least one but not more than 20 modifications thereof. The sequence encoding the TCR alpha constant domain may further encode a second antigen- or ligand-binding domain operably linked to the sequence encoding the TCR alpha constant domain. The second antigen- or ligand-binding domain may be the same as or different from the antigen- or ligand-binding domain of the TFP. The TCR alpha constant domain may comprise a mouse TCR alpha constant domain. The mouse TCR alpha constant domain may comprise amino acids 2-137 of the mouse TCR alpha constant domain. The mouse TCR alpha constant domain may comprise amino acids 2-137 of SEQ ID NO: 146. The mouse TCR alpha constant domain may comprise the sequence of SEQ ID NO: 207. The mouse TCR alpha constant domain may comprise amino acids 82-137 of SEQ ID NO: 146. The mouse TCR alpha constant domain comprises the sequence of SEQ ID NO: 17. The TCR constant domain may be a TCR beta constant domain, e.g., a TCR beta constant domain as described herein. The TCR beta constant domain may comprise the amino acid sequence of SEQ ID NO: 18, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 152, or SEQ ID NO: 209, functional fragments thereof, and at least one but not more than 20 modifications thereof. The sequence encoding the TCR beta constant domain may further encode a second antigen-binding domain or ligand-binding domain operably linked to the sequence encoding the TCR beta constant domain. The second antigen- or ligand-binding domain may be the same as or different from the antigen- or ligand-binding domain of the TFP.The TCR β constant domain may comprise a mouse TCR β constant domain. The mouse TCR β constant domain may comprise amino acids 2-173 of the mouse TCR β constant domain. The mouse TCR β constant domain may comprise amino acids 2-173 of SEQ ID NO: 152. The mouse TCR β constant domain may comprise SEQ ID NO: 209. The TCR β constant domain may comprise amino acids 123-173 of SEQ ID NO: 152. The TCR β constant domain may comprise SEQ ID NO: 18.

[0284]

[0363] The recombinant nucleic acid may comprise sequences encoding a TCR alpha constant domain and a TCR beta constant domain. The TCR alpha constant domain may comprise the amino acid sequence of SEQ ID NO: 17, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 146, or SEQ ID NO: 207, functional fragments thereof, and having at least one but not more than 20 modifications thereof. The TCR beta constant domain may comprise the amino acid sequence of SEQ ID NO: 18, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 152, or SEQ ID NO: 209, functional fragments thereof, and having at least one but not more than 20 modifications thereof. The intracellular signaling domain may be CD3 epsilon, CD3 gamma, or CD3 delta. The intracellular signaling domain may be CD3 epsilon.

[0285]

[0364] The sequence encoding the TCR constant domain may comprise, in the 5' to 3' direction, a first leader sequence, an antigen binding domain sequence, a linker, a TRAC gene sequence, a cleavable linker sequence, a second leader sequence, and a TRBC gene sequence. The sequence encoding the TCR constant domain may comprise, in the 5' to 3' direction, a first leader sequence, an antigen binding domain sequence, a linker, a TRAC gene sequence, a cleavable linker sequence, a second leader sequence, and a TRBC gene sequence. The sequence encoding the TCR constant domain may comprise, in the 5' to 3' direction, a first leader sequence, a TRAC gene sequence, a cleavable linker sequence, a second leader sequence, an antigen binding domain sequence, a linker, and a TRBC gene sequence. The sequence encoding the TCR constant domain may comprise, in the 5' to 3' direction, a first leader sequence, an antigen binding domain sequence, a linker, a TRAC gene sequence, a cleavable linker sequence, a second leader sequence, an antigen binding domain sequence, a linker, and a TRBC gene sequence. The sequence encoding the TCR constant domain may comprise, in the 5'-3' direction, a first leader sequence, a TRAC gene sequence, a first cleavable linker sequence, a second leader sequence, a TRBC gene sequence, a second cleavable linker sequence, a third leader sequence, an antigen binding domain sequence, a linker sequence, and a CD3ε gene sequence.

[0286]

[0365] As described herein, at least one but not more than 20 modifications to the sequences described herein may include modifications of amino acids that mediate cell signaling or modifications of amino acids that are phosphorylated in response to ligand binding to TFP.

[0287]

[0366] In some cases, the TCR subunit comprises an intracellular domain comprising an amino acid sequence having a stimulatory domain of a protein selected from a functional signaling domain of 4-1BB and / or a functional signaling domain of CD3ζ, or at least one modification thereto.

[0288]

[0367] Optionally, the recombinant nucleic acid further comprises a sequence encoding a costimulatory domain. Optionally, the costimulatory domain comprises a functional signaling domain of a protein selected from the group consisting of OX40, CD2, CD27, CD28, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), and 4-1BB (CD137), and amino acid sequences thereof having at least one but not more than 20 modifications.

[0289]

[0368] In some cases, the TCR subunit comprises an immunoreceptor tyrosine-based activation motif (ITAM) of a protein selected from the group consisting of CD3zeta TCR subunit, CD3ε TCR subunit, CD3γ TCR subunit, CD3δ TCR subunit, TCR zeta chain, Fcε receptor 1 chain, Fcε receptor 2 chain, Fcγ receptor 1 chain, Fcγ receptor 2a chain, Fcγ receptor 2b1 chain, Fcγ receptor 2b2 chain, Fcγ receptor 3a chain, Fcγ receptor 3b chain, Fcβ receptor 1 chain, TYROBP (DAP12), CD5, CD16a, CD16b, CD22, CD23, CD32, CD64, CD79a, CD79b, CD89, CD278, CD66d, functional fragments thereof, and amino acid sequences thereof having at least one but not more than 20 modifications. In some cases, the ITAM replaces an ITAM of a CD3γ, CD3δ, or CD3ε. In some cases, the ITAM is selected from the group consisting of a CD3ζ TCR subunit, a CD3ε TCR subunit, a CD3γ TCR subunit, and a CD3δ TCR subunit, and replaces another ITAM selected from the group consisting of a CD3ζ TCR subunit, a CD3ε TCR subunit, a CD3γ TCR subunit, and a CD3δ TCR subunit.

[0290]

[0369] In some cases, the TFP, the TCR gamma constant domain, the TCR delta constant domain, and any combination thereof, can functionally interact with an endogenous TCR complex and / or at least one endogenous TCR polypeptide. In some cases, (a) the TCR constant domain is a TCR gamma constant domain and the TFP is functionally integrated into a TCR complex that includes endogenous subunits of TCR delta, CD3 epsilon, CD3 gamma, CD3 delta, or a combination thereof, (b) the TCR constant domain is a TCR delta constant domain and the TFP is functionally integrated into a TCR complex that includes endogenous subunits of TCR gamma, CD3 epsilon, CD3 gamma, CD3 delta, or a combination thereof, or (c) the TCR constant domain is a TCR gamma constant domain and a TCR delta constant domain and the TFP is functionally integrated into a TCR complex that includes endogenous subunits of CD3 epsilon, CD3 gamma, CD3 delta, or a combination thereof.

[0291]

[0370] Optionally, at least one but not more than 20 of the modifications thereto comprises a modification of an amino acid that mediates cell signaling or a modification of an amino acid that is phosphorylated in response to ligand binding to the TFP.

[0292]

[0371] The antibody or antigen-binding domain may be an antibody fragment. The antibody or antigen-binding domain may be murine, human, or humanized. Optionally, the murine, human, or humanized antibody is an antibody fragment. Optionally, the antibody fragment is an scFv, a single domain antibody domain, a VH domain, or a VL domain. Optionally, the murine, human, or humanized antibody comprising the antigen-binding domain is selected from the group consisting of an anti-CD19 binding domain, an anti-B cell maturation antigen (BCMA) binding domain, an anti-mesothelin (MSLN) binding domain, an anti-CD22 binding domain, an anti-PD-1 binding domain, an anti-BAFF or BAFF receptor binding domain, and an anti-ROR-1 binding domain.

[0293]

[0372] The antigen binding domain described herein may be selected from the group consisting of an anti-CD19 binding domain, an anti-B cell maturation antigen (BCMA) binding domain, an anti-mesothelin (MSLN) binding domain, an anti-CD20 binding domain, an anti-CD70 binding domain, an anti-79b binding domain, an anti-HER2 binding domain, an anti-PMSA binding domain, an anti-MUC16 binding domain, an anti-CD22 binding domain, an anti-PD-L1 binding domain, an anti-BAFF or BAFF receptor binding domain, an anti-Nectin-4 binding domain, an anti-TROP-2 binding domain, an anti-GPC3 binding domain, and an anti-ROR-1 binding domain.

[0294]

[0373] Optionally, the nucleic acid is selected from the group consisting of DNA and RNA. Optionally, the nucleic acid is mRNA. Optionally, the recombinant nucleic acid comprises a nucleic acid analog, where the nucleic acid analog is not in the coding sequence of the recombinant nucleic acid. In some cases, the nucleic acid analog is selected from the group consisting of 2'-O-methyl, 2'-O-methoxyethyl (2'-O-MOE), 2'-O-aminopropyl, 2'-deoxy, T-deoxy-2'-fluoro, 2'-O-aminopropyl (2'-O-AP), 2'-O-dimethylaminoethyl (2'-O-DMAOE), 2'-O-dimethylaminopropyl (2'-O-DMAP), TO-dimethylaminoethyloxyethyl (2'-O-DMAEOE), 2'-ON-methylacetamide (2'-O-NMA) modifications, locked nucleic acid (LNA), ethylene nucleic acid (ENA), peptide nucleic acid (PNA), 1',5'-anhydrohexitol nucleic acid (HNA), morpholino, methylphosphonate nucleotides, thiolphosphonate nucleotides, and 2'-fluoro N3-P5'-phosphoramidites.

[0295]

[0374] Optionally, the recombinant nucleic acid further comprises a leader sequence. Optionally, the recombinant nucleic acid further comprises a promoter sequence. Optionally, the recombinant nucleic acid further comprises a sequence encoding a poly(A) tail. Optionally, the recombinant nucleic acid further comprises a 3'UTR sequence. Optionally, the nucleic acid is an isolated nucleic acid or a non-naturally occurring nucleic acid. Optionally, the nucleic acid is an in vitro transcribed nucleic acid.

[0296]

[0375] Optionally, the recombinant nucleic acid further comprises a sequence encoding a TCR alpha transmembrane domain. Optionally, the recombinant nucleic acid further comprises a sequence encoding a TCR beta transmembrane domain. Optionally, the recombinant nucleic acid further comprises a sequence encoding a TCR alpha transmembrane domain and a sequence encoding a TCR beta transmembrane domain. Alternatively, the recombinant nucleic acid comprises a sequence encoding a TCR gamma domain or a TCR delta domain, e.g., a transmembrane domain.

[0297]

[0376] In some cases, the TCR subunit comprises an immunoreceptor tyrosine-based activation motif (ITAM) of a protein selected from the group consisting of CD3zeta TCR subunit, CD3ε TCR subunit, CD3γ TCR subunit, CD3δ TCR subunit, TCR zeta chain, Fcε receptor 1 chain, Fcε receptor 2 chain, Fcγ receptor 1 chain, Fcγ receptor 2a chain, Fcγ receptor 2b1 chain, Fcγ receptor 2b2 chain, Fcγ receptor 3a chain, Fcγ receptor 3b chain, Fcβ receptor 1 chain, TYROBP (DAP12), CD5, CD16a, CD16b, CD22, CD23, CD32, CD64, CD79a, CD79b, CD89, CD278, CD66d, functional fragments thereof, and amino acid sequences thereof having at least one but not more than 20 modifications. In some cases, the ITAM replaces an ITAM of a CD3γ, CD3δ, or CD3ε. In some cases, the ITAM is selected from the group consisting of a CD3ζ TCR subunit, a CD3ε TCR subunit, a CD3γ TCR subunit, and a CD3δ TCR subunit, and replaces another ITAM selected from the group consisting of a CD3ζ TCR subunit, a CD3ε TCR subunit, a CD3γ TCR subunit, and a CD3δ TCR subunit.

[0298]

[0377] In some cases, the TFP, the TCR gamma constant domain, the TCR delta constant domain, the TCR alpha constant domain, the TCR beta constant domain, and any combination thereof, can functionally interact with an endogenous TCR complex and / or at least one endogenous TCR polypeptide. In some cases, (a) the TCR constant domain is a TCR gamma constant domain and the TFP is functionally integrated into a TCR complex that includes endogenous subunits of TCR beta, CD3 epsilon, CD3 gamma, CD3 delta, or a combination thereof, (b) the TCR constant domain is a TCR delta constant domain and the TFP is functionally integrated into a TCR complex that includes endogenous subunits of TCR gamma, CD3 epsilon, CD3 gamma, CD3 delta, or a combination thereof, or (c) the TCR constant domain is a TCR gamma constant domain and a TCR delta constant domain and the TFP is functionally integrated into a TCR complex that includes endogenous subunits of TCR gamma, CD3 epsilon, CD3 gamma, CD3 delta, or a combination thereof. (d) the TCR constant domain is a TCR alpha constant domain and the TFP is functionally integrated into a TCR complex comprising endogenous subunits of TCR beta, CD3 epsilon, CD3 gamma, CD3 delta, or a combination thereof; or (e) the TCR constant domain is a TCR beta constant domain and the TFP is functionally integrated into a TCR complex comprising endogenous subunits of TCR alpha, CD3 epsilon, CD3 gamma, CD3 delta, or a combination thereof.

[0299]

[0378] Optionally, at least one but not more than 20 of the modifications thereto comprises a modification of an amino acid that mediates cell signaling or a modification of an amino acid that is phosphorylated in response to ligand binding to the TFP.

[0300]

[0379] In some cases, the murine, human, or humanized antibody is an antibody fragment. In some cases, the antibody fragment is an scFv, a single domain antibody domain (sdAb), a VH domain, or a VL domain. In some cases, the murine, human, or humanized antibody comprising an antigen-binding domain is selected from the group consisting of an anti-CD19 binding domain, an anti-B cell maturation antigen (BCMA) binding domain, an anti-mesothelin (MSLN) binding domain, an anti-CD22 binding domain, an anti-PD-1 binding domain, an anti-PD-L1 binding domain, an anti-IL13Rα2 binding domain, an anti-BAFF or BAFFR binding domain, and an anti-ROR-1 binding domain.

[0301]

[0380] In some cases, the antigen domain comprises a ligand. In some cases, the ligand binds to a receptor on a cell. In some cases, the ligand binds to a polypeptide expressed on the surface of a cell. In some cases, the receptor or polypeptide expressed on the surface of a cell comprises a stress response receptor or polypeptide. In some cases, the receptor or polypeptide expressed on the surface of a cell is an MHC class I associated glycoprotein. In some cases, the MHC class I associated glycoprotein is selected from the group consisting of MICA, MICB, RAET1E, RAET1G, ULBP1, ULBP2, ULBP3, ULBP4, and combinations thereof. In some cases, the antigen domain comprises a monomer, dimer, trimer, tetramer, pentamer, hexamer, heptamer, octamer, 9-mer, or decamer. In some cases, the antigen domain comprises a monomer or dimer of a ligand or a fragment thereof. In some cases, the ligand or a fragment thereof comprises a monomer, dimer, trimer, tetramer, pentamer, hexamer, heptamer, octamer, 9-mer, or decamer. In some cases, the ligand or fragment thereof is a monomer or dimer. In some cases, the antigen domain does not comprise an antibody or fragment thereof. In some cases, the antigen domain does not comprise a variable region. In some cases, the antigen domain does not comprise a CDR. In some cases, the ligand or fragment thereof is a Natural Killer Group 2D (NKG2D) ligand or fragment thereof.

[0302]

[0381] In some cases, the TCR subunit and the antibody domain, antigen domain, or binding ligand, or fragments thereof, are operably linked by a linker sequence. In some cases, the linker sequence is 4 S) n (wherein n = 1 to 4).

[0303]

[0382] In some cases, the transmembrane domain is a TCR transmembrane domain from CD3ε, CD3γ, CD3δ, TCRα, TCRβ, TCRδ, or TCRγ. In some cases, the intracellular domain is derived from only CD3ε, only CD3γ, only CD3δ, only TCRα, only TCRβ, only TCRδ, or only TCRγ.

[0304]

[0383] In some cases, the TCR subunit comprises (i) at least a portion of a TCR extracellular domain, (ii) a TCR transmembrane domain, and (iii) a TCR intracellular domain, wherein at least two of (i), (ii), and (iii) are from the same TCR subunit.

[0305]

[0384] In some cases, the TCR extracellular domain comprises an extracellular domain of a protein or a portion thereof selected from the group consisting of a TCR alpha chain, a TCR beta chain, a TCR delta chain, a TCR gamma chain, a CD3 epsilon TCR subunit, a CD3 gamma TCR subunit, a CD3 delta TCR subunit, a functional fragment thereof, and an amino acid sequence thereof having at least one but not more than 20 modifications.

[0306]

[0385] In some cases, the TCR subunit comprises a transmembrane domain comprising a transmembrane domain of a protein selected from the group consisting of a TCR alpha chain, a TCR beta chain, a TCR delta chain, a TCR gamma chain, a TCR zeta chain, a CD3 epsilon TCR subunit, a CD3 gamma TCR subunit, a CD3 delta TCR subunit, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD28, CD37, CD64, CD80, CD86, CD134, CD137, CD154, functional fragments thereof, and amino acid sequences thereof having at least one but not more than 20 modifications.

[0307]

[0386] In some cases, the TFP, the TCR gamma constant domain, the TCR delta constant domain, the TCR alpha constant domain, the TCR beta constant domain, and any combination thereof, can functionally interact with an endogenous TCR complex and / or at least one endogenous TCR polypeptide. In some cases, (a) the TCR constant domain is a TCR gamma constant domain and the TFP is functionally integrated into a TCR complex that includes endogenous subunits of TCR beta, CD3 epsilon, CD3 gamma, CD3 delta, or a combination thereof, (b) the TCR constant domain is a TCR delta constant domain and the TFP is functionally integrated into a TCR complex that includes endogenous subunits of TCR gamma, CD3 epsilon, CD3 gamma, CD3 delta, or a combination thereof, or (c) the TCR constant domain is a TCR gamma constant domain and a TCR delta constant domain and the TFP is functionally integrated into a TCR complex that includes endogenous subunits of TCR gamma, CD3 epsilon, CD3 gamma, CD3 delta, or a combination thereof. (d) the TCR constant domain is a TCR alpha constant domain and the TFP is functionally integrated into a TCR complex comprising endogenous subunits of TCR beta, CD3 epsilon, CD3 gamma, CD3 delta, or a combination thereof; or (e) the TCR constant domain is a TCR beta constant domain and the TFP is functionally integrated into a TCR complex comprising endogenous subunits of TCR alpha, CD3 epsilon, CD3 gamma, CD3 delta, or a combination thereof.

[0308]

[0387] Optionally, at least one but not more than 20 of the modifications thereto comprises a modification of an amino acid that mediates cell signaling or a modification of an amino acid that is phosphorylated in response to ligand binding to the TFP.

[0309]

[0388] In some cases, the murine, human, or humanized antibody is an antibody fragment. In some cases, the antibody fragment is an scFv, a single domain antibody domain, a VH domain, or a VL domain. In some cases, the murine, human, or humanized antibody comprising an antigen-binding domain is selected from the group consisting of an anti-CD19 binding domain, an anti-CD20 binding domain, an anti-mesothelin binding domain, an anti-PMSA binding domain, an anti-CD70 binding domain, an anti-CD79b binding domain, an anti-MUC16 binding domain, an anti-B-cell maturation antigen (BCMA) binding domain, an anti-mesothelin (MSLN) binding domain, an anti-IL13Rα2 binding domain, an anti-CD22 binding domain, an anti-BAFF or BAFFR binding domain, an anti-PD-1 binding domain, an anti-PD-L1 binding domain, and an anti-ROR-1 binding domain.

[0310]

[0389] In some embodiments, the sequence encoding the antigen binding domain or the ligand binding domain is operably linked to a sequence encoding a δ constant domain. In some embodiments, the intracellular domain is a TCRγ intracellular domain. In some embodiments, the sequence encoding the antigen binding domain or the ligand binding domain is operably linked to a sequence encoding a γ constant domain. In some embodiments, the intracellular domain is a TCRδ intracellular domain. In some embodiments, the sequence encoding the antigen binding domain or the ligand binding domain is operably linked to both a sequence encoding a TCRδ constant domain or a fragment thereof and a sequence encoding a TCRγ constant domain or a fragment thereof. In some embodiments, the intracellular signaling domain is CD3ε, CD3γ, or CD3δ. In some embodiments, the intracellular signaling domain is CD3ε. In some embodiments, the recombinant nucleic acid further comprises at least one leader sequence and at least one linker. In some embodiments, the recombinant nucleic acid further comprises a portion of a TCRα constant domain, a portion of a TCRβ domain, or both. In some embodiments, the sequence comprises, from 5' to 3', a first leader sequence, an antigen binding domain sequence, a linker, a TRDC gene sequence, a cleavable linker sequence, a second leader sequence, and a TRGC gene sequence. In some embodiments, the sequence comprises, from 5'-3', a first leader sequence, a TRDC gene sequence, a cleavable linker sequence, a second leader sequence, an antigen binding domain sequence, a linker sequence, and a TRGC gene sequence. In some embodiments, the sequence comprises, from 5'-3', a first leader sequence, an antigen binding domain sequence, a first linker sequence, a TRDC gene sequence, a cleavable linker sequence, a second leader sequence, a second antigen binding domain sequence, a second linker sequence, and a TRGC gene sequence. In some embodiments, the sequence comprises, in the 5'-3' direction, a first leader sequence, a TRDC gene sequence, a first cleavable linker sequence, a second leader sequence, a TRGC gene sequence, a second cleavable linker sequence, a third leader sequence, an antigen binding domain sequence, a linker sequence, and a CD3ε gene sequence.In some embodiments, the sequence comprises, in the 5'-3' direction, a first leader sequence, a first antigen binding domain sequence, a first linker sequence, a TRDC gene sequence or a fragment thereof, a TRAC gene sequence or a fragment thereof, a cleavable linker sequence, a second leader sequence, a second antigen binding domain sequence, a second linker sequence, a TRGC gene sequence or a fragment thereof, and a TRBC gene sequence or a fragment thereof. In some embodiments, the binding ligand can bind to an Fc domain of an antibody. In some embodiments, the binding ligand can selectively bind to an IgG1 antibody. In some embodiments, the binding ligand can specifically bind to an IgG4 antibody. In some embodiments, the antibody or fragment thereof binds to a cell surface antigen. In some embodiments, the antibody or fragment thereof is murine, human, or humanized. In some embodiments, the antibody or fragment thereof binds to a cell surface antigen on the surface of a tumor cell. In some embodiments, the binding ligand comprises a monomer, a dimer, a trimer, a tetramer, a pentamer, a hexamer, a heptamer, an octamer, a nonamer, or a decamer. In some embodiments, the binding ligand does not comprise an antibody or fragment thereof. In some embodiments, the binding ligand comprises a CD16 polypeptide or fragment thereof. In some embodiments, the binding ligand comprises a CD16 binding polypeptide. In some embodiments, the binding ligand is human or humanized. In some embodiments, the recombinant nucleic acid further comprises a nucleic acid sequence encoding an antibody or fragment thereof to which the binding ligand can bind. In some embodiments, the antibody or fragment thereof is capable of being secreted from the cell.

[0311] Recombinant nucleic acids encoding IL-15 and / or IL-15Rα

[0390] Disclosed herein is a recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a TFP as described herein and a second nucleic acid sequence encoding an IL-15 polypeptide or a fragment thereof. Any recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a TFP as described herein may further comprise a second nucleic acid sequence encoding an IL-15 polypeptide or a fragment thereof. Disclosed herein further is a recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a TFP as described herein and a second nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof. Any recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a TFP as described herein may further comprise a second nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof.

[0312]

[0391] In some embodiments, disclosed herein is a recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a TFP as described herein and a second nucleic acid sequence encoding an IL-15 polypeptide or a fragment thereof, wherein the first nucleic acid sequence and the second nucleic acid sequence are comprised in two separate nucleic acid molecules. In some embodiments, disclosed herein is a recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a TFP as described herein and a second nucleic acid sequence encoding an IL-15 polypeptide or a fragment thereof, wherein the first nucleic acid sequence and the second nucleic acid sequence are comprised in a single nucleic acid molecule. In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are operably linked by a first linker. In some embodiments, further disclosed herein is a recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a TFP as described herein and a second nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof, wherein the first nucleic acid sequence and the second nucleic acid sequence are comprised in two separate nucleic acid molecules. In some embodiments, further disclosed herein is a recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a TFP as described herein and a second nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof, the first nucleic acid sequence and the second nucleic acid sequence being comprised in a single nucleic acid molecule. In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are operably linked by a first linker. For example, the first linker may be a cleavable linker. In some embodiments, the first linker may comprise a protease cleavage site. The cleavage site may be a self-cleaving peptide, e.g., a 2A cleavage site, such as a T2A, P2A, E2A, or F2A cleavage site. In some embodiments, the protease cleavage site is a T2A cleavage site. The cleavage site, when expressed, may comprise the sequence of SEQ ID NO: 365. In some embodiments, the first linker, when expressed, comprises the sequence of SEQ ID NO: 365.

[0313]

[0392] In some embodiments, the nucleic acid sequence encoding the IL-15 polypeptide or a fragment thereof may comprise a sequence encoding an IL-15 signal peptide. In some embodiments, the IL-15 signal peptide, when expressed, comprises amino acids 1-29 of SEQ ID NO: 385. In some embodiments, the IL-15 signal peptide, when expressed, comprises a sequence of SEQ ID NO: 374. In some embodiments, the nucleic acid sequence encoding the IL-15 polypeptide or a fragment thereof may comprise a sequence encoding amino acids 30-162 of SEQ ID NO: 385. In some embodiments, the nucleic acid sequence encoding the IL-15 polypeptide or a fragment thereof may comprise a sequence encoding a sequence of SEQ ID NO: 375. In some embodiments, the nucleic acid sequence encoding the IL-15 polypeptide or a fragment thereof may comprise a sequence encoding amino acids 1-162 of SEQ ID NO: 385. In some embodiments, the nucleic acid sequence encoding the IL-15 polypeptide or a fragment thereof may comprise a sequence encoding a sequence of SEQ ID NO: 374 and a sequence encoding a sequence of SEQ ID NO: 375. In some embodiments, the IL-15 polypeptide or a fragment thereof is secreted upon expression in a T cell. In some embodiments, the IL-15 polypeptide, when expressed, comprises a sequence of SEQ ID NO: 375.

[0314]

[0393] In some embodiments, disclosed herein is a recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a TFP as described herein and a second nucleic acid sequence encoding an IL-15 polypeptide or fragment thereof and an IL-15R subunit or fragment thereof, wherein the first nucleic acid sequence and the second nucleic acid sequence are comprised in two separate nucleic acid molecules. In some embodiments, disclosed herein is a recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a TFP as described herein and a second nucleic acid sequence encoding an IL-15 polypeptide or fragment thereof and an IL-15R subunit or fragment thereof, wherein the first nucleic acid sequence and the second nucleic acid sequence are comprised in a single nucleic acid molecule. In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are operably linked by a first linker as described herein. The IL-15R subunit can be IL-15Rα (IL-15Rα), IL-2Rβ (IL-2β), or IL-2Rγ / common γ chain (IL-2Rγ / γc). In some embodiments, the IL-15R subunit is IL-15Rα (IL-15Rα). In some embodiments, the IL-15 and IL-15R subunit are operably linked by a second linker. In some embodiments, the IL-15 and IL-15Rα are operably linked by a second linker. In some embodiments, the second linker is not a cleavable linker. For example, the second linker is (G 4 S) n where G is glycine, S is serine, and n is an integer from 1 to 10. In some embodiments, n is an integer from 1 to 4. In some embodiments, n is 3. In some embodiments, the second linker comprises the sequence of SEQ ID NO: 378. In some embodiments, the second linker comprises the sequence of SEQ ID NO: 405.

[0315]

[0394] In some embodiments, a nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof may comprise a sequence encoding the intracellular domain of IL-15Rα. In some embodiments, a nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof may comprise a sequence encoding amino acids 229-267 of IL-15Rα. In some embodiments, a nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof may comprise a sequence encoding amino acids 229-267 of SEQ ID NO:386. In some embodiments, a nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof may comprise a sequence encoding the sequence of SEQ ID NO:372.

[0316]

[0395] In some embodiments, a nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof may comprise a sequence encoding the Sushi domain of IL-15Rα. In some embodiments, a nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof may comprise a sequence encoding amino acids 31-95 of IL-15Rα. In some embodiments, a nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof may comprise a sequence encoding amino acids 31-95 of SEQ ID NO:386. In some embodiments, a nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof may comprise a sequence encoding the sequence of SEQ ID NO:382.

[0317]

[0396] In some embodiments, a nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof may comprise a sequence encoding the transmembrane and intracellular domains of IL-15Rα. In some embodiments, a nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof may comprise a sequence encoding amino acids 96-267 of IL-15Rα. In some embodiments, a nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof may comprise a sequence encoding amino acids 96-267 of SEQ ID NO:386. In some embodiments, a nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof may comprise a sequence encoding the sequence of SEQ ID NO:383.

[0318]

[0397] In some embodiments, the nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof may comprise a sequence encoding the Sushi domain, the transmembrane domain, and the intracellular domain of IL-15Rα. In some embodiments, the nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof may comprise a sequence encoding amino acids 31-267 of IL-15Rα. In some embodiments, the nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof may comprise a sequence encoding amino acids 31-267 of SEQ ID NO:386. In some embodiments, the nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof may comprise a sequence encoding the sequence of SEQ ID NO:382 and the sequence of SEQ ID NO:383. In some embodiments, the IL-15Rα comprises the sequence of SEQ ID NO:403.

[0319]

[0398] In some embodiments, a nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof may comprise a sequence encoding soluble IL-15Rα (sIL-15Rα). In some embodiments, a nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof may comprise a sequence encoding amino acids 21-205 of IL-15Rα. In some embodiments, a nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof may comprise a sequence encoding amino acids 21-205 of SEQ ID NO:386. In some embodiments, a nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof may comprise a sequence encoding the sequence of SEQ ID NO:379.

[0320]

[0399] In some embodiments, disclosed herein is a recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a TFP as described herein and a second nucleic acid sequence encoding a fusion protein comprising an IL-15 polypeptide linked to an IL-15Rα subunit, the first nucleic acid sequence and the second nucleic acid sequence being comprised in two separate nucleic acid molecules. In some embodiments, disclosed herein is a recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a TFP as described herein and a second nucleic acid sequence encoding a fusion protein comprising an IL-15 polypeptide linked to an IL-15Rα subunit, the first nucleic acid sequence and the second nucleic acid sequence being comprised in a single nucleic acid molecule. In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are operably linked by a first linker as described herein. For example, the IL-15 polypeptide can be linked to the N-terminus of the IL-15Rα subunit. For example, the IL-15 polypeptide can be linked to the C-terminus of the IL-15Rα subunit.

[0321]

[0400] In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding amino acids 1-29 of IL-15. In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding amino acids 1-29 of SEQ ID NO: 385. In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding the sequence of SEQ ID NO: 374. In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding amino acids 30-162 of IL-15. In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding amino acids 30-162 of SEQ ID NO: 385. In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding the sequence of SEQ ID NO: 375. In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding amino acids 1-162 of IL-15. In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding amino acids 1-162 of SEQ ID NO: 385. In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding the sequence of SEQ ID NO: 374 and a sequence encoding the sequence of SEQ ID NO: 375.

[0322]

[0401] In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding the intracellular domain of IL-15Rα. In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding amino acids 229-267 of IL-15Rα. In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding amino acids 229-267 of SEQ ID NO:386. In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding the sequence of SEQ ID NO:372.

[0323]

[0402] In some embodiments, the nucleic acid sequence encoding the fusion protein may further comprise a sequence encoding the Sushi domain of IL-15Rα. In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding amino acids 31-95 of IL-15Rα. In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding amino acids 31-95 of SEQ ID NO:386. In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding the sequence of SEQ ID NO:382.

[0324]

[0403] In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding the transmembrane and intracellular domains of IL-15Rα. In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding amino acids 96-267 of IL-15Rα. In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding amino acids 96-267 of SEQ ID NO:386. In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding the sequence of SEQ ID NO:383.

[0325]

[0404] In some embodiments, the nucleic acid sequence encoding the fusion protein may include sequences encoding the Sushi domain, the transmembrane domain, and the intracellular domain of IL-15Rα. In some embodiments, the nucleic acid sequence encoding the fusion protein may include sequences encoding amino acids 31-267 of IL-15Rα. In some embodiments, the nucleic acid sequence encoding the fusion protein may include sequences encoding amino acids 31-267 of SEQ ID NO:386. In some embodiments, the nucleic acid sequence encoding the fusion protein may include sequences encoding the sequence of SEQ ID NO:382 and the sequence of SEQ ID NO:383. In some embodiments, IL-15Rα includes the sequence of SEQ ID NO:403.

[0326]

[0405] In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding soluble IL-15Rα (sIL-15Rα). In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding amino acids 21-205 of IL-15Rα. In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding amino acids 21-205 of SEQ ID NO:386. In some embodiments, the nucleic acid sequence encoding the fusion protein may comprise a sequence encoding the sequence of SEQ ID NO:379.

[0327]

[0406] In some embodiments, the nucleic acid sequence encoding the fusion protein may further comprise a sequence encoding an epitope tag. The epitope tag described herein may be a peptide epitope tag or a protein epitope tag. Examples of peptide epitope tags include, but are not limited to, 6xHis (also known as His tag or hexahistidine tag), FLAG (e.g., 3xFLAG), HA, Myc, and V5. Examples of protein epitope tags include, but are not limited to, green fluorescent protein (GFP), glutathione-S-transferase (GST), β-galactosidase (β-GAL), luciferase, maltose binding protein (MBP), red fluorescent protein (RFP), and vesicular stomatitis virus glycoprotein (VSV-G). In some embodiments, the nucleic acid sequence encoding the fusion protein further comprises a sequence encoding a FLAG tag. In some embodiments, the nucleic acid sequence encoding the fusion protein further comprises a sequence encoding a 3xFLAG tag. In some embodiments, the nucleic acid sequence encoding the fusion protein further comprises a sequence encoding the sequence of SEQ ID NO:384.

[0328]

[0407] In some embodiments, the fusion protein is expressed on the cell surface when expressed from a recombinant nucleic acid molecule described herein in a T cell. In some embodiments, the fusion protein is secreted when expressed from a recombinant nucleic acid molecule described herein in a T cell.

[0329]

[0408] In some embodiments, disclosed herein is a recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a TFP as described herein, a second nucleic acid sequence encoding an IL-15 polypeptide or fragment thereof, and a third nucleic acid sequence encoding an agent capable of enhancing the activity of an engineered T cell expressing the TFP. In some embodiments, the third nucleic acid sequence is comprised in a separate nucleic acid sequence. In some embodiments, the third nucleic acid sequence is comprised in the same nucleic acid molecule as the first nucleic acid sequence or the second nucleic acid sequence, or the first and second nucleic acid sequences. For example, in one embodiment, the agent capable of enhancing the activity of an engineered T cell can be a PD-1 polypeptide. In these embodiments, the PD-1 polypeptide can be operably linked to the N-terminus of the intracellular domain of the costimulatory polypeptide through the C-terminus of the PD-1 polypeptide. For example, in another embodiment, the agent capable of enhancing the activity of an engineered T cell can be an anti-PD-1 antibody, or an antigen-binding fragment thereof. In this embodiment, the anti-PD-1 antibody, or an antigen-binding fragment thereof, can be operably linked to the N-terminus of the intracellular domain of the costimulatory polypeptide through the C-terminus of the anti-PD-1 antibody, or an antigen-binding fragment thereof. In some embodiments, the PD-1 polypeptide or anti-PD-1 antibody is linked to the intracellular domain of a costimulatory polypeptide via the transmembrane domain of PD-1. In some embodiments, the costimulatory polypeptide is selected from the group consisting of OX40, CD2, CD27, CDS, ICAM-1, ICOS (CD278), 4-1BB (CD137), GITR, CD28, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, CD226, FcγRI, FcγRII, and FcγRIII.

[0330]

[0409] In some embodiments, disclosed herein is a recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a TFP as described herein and a second nucleic acid sequence encoding an IL-15Rα polypeptide or a fragment thereof, the first and second nucleic acid sequences being operably linked by a first linker as described herein, and the second nucleic acid sequence further encoding an agent capable of enhancing the activity of a modified T cell expressing the TFP. For example, the agent can be an agent capable of inhibiting an inhibitory molecule that can reduce the ability of a T cell expressing the TFP to mount an immune effector response. In some embodiments, the agent that inhibits an inhibitory molecule comprises a first polypeptide, e.g., an inhibitory molecule, associated with a second polypeptide that provides a positive signal to the cell, e.g., an intracellular signaling domain as described herein. In one embodiment, the agent may comprise a first polypeptide, e.g., a polypeptide of an inhibitory molecule such as PD-1, LAG3, CTLA4, CD160, BTLA, LAIR1, TIM3, 2B4, and TIGIT, or a fragment of any of these (e.g., at least a portion of the extracellular domain of any of these), and a second polypeptide that is an intracellular signaling domain as described herein (e.g., including a costimulatory domain (e.g., 4-1BB, CD27, or CD28 as described herein)) and / or a primary signaling domain (e.g., IL-15Rα as described herein). In some embodiments, the second nucleic acid sequence further comprises a sequence encoding PD-1 or a fragment thereof. In some embodiments, the second nucleic acid sequence comprises a sequence encoding the extracellular domain of PD-1. In some embodiments, the second nucleic acid sequence comprises a sequence encoding the extracellular domain and transmembrane domain of PD-1. In some embodiments, the second nucleic acid sequence may further comprise a sequence encoding CD28 or a fragment thereof. In some embodiments, the second nucleic acid sequence comprises a sequence encoding the intracellular domain of CD28. In some embodiments, the second nucleic acid sequence comprises a sequence encoding a fusion protein comprising the PD-1 extracellular domain and transmembrane domain linked to a CD28 intracellular domain linked to IL-15Rα.In some embodiments, the CD28 intracellular domain is linked to the intracellular domain of IL-15Rα. In some embodiments, the intracellular domain of IL-15Rα comprises amino acids 229-267 of IL-15Rα. In some embodiments, the intracellular domain of IL-15Rα comprises amino acids 229-267 of SEQ ID NO: 386. In some embodiments, the intracellular domain of IL-15Rα comprises the sequence of SEQ ID NO: 372.

[0331]

[0410] In some embodiments, the second nucleic acid sequence encoding PD-1 or a fragment thereof may comprise a nucleic acid sequence encoding a sequence of SEQ ID NO:366. In some embodiments, the second nucleic acid sequence encoding a PD-1 polypeptide or a fragment thereof may comprise a nucleic acid sequence encoding a sequence of SEQ ID NO:367. In some embodiments, the second nucleic acid sequence encoding a PD-1 polypeptide or a fragment thereof may comprise a nucleic acid sequence encoding a sequence of SEQ ID NO:368. In some embodiments, the second nucleic acid sequence encoding a PD-1 polypeptide or a fragment thereof may comprise a nucleic acid sequence encoding a sequence of SEQ ID NO:369. In some embodiments, the nucleic acid sequence encoding the transmembrane domain of PD-1 may comprise a nucleic acid sequence encoding a sequence of SEQ ID NO:370. In some embodiments, the nucleic acid sequence encoding the intracellular domain of CD28 may comprise a nucleic acid sequence encoding a sequence of SEQ ID NO:371. In some embodiments, the intracellular domain of IL-15Rα comprises amino acids 229-267 of IL-15Rα. In some embodiments, the nucleic acid encoding the intracellular domain of IL-15Rα comprises a nucleic acid encoding amino acids 229-267 of SEQ ID NO:386. In some embodiments, the nucleic acid encoding the intracellular domain of IL-15Rα comprises a nucleic acid encoding the sequence of SEQ ID NO:372.

[0332]

[0411] In some embodiments, disclosed herein is a recombinant nucleic acid molecule comprising a first nucleic acid sequence encoding a TFP as described herein, a second nucleic acid sequence encoding an agent capable of enhancing the activity of an IL-15Rα polypeptide or fragment thereof and a modified T cell expressing a TFP as described herein, and a third nucleic acid sequence encoding an IL-15 polypeptide or fragment thereof. In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are comprised in two separate nucleic acid sequences. In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are comprised in a single nucleic acid sequence. In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are operably linked by a first linker as described herein. In some embodiments, the third nucleic acid sequence is comprised in a separate nucleic acid sequence. In some embodiments, the third nucleic acid sequence is comprised in the same nucleic acid molecule as the first nucleic acid sequence or the second nucleic acid sequence, or the first and second nucleic acid sequences. In some embodiments, the third nucleic acid sequence encoding an IL-15 polypeptide may comprise a sequence encoding amino acids 1-29 of IL-15. In some embodiments, the third nucleic acid sequence encoding the IL-15 polypeptide may comprise a sequence encoding amino acids 1-29 of SEQ ID NO:385. In some embodiments, the third nucleic acid sequence encoding the IL-15 polypeptide may comprise a sequence encoding the sequence of SEQ ID NO:374. In some embodiments, the third nucleic acid sequence encoding the IL-15 polypeptide may comprise a sequence encoding amino acids 30-162 of IL-15. In some embodiments, the third nucleic acid sequence encoding the IL-15 polypeptide may comprise a sequence encoding amino acids 30-162 of SEQ ID NO:385. In some embodiments, the third nucleic acid sequence encoding the IL-15 polypeptide may comprise a sequence encoding the sequence of SEQ ID NO:375. In some embodiments, the IL-15 polypeptide is secreted upon expression in T cells. In some embodiments, the third nucleic acid sequence encoding the IL-15 polypeptide may comprise a sequence encoding amino acids 1-162 of IL-15. In some embodiments, the third nucleic acid sequence encoding the IL-15 polypeptide may comprise a sequence encoding amino acids 1-162 of SEQ ID NO:385.In some embodiments, the third nucleic acid sequence encoding an IL-15 polypeptide may comprise a sequence encoding the sequence of SEQ ID NO:374 and the sequence of SEQ ID NO:375.

[0333]

[0412] In some embodiments, disclosed herein is a recombinant nucleic acid molecule comprising a nucleic acid sequence encoding a TFP as described herein, a nucleic acid sequence encoding a PD-1 polypeptide or a fragment thereof, a nucleic acid sequence encoding a CD28 polypeptide or a fragment thereof, a nucleic acid sequence encoding an IL-15Rα or a fragment thereof as described herein, and a nucleic acid sequence encoding an IL-15 polypeptide or a fragment thereof as described herein. In some embodiments, the nucleic acid sequence encoding the TFP may comprise a sequence encoding a CSF2RA signal peptide. In some embodiments, the nucleic acid sequence encoding the TFP may comprise a nucleic acid sequence encoding a sequence of SEQ ID NO: 362. In some embodiments, the nucleic acid sequence encoding the TFP may comprise a sequence encoding an anti-MSLN antibody. In some embodiments, the nucleic acid sequence encoding the TFP may comprise a nucleic acid sequence encoding a sequence of SEQ ID NO: 363. In some embodiments, the nucleic acid sequence encoding the TFP may comprise a sequence encoding a CD3ε. In some embodiments, the nucleic acid sequence encoding the TFP may comprise a nucleic acid sequence encoding a sequence of SEQ ID NO: 364. In some embodiments, the nucleic acid sequence encoding the PD-1 polypeptide or a fragment thereof comprises a sequence encoding a PD-1 signal peptide. In some embodiments, the nucleic acid sequence encoding a PD-1 polypeptide or fragment thereof comprises a nucleic acid sequence encoding a sequence of SEQ ID NO:366. In some embodiments, the nucleic acid sequence encoding a PD-1 polypeptide or fragment thereof comprises a sequence encoding the PD-1 N-loop. In some embodiments, the nucleic acid sequence encoding a PD-1 polypeptide or fragment thereof comprises a nucleic acid sequence encoding a sequence of SEQ ID NO:367. In some embodiments, the nucleic acid sequence encoding a PD-1 polypeptide or fragment thereof comprises a sequence encoding the PD-1 IgV. In some embodiments, the nucleic acid sequence encoding a PD-1 polypeptide or fragment thereof comprises a nucleic acid sequence encoding a sequence of SEQ ID NO:368. In some embodiments, the nucleic acid sequence encoding a PD-1 polypeptide or fragment thereof comprises a sequence encoding the PD-1 Stalk. In some embodiments, the nucleic acid sequence encoding a PD-1 polypeptide or fragment thereof comprises a nucleic acid sequence encoding a sequence of SEQ ID NO:369.In some embodiments, the nucleic acid sequence encoding a PD-1 polypeptide or fragment thereof comprises a sequence encoding the transmembrane domain of PD-1. In some embodiments, the nucleic acid sequence encoding a PD-1 polypeptide or fragment thereof comprises a nucleic...

Claims

1. A first nucleic acid sequence encoding a T cell receptor (TCR) fusion protein (TFP), said TFP comprising: (a) Below: (i) at least a portion of a TCR extracellular domain, and (ii) a TCR transmembrane domain, A TCR subunit comprising: (b) an antigen-binding domain; and wherein the TCR subunit and the antigen binding domain are operably linked; a second nucleic acid sequence encoding an interleukin-15 (IL-15) polypeptide or fragment thereof and / or an IL-15 receptor (IL-15R) polypeptide or fragment thereof; A recombinant nucleic acid molecule comprising:

2. The recombinant nucleic acid molecule of claim 1 , wherein the TFP further comprises a TCR intracellular signaling domain.

3. 3. The recombinant nucleic acid molecule of claim 1, wherein the first nucleic acid sequence and the second nucleic acid sequence are operably linked by a first linker comprising a protease cleavage site.

4. The recombinant nucleic acid molecule of any one of claims 1 to 3, wherein the IL-15 polypeptide is secreted upon expression in T cells.

5. The recombinant nucleic acid molecule of any one of claims 1 to 4, wherein the second nucleic acid sequence encodes an IL-15 polypeptide and an IL-15Rα polypeptide.

6. 6. The recombinant nucleic acid molecule of claim 5, wherein said IL-15 polypeptide comprises the sequence of SEQ ID NO:375 and said IL-15Rα polypeptide comprises the sequence of SEQ ID NO:

403.

7. The recombinant nucleic acid molecule of claim 6, wherein the IL-15 polypeptide and the IL-15Rα polypeptide are operably linked by a second linker.

8. 8. The recombinant nucleic acid molecule of claim 7, wherein the second linker comprises the sequence of SEQ ID NO:378 or SEQ ID NO:

405.

9. 9. The recombinant nucleic acid molecule of claim 5, wherein the second nucleic acid sequence encodes a fusion protein comprising the IL-15 polypeptide linked to the N-terminus of the IL-15Rα polypeptide.

10. 10. The recombinant nucleic acid molecule of claim 9, wherein the fusion protein comprises a sequence having at least 95% sequence identity to SEQ ID NO:

389.

11. 11. The recombinant nucleic acid molecule of any one of claims 1 to 10, encoding an amino acid sequence comprising the sequence of SEQ ID NO:377, SEQ ID NO:380, SEQ ID NO:381, SEQ ID NO:402, or SEQ ID NO:

404.

12. 12. The recombinant nucleic acid molecule of any one of claims 2 to 11, wherein the TCR intracellular signaling domain comprises a stimulatory domain from the intracellular signaling domain of CD3γ, CD3δ, or CD3ε.

13. 13. The recombinant nucleic acid molecule of any one of claims 1 to 12, wherein the antigen-binding domain is linked to at least a portion of the TCR extracellular domain by a third linker sequence.

14. 14. The recombinant nucleic acid molecule of any one of claims 2 to 13, wherein at least two of the TCR extracellular domain, the TCR transmembrane domain, and the TCR intracellular signaling domain are derived from the same TCR subunit, the same TCR subunit being selected from the group consisting of CD3ε, CD3δ, and CD3γ.

15. 15. The recombinant nucleic acid molecule of any one of claims 1 to 14, wherein the antigen-binding domain is a camelid antibody or binding fragment thereof, a murine antibody or binding fragment thereof, or a human antibody or humanized antibody or binding fragment thereof.

16. 16. The recombinant nucleic acid molecule of any one of claims 1 to 15, wherein the antigen binding domain is selected from the group consisting of an anti-CD19 binding domain, an anti-B cell maturation antigen (BCMA) binding domain, and an anti-mesothelin (MSLN) binding domain, an anti-CD20 binding domain, an anti-CD70 binding domain, an anti-MUC16 binding domain, an anti-nectin-4 binding domain, an anti-GPC3 binding domain, and an anti-TROP-2 binding domain.

17. A polypeptide encoded by a recombinant nucleic acid molecule according to any one of claims 1 to 16.

18. A vector comprising a recombinant nucleic acid molecule according to any one of claims 1 to 16.

19. A cell comprising a recombinant nucleic acid molecule according to any one of claims 1 to 16, a polypeptide according to claim 17, or a vector according to claim 18.

20. 20. A pharmaceutical composition comprising the cells of claim 19 and a pharma- ceutically acceptable carrier.